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Abstract  
 
Infectious bronchitis virus (IBV) is the most economically damaging virus to the poultry 
industry, presenting a major threat to the health and productivity of both commercial and 
backyard flocks. Better understanding of the molecular mechanisms involved in virus 
infection and the properties that allow it to be such a successful pathogen is required to 
improve vaccination strategies and control of the disease. The spike (S) protein of IBV is 
responsible for attachment and entry into host cells. Like other viral attachment proteins, 
IBV S is highly glycosylated. Using mass spectrometry techniques as well as cellular inhibitors 
and deglycosylating enzymes, the glycan profile of IBV was further elucidated and a possible 
role for glycosylation in reducing antibody binding was suggested. The role of the S protein 
in pathogenicity is somewhat unclear. Previous studies have investigated IBV pathogenicity 
using recombinant viruses with a non-pathogenic backbone expressing heterologous spikes. 
In the present study, the S gene has been modified within a pathogenic backbone to assess 
the potential to alter pathogenicity. Firstly, a pathogenic virus expressing a non-pathogenic 
S protein was generated and characterised in vitro and in vivo. These studies revealed that 
the S gene was a factor in IBV pathogenicity. This was confirmed as a gene-specific effect 
through the generation and characterisation of a second virus, expressing the S protein from 
a heterologous pathogenic strain of IBV. This virus retained the ability to cause disease 
despite replacement of the S gene. Defining the cellular factors required by the virus to enter 
and successfully replicate in a given cell enables propagation of viruses not usually able to 
replicate in cell culture. Lastly, the cellular conditions necessary for IBV infection were 
investigated in the context of protease cleavage of the spike glycoprotein and in terms of 
temperature sensitivity, offering a possible mechanism of attenuation in some strains and a 
platform for more efficient vaccine production.  
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Chapter 1: Introduction 
 
1.1 The Nidovirales  
The Nidovirales are an order of viruses encoded by positive sense, single stranded RNA 
genomes. The order comprises three distinct families known as the Arteriviridae, the 
Roniviridae and the Coronaviridae. The Coronavirinae and Torovirinae are distinct genera 
within the Coronaviridae family (King et al., 2012, Gonzalez et al., 2003). While the members 
of the Nidovirales are genetically diverged, they all use very similar mechanisms to replicate 
their RNA genomes, involving the production of sub-genomic RNA molecules. All nidoviruses 
encode a complex set of proteins within their genomes which facilitate efficient transcription 
and translation. In all nidoviruses, the genes encoding these proteins make up at least two 
thirds of the whole genome (reviewed by Posthuma et al. 2017). The process of replication 
as well as the functions of these proteins are described in more detail in future sections.  
While the nidoviruses are united in their mechanisms of replication, they can exhibit very 
different virion morphologies. Coronaviruses are classically spherical in shape with spike-like 
projections on the virion surface whereas toroviruses and bafiniviruses are often rod-shaped 
(International Committee for the Taxonomy of Viruses (ICTV) 9th Report 2011). These viruses 
can also be distinguished by the size of their genome. Coronaviruses boast extremely large 
genomes of approximately 26-32 kilobases (kb), the largest of any RNA virus (Gorbalenya et 
al., 2006, Sawicki, 2009). In contrast, arterivirus genomes are much shorter, comprising 
approximately 13kb. Arterivirus virions are also considerably smaller in diameter than those 
of related nidoviruses (Snijder and Meulenberg, 1998). Nidoviruses infect a wide range of 
hosts including vertebrate and invertebrate species. They include many pathogens of great 
importance in both human and animal health, some of which are considered significant 
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emerging pathogens (Weiss and Navas-Martin, 2005). The phylogenetic relationships 
between the families of viruses within the Nidovirales is demonstrated in Figure 1.1.  
 
 
 
 
Figure 1.1: Phylogenetic relationships between members of the Nidovirales. The three 
groups within the order are Arteriviridae, Roniviridae and the Coronaviridae, containing the 
Coronavirinae and the Torovirinae. Examples are given for each group and their divergence 
is stated. Taken from the International Committee for the Taxonomy of Viruses (ICTV) 9th 
Report, 2011.  
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1.2 The Coronavirinae 
The Coronavirinae are a subfamily of viruses within the order Nidovirales, alongside the 
Torovirinae and Arterivirinae. The Coronavirinae are divided into four genera, alpha, beta, 
gamma and the more recently established genus, Deltacoronavirus. Examples of 
coronaviruses belonging to each genus are detailed in Table 1.1. Viruses included in these 
genera pose significant threats to both human and animal health as well as global food 
security. Coronaviruses include the emerging pathogens such as severe acute respiratory 
syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome virus (MERS-CoV), 
both of which caused significant outbreaks in 2003 and 2012, respectively (Zaki et al., 2012, 
Peiris et al., 2003).  
Coronaviruses of veterinary importance affect a wide range of species causing both 
respiratory and enteric disease. They include feline coronavirus or feline infectious 
peritonitis virus (FCoV/FIPV) and infectious bronchitis virus (IBV), an endemic pathogen of 
chickens. Those affecting pigs include porcine epidemic diarrhoea virus (PEDV) and 
transmissible gastroenteritis virus (TGEV). Bovine coronavirus (BCoV) is an important 
pathogen causing disease in calves. In domestic animals, infection with coronaviruses is often 
associated with concurrent or secondary bacterial infections, resulting in increased mortality 
and severe economic losses in the meat and dairy industries (Weiss and Navas-Martin, 2005).  
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Table 1.1: Coronavirinae genera and species 
Genus Species 
ALPHACORONAVIRUS 
Minopterus bat coronavirus 1 
Transmissible gastroenteritis virus (TGEV) 
Scotophilus bat coronavirus 512 
Porcine epidemic diarrhoea virus (PEDV) 
Human coronavirus 229E  
Human coronavirus NL63 
Rhinolophus bat coronavirus HKU2 
Feline coronavirus (FCoV)  
BETACORONAVIRUS 
Murine Coronavirus (MHV) 
Human coronavirus HKU1 
Betacoronavirus 1 
SARS coronavirus 
Bovine coronavirus (BCoV) 
Tylonycteris bat coronavirus HKU4 
Pipistrellus bat coronavirus HKU5 
GAMMACORONAVIRUS 
Beluga whale coronavirus SW1 
Avian coronavirus (IBV) 
DELTACORONAVIRUS 
Munia coronavirus 
Bulbul coronavirus 
Thrush coronavirus 
 
The coronaviruses are classified into four genera: the alpha, beta, gamma and Deltacoronaviruses. Here, IBV is 
referred to as avian coronavirus. Adapted from the International Committee for the Taxonomy of Viruses (ICTV), 
Coronavirinae Figures, 2009. 
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1.3 Infectious bronchitis virus (IBV) 
IBV is the prototype Gammacoronavirus, infecting domestic chickens (Gallus gallus) in both 
commercial flocks for food production and so-called “backyard” settings. It is a highly 
contagious pathogen spread by droplet transmission. Virus infection causes severe disease 
in poultry and can lead to fatal secondary bacterial infections, resulting in massive economic 
losses in the poultry industry worldwide. Frequent mutations in its large genome mean the 
virus exists as many different serotypes, with new variants continuously emerging (de Wit et 
al., 2011).  
There is no universally agreed method for classifying IBV types, creating difficulty in arranging 
the viruses into groups and analysing their phylogenetic relationships. Historically, viruses 
were classified according to their pathologies and in vitro immunology, into pathotypes and 
serotypes respectively. More recently, genotyping has become a more widely used method 
of classification, achieved through RT-PCR analysis of the nucleotide sequences of gene 
encoding the attachment protein, the spike (S) gene (Lee et al., 2003, Handberg et al., 1999).  
Serotyping has become less practical as a method of differentiation due to the constant 
emergence of new variants. Additionally, minor sequence variation in the S gene can lead to 
major changes in the serotype of the virus (Cavanagh et al., 1992).  With the high rate of 
mutation observed in IBV and the fact that each serotype requires a validated neutralisation 
test, this method is unable to accurately classify all new variants. IBV strains can also be 
classified into protectotypes, based on the complete immune response to infection. While 
this method provides the most information about the efficacy of vaccine candidates, 
expensive resources and a lot of time are required to achieve accurate classification, making 
it impractical on a large scale (reviewed by de Wit et al., 2011).   
Recently, a method was proposed for centralising and streamlining the classification process 
of IBV strains, based on grouping viruses by their S phylogeny. Within this system, 32 distinct 
6 
 
viral lineages have been identified, making up 6 different genotypes of IBV (Valastro et al., 
2016).  
Two of the most well studied strains of IBV both belong to the Massachusetts (Mass) 
serotype: M41 and Beaudette. These strains are both adapted to replication in cell culture 
and so are easier to propagate and characterise in vitro compared to many of the circulating 
field strains. Other widely studied serotypes include Connecticut and Arkansas (Ark) types. 
Vaccines against IBV are often based on strains within these genotypes, all of which originate 
from the USA. Viruses in the originally European 4/91 genotype have been identified in 
affected regions across the world, including Latin America, the Middle East and more 
recently, Japan (reviewed by Bande, 2017). Viruses belonging to the QX and Q1 genotypes 
are also prominent throughout the world and have caused major problems in infected flocks 
since their original isolation in China in the 1990s, with disease characterised by 
proventriculitis and oviduct swelling (YuDong et al., 1998). The disease symptoms associated 
with infection with these serotypes differ greatly from the cold-like respiratory symptoms 
associated with Mass infections, highlighting the variety of ways in which IBV can cause 
economic losses and reiterating the importance for effective detection and control.  
1.4 Genome organisation:  
Coronaviruses are large, enveloped viruses with single stranded (ss) positive sense RNA 
genomes ranging from 26-31kb in length, the largest of any RNA virus. The IBV genome is 
27.6kb (Boursnell et al., 1987). Organisation of the genome is detailed in Figure 1.2. 
Coronavirus genomes are polyadenylated at the 3′ end and include a 5′ methylated cap. 
Untranslated regions (UTRs) are found at both the 5' and 3' ends of the genome and have 
been implicated in regulating replication and translation through the presence of cis-acting 
sequences (Senanayake and Brian, 1999, Yang and Leibowitz, 2015).  
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Figure 1.2: Coronavirus genome organisation. The 5′ two thirds of the genome encode the 
two replicase polyproteins (pp1a and pp1b). The 3′ third encodes the structural and 
accessory genes. The genome depicted at the top is MHV and examples of each genus of 
coronavirus are detailed below. IBV is the representative for the gammacoronaviruses. 
Figure taken from Fehr and Perlman, 2015.  
 
The 5′ two thirds of the coronavirus genome are comprised of the replicase gene which is 
translated into two large polyproteins (pp) and subsequently cleaved by virus-encoded 
proteases into 16 non-structural proteins (nsps), performing a variety of functions in the 
replication cycle. The nsps and their related functions are detailed in Table 1.2. The replicase 
genes of IBV and other gammacoronaviruses encode only 15 nsps as they do not encode 
nsp1; however nsp2-16 correspond to the proteins expressed in other coronaviruses. 
Notable functions of the nsps include the exonuclease activity of nsp14, the RNA-dependent 
RNA polymerase (RdRp) encoded in nsp12 and the methyltransferase activity exhibited by 
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nsp16, involved in the capping mechanisms required for translation of viral RNA (Ziebuhr et 
al., 2000). The exact function of nsp11 is unclear but there have been studies showing that 
the cleavage events that result in the formation of nsp11 and 12 are not required for viral 
replication in vitro (Fang et al., 2008). The 3′ third of the genome includes the genes encoding 
the structural and accessory proteins. 
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Table 1.2: List of non-structural proteins (nsp) expressed from the coronavirus replicase 
gene.  
 
The function or putative function of each protein is listed. IBV does not express nsp1. Adapted from Fehr and 
Perlman, 2015 (Fehr and Perlman 2015). 
Protein Function 
nsp1 Promotes cellular mRNA degradation and blocks host cell translation, results in 
blocking innate immune response 
nsp2 No known function, binds to prohibitin proteins 
nsp3 Large, multi-domain transmembrane protein, activities include: 
 Ubl1 and Ac domains, interact with N protein 
 ADRP activity, promotes cytokine expression 
 PLPro/Deubiquitinase domain, cleaves viral polyprotein and blocks 
host innate immune response 
 Ubl2, NAB, G2M, SUD, Y domains, unknown functions 
nsp4 Potential transmembrane scaffold protein, important for 
proper structure of DMVs 
nsp5 Mpro, cleaves viral polyprotein 
nsp6 Potential transmembrane scaffold protein 
nsp7 Forms hexadecameric complex with nsp8, may act as 
processivity clamp for RNA polymerase 
nsp8 Forms hexadecameric complex with nsp7, may act as processivity clamp for 
RNA polymerase; may act as primase 
nsp9 RNA binding protein 
nsp10 Cofactor for nsp16 and nsp14, forms heterodimer with both and stimulates 
ExoN and 2-O-MT activity 
nsp11 Unknown function 
nsp12 RdRp 
nsp13 RNA helicase, 5′ triphosphatase 
nsp14 N7 MTase) and 3′-5′ exoribonuclease, ExoN; N7 MTase adds 5′ cap to viral 
RNAs, ExoN activity is important for proofreading of viral genome 
nsp15 Viral endoribonuclease, NendoU 
nsp16 2′-O-MT; shields viral RNA from MDA5 recognition 
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1.5 Coronavirus structural proteins  
Four structural proteins are encoded in the 3′ end of the coronavirus genome. They include 
the spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins and are arranged 
in the order S-E-M-N. They perform a variety of functions during infection from attachment 
and fusion to genome packaging and virus release. 
1.5.1 Envelope (E) protein  
The E protein is a small membrane protein between 76 and 109 amino acids in size. It has a 
single hydrophobic domain and is present in small quantities in the viral membrane (Ruch 
and Machamer, 2012). It is thought to be a transmembrane protein involved in a number of 
viral processes during infection. Similar to that of the influenza M2 protein and the SH 
protein of respiratory syncytial virus (RSV) (Alvarado-Facundo et al., 2015, Gan et al., 2012), 
ion channel activity has been observed in the coronavirus E protein (Verdia-Baguena et al., 
2012, Nieto-Torres et al., 2015b). This activity is a common target for antivirals, as inhibition 
of the ion channel activity has been shown to restrict coronavirus replication (Wilson et al., 
2006, Nieto-Torres et al., 2015a). Roles for the E protein have been suggested in MHV 
assembly and exit (Ye and Hogue, 2007). The protein has also been implicated in 
pathogenesis in SARS-CoV (DeDiego et al., 2007).  
1.5.2 Membrane (M) protein  
The M protein has three transmembrane domains. It is a small protein of around 220 amino 
acids and is the most abundant protein in the virus membrane (Klumperman et al., 1994). 
The M protein is thought to be involved in virus assembly and also interacts with the other 
viral proteins (Corse and Machamer, 2003). It has been suggested that the protein exhibits 
two different conformations in order to function in creating the shape of the virus particle 
and interacting with the N protein (Neuman et al., 2011). During virus assembly, M self-
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associates, incorporates S into the virion and also selectively packages the section of N that 
interacts with the RNA genome.  
1.5.3 Nucleocapsid (N) protein  
The coronavirus N protein is a basic protein produced in large quantities during infection 
(Lomniczi and Morser, 1981). The IBV N protein consists of 409 amino acids. It performs 
multiple functions in the virus lifecycle including encapsulating the genomic RNA through 
interactions with its N-terminus, regulating host translation and facilitating efficient viral 
transcription (Hurst et al., 2005, McBride et al., 2014). N-mediated interference with the host 
immune response to IBV infection has also been suggested (Hu et al., 2017, Chen and Ly, 
2017).  
1.5.4 Spike (S) protein  
The coronavirus S protein is a  type I membrane glycoprotein that protrudes from the surface 
of the virion, providing the characteristic corona morphology (Bosch et al., 2003). It is the 
largest protein encoded in the genome and is responsible for both attachment to host cells 
and fusion of viral and cellular membranes. The size of the protein varies between 
coronaviruses; the IBV S protein is 1162 amino acids in length and has a molecular weight of 
approximately 180 kilodaltons (kDa). 
In some coronaviruses, including IBV and MHV, the S protein is cleaved by furin during 
protein synthesis into two non-covalently linked subunits termed S1 and S2. In the Beaudette 
strain of IBV, this cleavage event occurs at the amino acid sequence RRFRR (Cavanagh et al., 
1986), although the exact sequence varies among strains (Jackwood et al., 2001). IBV S1 is 
approximately 519 amino acids long and makes up the globular head of the glycoprotein, 
containing the receptor binding domain (RBD). The S1 subunit consists of two distinct 
domains, the N-terminal domain (S1-NTD) and the C-terminal domain (S1-CTD). The RBD for 
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IBV has previously been mapped to amino acids in the NTD. More recent evidence has shown 
that IBV S1-CTD also contains receptor binding motifs, similar to coronaviruses belonging to 
the other genera (Shang et al., 2018). IBV S2 (625 amino acids) makes up the stalk portion of 
the protein and has been implicated in cellular tropism (Bickerton et al., 2018). Morphology 
of coronavirus virions and the structure of their S genes are shown in Figure 1.3.  
 
 
 
 
 
 
 
Figure 1.3: Coronavirus virion morphology and S gene structure. (A) Schematic 
representation of a coronavirus virion with S protein projections shown in purple, M protein 
shown in green, E protein shown in yellow and N protein shown in blue surrounding the RNA 
genome. (B) Electron micrograph image of IBV virions, approximately 120nm in diameter, 
with clear spike-like projections in a characteristic corona formation.  EM image taken from 
Lanser and Howard, 1980 (Lanser and Howard, 1980). (C) Schematic representation of a 
coronavirus S gene. The S1 subunit encodes the signal sequence and the receptor binding 
domain (RBD). The S2 subunit encodes two heptad repeat (HR) regions, the transmembrane 
domain and the cytoplasmic tail. Gene sections are not to scale.  
 
A B 
C 
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The S protein consists of a signal sequence, stated as amino acids 1-18 in the M41 strain 
(Promkuntod et al., 2014) at the N-terminal end followed by the ectodomain, 
transmembrane (TM) domain and cytoplasmic tail (CT). The latter regions are responsible for 
anchoring the protein to the virion membrane. The ectodomain contains a furin cleavage site 
(S1/S2) and two heptad repeat (HR) regions. The HR regions are involved in protein monomer 
oligomerisation (Groot et al., 1987). During infection, the protein localises to the 
endoplasmic reticulum (ER) (Delmas and Laude, 1990) and is then translocated to the ER-
Golgi intermediate compartment (ERGIC) and Golgi for further processing including 
glycosylation (Cavanagh, 1983). Oligosaccharides are added to the protein surface via 
specific asparagine residues as part of the N-linked glycosylation process of protein 
modification (described in Sections 1.8 and 9).  
Attachment to the host cell and processing by cellular proteases results in major 
conformational changes in the structure of the S glycoprotein leading to fusion of the viral 
and cellular membranes (Walls et al., 2017, Belouzard et al., 2012). The post-fusion 
conformation of the protein must be achieved in order for fusion and entry to occur. The 
virus is thought to enter the cell by endocytosis which, in the case of IBV, is pH dependent 
(Chu et al., 2006). The viral fusion peptide (located in the S2 subunit) is then exposed and 
inserted into the membranes of vesicles, mediating fusion with the viral envelope (Bosch et 
al., 2003).  The result of these fusion events is the release of the ribonucleoprotein (RNP) 
containing the viral genome into the cytoplasm, beginning the process of genome 
replication.  
Further understanding of the molecular mechanisms employed by the S protein to mediate 
attachment and fusion have been revealed recently. The structures of certain coronavirus S 
proteins have recently been elucidated using electron microscopy (EM) techniques. Walls et 
al have studied the S protein of the human coronavirus NL63 (HCoV NL63) and MHV using 
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cryo-EM, revealing the pre-fusion structure of the protein (Walls et al., 2016a, Walls et al., 
2017). Others have also identified key conformational changes required to allow proper 
receptor binding and fusion in the SARS-CoV S glycoprotein (Gui et al., 2017).  
More recently still, the structure of the IBV S protein ectodomain was solved using similar 
techniques. The protein structure of the S protein of a pathogenic IBV strain (M41) was 
revealed by Shang et al in order to investigate functional evolution. This study investigated 
the structure of the S proteins of the different coronavirus genera, providing crucial insight 
into how these proteins have diverged, allowing such a wide host range between viruses 
(Shang et al., 2018). Their results revealed a so called evolutionary spectrum of coronavirus 
S proteins, in which gamma- and betacoronavirus S1-NTDs appeared to be the most evolved 
compared to the other genera. This study postulates that coronavirus S1-NTDs are evolved 
from host galectin molecules, in order to imitate host proteins and avoid recognition by the 
immune system. They identified similarities in the structures of all coronavirus S1-NTDs in 
the structural folds within the protein. Differences were identified between the proteins of 
different genera, in that gamma and Betacoronavirus S1-NTDs have evolved to include partial 
ceilings covering the sugar binding site within this domain. This is thought to function as 
protection from the immune response, however the ceiling in the Betacoronavirus MHV has 
further evolved to become a binding partner for a novel protein receptor. Through the 
investigations of the S protein structure, this study also identified 20 sites at which the 
protein is glycosylated. This study was the first of its kind to describe in detail the ectodomain 
of a Gammacoronavirus S protein, with two distinct domains in S1, and two HR regions and 
the fusion peptide (FP) located in the S2 subunit.  
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1.5.5 S1 subunit  
The S1 subunit is responsible for attachment to host cells through interactions with cellular 
receptors. As described previously, the receptor with which the IBV S protein interacts 
remains unknown however the RBD has been mapped to amino acids 19-272 in M41 
(Promkuntod et al., 2014). Other coronaviruses are known to interact with a variety of 
molecules on the surface of host cells. The S protein of SARS-CoV binds to human angiotensin 
I converting enzyme 2 (ACE2) (Li et al., 2003). MERS-CoV S1 interacts with specific residues 
of dipeptidyl peptidase 4 (DPP4) to enter the cells of susceptible hosts including humans and 
camels (Raj et al., 2013). MHV enters cells through interactions with the adhesion molecule 
carcinoembryonic antigen-cell adhesion molecule (CEACAM1), the first coronavirus 
receptor to be identified (Belouzard et al., 2012, Dveksler et al., 1991). The receptor for IBV 
and other gammacoronaviruses is yet to be identified. Interactions with sialic acids have 
been suggested as a possible mechanism for virus entry (Li, 2015, Schwegmann-Wessels and 
Herrler, 2006, Winter et al., 2006). For other avian gammacoronaviruses such as the closely 
related turkey coronavirus (TCoV), recent studies have also identified glycan receptors as 
possible interacting partners during virus entry (Wickramasinghe et al., 2015).  
The S1 subunit is the main antigenic target of IBV, against which the host immune response 
is directed (Kant et al., 1992). There is huge diversity among the S1 sequences of IBV strains, 
rendering broad cross-protection through vaccination near-impossible. IBV detection, 
genotyping and strain differentiation are achieved through sequencing of the S1 subunit 
(Ariyoshi et al., 2010, De Wit, 2000). Figure 1.4 shows an example of the phylogenetic 
relationships between a variety of IBV strains based on their S1 nucleotide sequences, 
highlighting the vast variability between genotypes (Manswr et al., 2018).  
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Figure 1.4: Example of phylogenetic relationships of a variety of IBV strains based on full 
(black triangles) and partial (grey circles) amino acid sequences of the S1 gene. Field strains 
collected in the Middle East and reference strains were analysed based on the sequences of 
the S1 gene. Figure taken from Manswr et al (2018).   
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1.5.6 S2 subunit  
The primary function of the S2 subunit is fusion of the viral and cellular membranes following 
attachment to host cells. This segment of the protein contains two HR regions. Mutations 
within these regions have been shown to affect fusion activity. Disruption of the leucine-rich 
motifs within the HR regions can affect protein oligomerisation and abolish cell to cell fusion 
(Luo et al., 1999). In other studies, mutations in HR1 increased fusion activity and influenced 
coronavirus infectivity in cell culture (Yamada et al., 2009). S2 fusion mechanisms have been 
investigated as a possible option for treatment of MERS-CoV infections, through action of 
synthetic HR peptides (Lu et al., 2014).  
As well as attachment and fusion, the IBV S protein as a whole is known to be a determinant 
of in vitro cellular tropism, as shown by the generation of recombinant viruses with modified 
S proteins altering the tropism of the resultant virus. This was demonstrated through the 
insertion of the M41 S gene into the Beaudette genome, resulting in the loss of the extended 
host tropism usually observed with Beaudette strains (Casais et al., 2003). More recently, 
tropism was found to be directly influenced by the S2 subunit. Beaudette strains are known 
to infect and replicate in Vero cells as well as primary avian cells, a feature that has been 
attributed to the presence of a secondary cleavage site in the S2 sequence, located within 
the amino acid motif RRR at position 690 (Yamada and Liu, 2009). This motif is known as the 
S2′ cleavage site and has been studied by several groups in the context of host tropism, 
where the insertion of this specific sequence into the S protein allowed virus replication in 
classically non-permissive cells (Bickerton et al., 2018, Madu et al., 2007). S2′ cleavage has 
been observed in other coronaviruses from different genera, including MERS-CoV (Millet et 
al., 2016). 
Compared to the S1 subunit, the sequences of IBV S2 genes are much more conserved 
between strains. Epitopes recognised by neutralising antibodies have been located in the S2 
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subunits of the SARS-CoV and MERS-CoV S proteins (Keng et al., 2005, Yang et al., 2014). The 
presence and conservation of these epitopes has implications for cross-protection by 
vaccination. 
1.6 IBV accessory proteins and functions 
IBV expresses four well known and one more recently identified accessory proteins, encoded 
by three genes termed 3, 4b and 5. 3a and 3b and 5a and 5b are expressed from gene 3 and 
gene 5, respectively. Although they are non-essential for in vitro replication, recent studies 
have shown reductions in pathogenicity following deletions in the accessory genes 3 and 5 
(Laconi et al., 2018, van Beurden et al., 2018). IBV 3a has been implicated in modulation of 
the interferon (IFN) response to IBV infection (Kint et al., 2015). IBV 5b has been implicated 
in host cell shutoff (Kint et al., 2016).  Gene 5 as a whole has been shown to be dispensable 
for in vitro replication (Casais et al., 2005) and has more recently been studied  in the context 
of pathogenicity and vaccination (van Beurden et al., 2018). The transcript for a fifth, IBV-
specific accessory gene was identified more recently. The function of this putative protein, 
termed 4b, is still unknown  (Bentley et al., 2013).  
1.7 Coronavirus genome replication and lifecycle  
Coronavirus replication takes place in the cytoplasm following virus entry into the host cell 
by endocytosis. Each stage of the coronavirus lifecycle is outlined in Figure 1.5.  
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Figure 1.5: Schematic representation of a coronavirus replication cycle. The virus enters the 
cell by endocytosis following attachment and fusion via the S protein (A). The genome is then 
released into the cytoplasm (B) initiating translation of ORF1a and b and generation of the 
nested set of sub-genomic mRNAs (C) encoding the accessory and structural proteins (D). 
The structural proteins are transported to the ER via the secretory pathway and then to the 
ERGIC where the genome is packaged by the nucleocapsid (N) protein and structural proteins 
are incorporated into the virions (E). Mature virions are transported to the Golgi and are 
released from the cell by budding (F). Schematic courtesy of Dr Ross Hall.  
 
1.7.1 Virus entry and cellular tropism  
As previously discussed, coronaviruses enter the cell through interactions with a range of 
host cell receptors. Since the receptor for IBV is still unidentified, the exact mechanisms of 
virus entry are not well defined. It has been shown that major conformational changes occur 
within coronavirus S proteins following attachment to the appropriate receptor, which are 
essential for the induction of fusion and thus completion of the entry process (Walls et al., 
2017, Matsuyama and Taguchi, 2009).  
The post-fusion structure of the S protein is induced by cellular factors such as exposure to 
proteases (Li et al., 2006, Xu et al., 2004). Cleavage of the gammacoronavirus S protein into 
its two functional subunits S1 and S2 is mediated by furin. However this cleavage event is not 
required in all coronaviruses and is rarely seen in alpha- and betacoronaviruses. 
Susceptibility to secondary cleavage events by cellular proteases such as trypsin, have been 
implicated in cellular tropisms of various coronaviruses including IBV, where the presence of 
the S2′ site is suggested to be responsible for the extended host tropism of the Beaudette 
strain (Belouzard et al., 2012, Millet and Whittaker, 2015). The S2′ site has also been 
associated with heparan sulphate (HS) binding (Madu et al., 2007). The combination of the 
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S2′ site and the protease environment of the host cell are thought to heavily influence 
coronavirus tropism. Extended tropism as a result of S protein processing by exogenous 
cellular proteases has also been observed in MERS-CoV (Park et al., 2016). Increases in 
pathogenesis and virulence in SARS-CoV have also been associated with proteolytic 
processing of the S protein, with reductions in virus neutralisation observed following 
cleavage by serine proteases (Glowacka et al., 2011).  
The range of in vitro tropisms exhibited by IBV strains varies quite significantly. Field strains 
are often only capable of replicating in ex vivo organ cultures or even in embryonated eggs, 
creating difficulty during attempts to characterise the strains in laboratory settings. Strains 
within the same serotype can exhibit very different tropisms. This can be demonstrated by 
two cell culture-adapted strains of the Massachusetts serotype where, in contrast to the 
extended tropism of Beaudette, M41 is only able to grow in primary avian cells such as chick 
kidney (CK) cells.  Alterations in the cellular tropism of IBV strains have been demonstrated 
using recombinant viruses expressing heterologous S proteins (Hodgson et al., 2004, 
Armesto et al., 2011). Other factors such as temperature are also thought to influence 
coronavirus tropism (Dubois-Dalcq et al., 1982). 
1.7.2 Transcription and translation 
Following virus entry and genome release, viral replication begins. The first stage in 
coronavirus genome replication is the translation of the proteins encoded by the replicase 
gene, the largest gene in the genome comprising two open reading frames (ORF) known as 
ORF 1a and ORF1b. These two ORFs encode polyproteins pp1a and pp1ab. Expression of both 
of these proteins is achieved through use of a slippery sequence and an RNA pseudoknot, 
causing a ribosomal frameshift from ORF1a to ORF1b. The pseudoknot is unwound by the 
ribosome and translation continues until a pp1a stop codon is reached. If the pseudoknot 
interrupts elongation and the ribosome pauses on the slippery sequence, a -1 frameshift 
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occurs in which the reading frame moves back by one nucleotide. Following this frameshift 
the ribosome is able to disrupt the pseudoknot and move on to translate the pp1b ORF (Fehr 
and Perlman, 2015; Sawicki et al., 2007).  
Coronavirus pp1a and pp1ab encode 16 non-structural proteins (nsps) or 15 in the case of 
IBV and other gammacoronaviruses. Following translation, the polyproteins are cleaved by 
the viral papain-like proteases (PLpro) encoded in nsp3 into the remaining nsps, the functions 
of which are summarised in Table 1.2. Additionally, nsp5 acts as a 3C-like protease (3CLpro), 
which has been shown to be essential for Betacoronavirus translation (Lu et al., 1995).  
Some of the nsps assemble to form the replication transcription complexes (RTC), where 
nascent RNA is synthesised. During replication, negative sense sub-genomic (sg) RNAs are 
generated through discontinuous transcription. Negative sense full length genome 
templates are simultaneously produced by continuous transcription (Sawicki et al., 2007). 
The mechanisms involved in these processes are not yet fully elucidated. However it is known 
that coronavirus transcription involves transcription regulatory sequences (TRSs), which are 
short sequences of 6-8 nucleotides (Hiscox et al., 1995, Sola et al., 2005). In IBV the sequence 
is usually CUUAACAA. There is a TRS at the 5′ end of the genome known as the TRS leader 
sequence (TRS-L) and at the beginning of each ORF downstream of ORF1ab, known as the 
TRS body sequence (TRS-B).  In most cases, the TRS-B preceding each individual gene is 
complementary to the 5′ TRS-L, however there are exceptions depending on the nature of 
the TRS in that some are canonical and some are non-canonical. Secondary structures of the 
TRS-B are also thought to be involved (Sawicki and Sawicki, 2005, Bentley et al., 2013).  
Like all positive-sense RNA viruses, coronaviruses are known to induce extensive membrane 
rearrangements upon infection of the host cells (Mackenzie, 2005). Double membrane 
vesicles (DMVs) serve as the location for the RTCs in infected cells. These RTCs are the 
structures in which genome replication takes place (Miller and Krijnse-Locker, 2008). DMVs, 
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spherules and zippered ER can all be observed during IBV infection (Maier et al., 2016, Maier 
et al., 2013). The RTC initiates transcription at the 3′ end of the viral genome and proceeds 
upstream until a TRS-B is encountered and transcription pauses. At this point the process can 
either continue until another TRS-B is detected or undergo a translocation to the 5′ end, 
resulting in the presence of a so-called anti-leader sequence at the 3′ end of the newly 
synthesised sgRNA. The process culminates in a selection of sgRNAs of different lengths. 
Negative sgRNAs and full length genome transcripts then serve as templates for the 
generation of positive sense sgRNAs and entire viral genome copies. The process of genome 
transcription is summarised in Figure 1.6.  
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Figure 1.6: Coronavirus genome transcription. Coronavirus genomic RNA is transcribed by 
both continuous and discontinuous transcription, initiated at the 3′ end of the genome by 
the viral replication-transcription complex (RTC). It continues upstream until a transcription 
regulatory sequence-body (TRS-B) is detected and transcription either continues (continuous 
transcription) or undergoes a translocation to the TRS-Leader sequence (TRS-L) at the 5′ end 
of the genome (discontinuous transcription). The process of discontinuous transcription 
generates a nested set of negative sense sub-genomic RNAs (sgRNAs) which act as templates 
for positive sense sgRNAs. These are translated into viral proteins. Continuous transcription 
generates negative sense copies of the viral genome which are used as templates for the 
synthesis of full-length, positive sense single stranded RNA genomes (Sawicki et al. 2007; 
Yang and Leibowitz 2015).  
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1.7.3 Virus assembly and exit  
The structural proteins (S, E, M and N) are translated from the sgRNAs, as are the accessory 
proteins. Following translation, the structural proteins are transported to the ER and then 
via the secretory pathway to the ERGIC where mature virions are formed (Fehr and Perlman, 
2015, Krijnse-Locker, 1994). The E and M proteins are known to be involved in coronavirus 
assembly and exit (Vennema et al., 1996, Neuman et al., 2011, Ruch and Machamer, 2011). 
Once mature virions are completely assembled they are transported to the cell surface and 
released by exocytosis. 
 
1.8 N-linked protein glycosylation  
N-linked glycosylation is a form of co- and post-translational modification where 
oligosaccharides are attached to proteins at the asparagine (Asn/N) residue in the sequence 
Asn-X-Serine (Ser/S)/Threonine (Thr/T), where X represents any amino acid except Proline 
(Pro/P). The oligosaccharide core is synthesised and attached to the appropriate Asn residue 
on a nascent protein in the ER before the protein moves through the secretory pathway to 
the Golgi for further processing and enzymatic trimming.  
The process of N-linked glycosylation of proteins in the ER can be broadly divided into two 
stages. Firstly, the core glycan is assembled on the membrane-anchored ER lipid dolichol 
phosphate (Dol-P) in the cytosol (Schwarz and Aebi, 2011). This begins with the attachment 
of the initial N-Acetylglycosamine (NAc) to the Dol-P followed by the sequential addition of 
mannose molecules. At this point the oligosaccharide is flipped into the luminal side of the 
ER by an enzyme known as flippase (Rush, 2015, Sanyal and Menon, 2009). This is followed 
by a series of assembly steps involving various glycosyltransferases which catalyse the 
transfer of more mannose and glucose molecules to the growing glycan, resulting in the 
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preparation of a tetradecaoligosachharide (Glc3Man9GlcNAc2) that is ready for transfer onto 
the appropriate Asn residue in the nascent peptide. The second stage of N-linked 
glycosylation in the ER occurs when the enzyme oligosaccharyltransferase (OST) catalyses 
the covalent linkage of the core Glc3Man9GlcNAc2 structure to the amide group of the Asn in 
suitable N-glycosylation seqons (Asn-X-Ser/Thr) (Ferris et al., 2014, Hubbard, 1988). 
Following this reaction, ER mannosidases act on the glycan structures to remove and add 
specific sugars in a step-wise fashion until the protein is correctly folded and ready to be 
transferred to the Golgi for further processing. The processes involved in N-glycan core 
assembly in the ER are summarised in Figure 1.7. 
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Figure 1.7: A simplified schematic detailing synthesis of the N-glycan core oligosaccharide 
in the ER. 1. Generation of the oligosaccharide core begins in the cytosol where the initial 
oligosaccharide composed of N-Acetylglucosamine and glucose (GlcNAc) is assembled onto 
dolichol phosphate (Dol-P), which resides in the membrane of the ER. These reactions are 
catalysed by glycosyltransferases, using uridine diphosphate (UDP)-GlcNac and UDP-Man as 
substrates from which the GlcNAc and mannose molecules are donated. 2. Following several 
reactions in which sugar molecules are added sequentially to the Dol-P GlcNAc molecule, the 
core is “flipped” into the ER lumen where more molecules are added to the core structure. 
This is catalysed by an enzyme known as flippase. 3. The oligosaccharide is transferred to 
nascent protein (blue squiggle) at an appropriate Asn residue through interaction with the 
oligosaccharyltransferase (OST) complex. 4. Once attached, the glycan core undergoes a 
series of trimming reactions, catalysed by enzymes such as ER α-mannosidase I before 
transportation to the Golgi for further trimming and processing. Figure adapted from Aebi, 
2013 (review).  
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As the glycans are attached and processed in the ER, the folding protein must also pass 
certain check-points in order to continue and avoid being directed to the ER-associated 
degradation (ERAD) pathway (protein folding and quality control mechanisms reviewed by 
Xu and Ng, 2015). After the first glucose residue is removed from the glycan chain on the 
luminal side of the ER, the protein enters the calnexin cycle, in which the protein is bound by 
other enzymes and factors in order to ensure it achieves a native conformation and the 
correct disulphide bonds. This results in the engagement of the enzyme UDP-
Glc:glycoprotein glucosyltransferase I (UGGT1) which selectively binds to N-glycans which 
have been subjected to the action of different glucosidases and are now fully deglucosylated 
(Braakman and Bulleid, 2011). Once bound, UGGT1 determines whether the protein has 
achieved the correct conformation. If the protein is correctly folded, it is released and 
allowed to proceed to the Golgi for further trimming and processing. Those that are not in 
the correct native conformation are reglucosylated (with the addition of a glucose molecule), 
and re-entered into the calnexin cycle until the correct conformation is achieved, or until  
quality control mechanisms interrupt the cycle and the protein is targeted for degradation 
(Maattanen et al., 2010). The involvement of N-glycans in these processes is vital to ensure 
that the nascent protein folds correctly and can thus exit the calnexin cycle in order to 
progress through to the Golgi along the secretory pathway (Hebert and Molinari, 2012). 
Further processing of glycans occurs here, where glycan structures are shaped and trimmed 
by mannosidase II (reviewed by Rose (2012)) . This results in the formation of a range of 
glycan structures on the surface of proteins. The stacking formation of the Golgi 
compartments is thought to be crucial in protein glycosylation pathways. It has been shown 
that disruption of the factors that affect stacking can have dramatic effects on the numbers 
of glycans present on the proteins (Zhang and Wang, 2016, Veenendaal et al., 2014).  
After emerging from the Golgi, the newly glycosylated proteins move through the Golgi 
network where their glycans are subjected to extensive trimming and processing by cellular 
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enzymes including mannosidases and glucosidases. The extent to which the glycans are 
trimmed results in the formation of different classes of glycan, divided into simple, complex 
and hybrid type depending on their composition. Simple, or high mannose, glycans are 
composed primarily of mannose molecules and are not subject to such extensive processing 
as the other classes of glycan (Schwarz and Aebi, 2011). The different classes of glycan arise 
in different compartments within the Golgi apparatus, owing to the fact that the enzymes 
which produce each type are only resident in specific places (for a comprehensive review of 
the location of enzymes within the Golgi apparatus, see Nilsson et al., 2009).  High mannose 
glycans are usually generated as a result of the actions of mannosidases in the cis- and 
medial-Golgi, whereas complex glycans, which comprise a more diverse range of sugar 
residues including sialic acids, are produced as a result of enzyme reactions leading to 
terminal glycosylation in the trans-Golgi (Stanley, 2011). Examples of each glycan type and 
the location in which they are produced is detailed in Figure 1.8.  
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Figure 1.8: Schematic representation of glycan structures generated as a result of 
processing in the Golgi. Simple or high mannose glycans consist mainly of mannose (orange) 
residues and are generated from enzymatic processing in the cis- and medial-Golgi. Hybrid 
glycans comprise a mannose branch and a branch with a more diverse range of sugar 
residues including galactose (pink), for example. These are produced due to processing by 
enzymes in the medial- and trans-Golgi. Complex glycans are produced in the trans-Golgi and 
are made up of a range of sugar molecules including glucose, galactose and sialic acids.  
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1.9 N-linked glycosylation in viral proteins 
The complexities of the processes described above highlight the key role that N-glycans play 
within the cycles of protein folding and quality control in mammalian cells. As viruses utilise 
and hijack the host cellular pathways to decorate their own proteins, naturally any deviation 
or interference with the mechanisms involved in these events can majorly disrupt the 
production of viral as well as host-derived proteins in infected cells. Alterations to this 
process by modifying the glycan processing pathways have been investigated in viral proteins 
such as influenza HA, where the addition of glycans to the protein resulted in vastly altered 
folding and intracellular transport (Gallagher, 1988). In addition to contributing to the correct 
folding patterns of the proteins, modified glycosylation can have major downstream effects 
on function and its interactions with other viral components.  
N-linked glycosylation has been extensively characterised in viruses such as influenza and 
human immunodeficiency virus (HIV-1). The gp120 envelope protein of HIV-1 is heavily 
glycosylated, with the weight of the attached oligosaccharides contributing to over half of 
the protein’s molecular weight. It is suggested that the glycans present on gp120 are involved 
in modulating immunogenicity. Research has been undertaken to investigate the 
involvement of the glycosylation profile of gp120 in virus infectivity and antibody mediated 
virus neutralisation. Removal of glycosylation at specific sites can increase sensitivity to 
neutralising antibodies in some cases without affecting viral infectivity (Wang et al., 2013).  
There is also a large body of work surrounding the glycosylation observed in the 
hemagglutinin (HA) protein of influenza. N-linked glycosylation has been shown to influence 
both virulence and antigenicity of influenza strains, as well as affecting viral replication in 
vitro (Baigent and McCauley, 2001, Sun et al., 2013). Removal of specific glycosylation sites 
in HA has been shown to increase the virulence of influenza in infected mice as well as 
increasing resistance to virus neutralisation (Reading et al., 2009), highlighting the 
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importance of individual sites as well as the overall levels of glycosylation in the protein. HA 
glycosylation is also implicated in the mechanisms of virus escape, exhibited by influenza 
viruses under immune pressures. In this case it is the addition of glycosylation sites that 
contributes to the distortion or masking of epitopes required for antibody recognition and 
neutralisation (Zhu et al., 2015, Ping et al., 2008).  
The involvement of N-linked glycosylation on the surface of viral proteins is known to 
contribute to the interactions between the viral protein and the components of the immune 
system. In HIV-1 gp120, neutralising epitopes are masked by the presence of N-linked 
glycans, thus providing a mechanism for immune escape (Wolk and Schreiber, 2006). In other 
viruses, such as classical swine fever virus (CSFV), removal of glycans from the envelope 
glycoproteins can reduce antibody interactions with specific epitopes resulting in reduced 
neutralisation, perhaps due to improper protein folding (Gavrilov et al., 2011). Changes in 
the glycosylation patterns of viral proteins can also interfere with receptor interactions and 
render the proteins more susceptible to targeting and recognition by various components of 
the host immune pathways. This is thought to be as a result of changes in the way epitopes 
are displayed or shielded from recognition by antibodies.  
The removal of glycans on the surface of the glycoprotein of lymphocytic choriomeningitis 
virus (LCMV), an arenavirus, was shown to result in an altered cellular tropism and overall 
viral fitness in neurons and macrophages, where the deletions led to increased viral 
replication in one and decreased replication in the other. Addition of glycans onto the already 
glycosylated protein resulted in reduced viral fusion, highlighting the balance required to 
achieve optimal protein function (Bonhomme et al., 2013).  
1.10 Coronavirus S glycoprotein glycosylation 
The coronavirus S glycoprotein exhibits an extremely high level of N-linked glycosylation, 
similar to what is observed in the HIV gp120 envelope glycoprotein (Binns et al., 1985). Other 
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viral proteins including the M protein in coronaviruses exhibit some level of glycosylation 
which may either be N- or O-linked (where the oligosaccharide is attached to a specific 
oxygen molecule as opposed to an asparagine). The SARS-CoV 3a protein is also known to be 
O-glycosylated (Oostra et al., 2006). While the most common form of glycosylation among 
the S glycoproteins of coronaviruses is N-linked, MHV S primarily exhibits O-linked 
glycosylation, with a very low level of N-linked sites present in some of the strains. (Yamada 
et al 2000).  
Glycosylation in the IBV S glycoprotein is exclusively N-linked. High numbers of potential 
glycosylation sites have been identified in a variety of coronaviruses (reviewed by Belouzard 
et al. 2012). The glycosylation observed in these proteins is thought to contribute to a 
number of processes during virus infection. Interactions between the SARS-CoV S protein 
and surface lectin molecules have been identified as an alternative entry mechanism (Jeffers 
et al., 2004, Han et al., 2007). These interactions suggest an important role for spike 
glycosylation in the mechanisms of vial entry. In the Alphacoronavirus TGEV, the glycan 
composition on the surface of the S and M proteins contributes to conformational changes 
that influence the antigenicity of these two viral proteins (Delmas and Laude, 1991).  
Glycosylation contributes to the overall structure and folding of viral proteins and as such 
can be utilised by the virus to mask specific epitopes recognised by neutralising antibodies 
during infection, as observed in HIV-1 infections. The dense glycan shield of the coronavirus 
S glycoprotein has been investigated in this context using cryo-EM techniques to model the 
structure of the protein and to elucidate epitopes obscured by the presence of 
oligosaccharides on the surface of the protein (Walls et al., 2016b).  
As with related coronaviruses, the structure and function of the glycan shield in IBV is 
beginning to be elucidated. Recent studies have identified a high density of glycans on the 
surface of the IBV S protein (Shang et al., 2018). The role of individual glycans has also been 
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assessed in certain strains, indicating possible functions in cell-cell fusion during in vitro 
replication (Zheng et al., 2018). Although the role of glycosylation in the context of in vivo 
infection is yet to be defined for IBV, differences between the predicted glycosylation profiles 
of certain strains have been identified, suggesting a possible correlation between these 
differences and variations in pathogenicity (Abro et al., 2012).  
 
1.11 IBV pathogenicity factors and determinants  
The molecular basis of IBV pathogenesis is not well characterised. Reverse genetics systems 
have been developed to study the role of specific genes in pathogenicity. A variety of 
methods are employed to modify the IBV genome, including the use of vaccinia virus (VV) as 
a vector for the IBV genome (Casais et al., 2001). Others use targeted RNA recombination to 
produce recombinant viruses (van Beurden et al., 2017).  
Pathogenicity in IBV and other coronaviruses is a multifactorial process, with many viral 
genes implicated in the development of disease. Using a variety of reverse genetics systems, 
the involvement of various individual genes in viral pathogenicity has been investigated. The 
replicase gene has been implicated in determining IBV pathogenicity through generation of 
a chimeric virus containing the replicase gene of the Beaudette strain and the structural and 
accessory genes of M41. The resultant recombinant virus was non-pathogenic in chickens, 
implying that the replicase gene was responsible for the attenuation (Armesto et al., 2009). 
The S gene has been identified as a virulence factor in MHV and has also been implicated in 
hepatotropism (Phillips et al., 1999). Modifications at specific sites in the S gene of TGEV 
have been shown to reduce pathogenicity, again indicating an important role for this gene 
in pathogenesis (Bernard and Laude, 1995). However there has been some contention 
surrounding the involvement of the IBV S gene in pathogenicity, with previous studies 
showing that the ectodomain of a heterogeneous strain of IBV was not sufficient to alter the 
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pathogenicity of the attenuated Beaudette strain (Armesto et al., 2011, Hodgson et al., 
2004).  
1.12 Infectious bronchitis (IB)  
The disease caused by IBV is known as infectious bronchitis (IB), affecting both commercial 
and back-yard flocks worldwide. The disease was first observed in chicks in the 1930s as a 
respiratory disease of unknown origin (Schalk and Hawn, 1931). IBV was later identified as 
the aetiological agent and since then the virus has been detected in countries across the 
world, with new variants constantly emerging (de Wit et al., 2011).   
IB manifests primarily as respiratory disease, characterised by clinical symptoms including 
snicking (sneezing), rales, watery eyes and lethargy. The primary site of IBV replication in 
infected birds is the epithelial cells of the trachea. This leads to damage to the cilia that line 
the organ, resulting in cessation of ciliary activity or ciliostasis. Consequently, secondary 
bacterial infection is a major problem following IB and is the reason for most of the mortality 
associated with the disease (Cavanagh and Naqi, 2003). 
In addition to respiratory disease, some strains are known to cause extensive pathology in 
the kidneys and oviducts of infected birds. Examples of this pathology are noted during 
infection with the QX strain of IBV, where infection causes fluid retention in the oviduct, 
leading to extreme swelling and a characteristic “penguin-like” stance in affected birds. IBV 
QX was first identified in the Qingdao region of China in 1996 after an outbreak of disease 
characterised by swelling of the stomach and oviducts (YuDong et al., 1998).  
As a result of the clinical symptoms of infection, IBV-infected broiler birds are prone to 
reduced weight gain and poorer meat quality. Affected laying birds produce fewer eggs and 
those that are produced are of lower quality, with soft shells and watery albumen. These 
clinical manifestations cause significant economic losses in the poultry industry worldwide. 
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IB is now the number one cause of infectious disease related loss in the poultry industry, 
with an economic burden of approximately £23million in the UK alone (DEFRA Report 2005).  
1.13 IBV vaccination strategies  
The vaccine industry for poultry production is worth upwards of $1billion, with the market 
for IBV vaccines comprising $350million alone. It is estimated that a 10% reduction in 
productivity as a result of IBV infection costs the global poultry industry £654million (Animal 
and Veterinary Vaccines Report, Markets and Markets 2017). Control of IBV is therefore 
essential in protecting both animal welfare and global food security.  
Live-attenuated vaccines are the most common method currently used to control IBV in 
commercial flocks. Inactivated or killed vaccines are used to a lesser extent and do not show 
the same levels of protection induced by live-attenuated vaccines. The most frequently used 
vaccine strains are derived from the Massachusetts serotype and include the H120 and H52 
strains, both originating from the Netherlands (Bijlenga et al., 2004). Protection offered by 
these vaccines is often short-lived and due to the ever-emerging new IBV serotypes, cross-
protection between strains is inadequate (Cook et al., 2012). As result, individual birds are 
likely to require multiple vaccines on multiple occasions during their short life-span.  
Generation of the vaccine strains is currently achieved through extensive serial passage in 
embryonated hens’ eggs. The process is lengthy and the mechanism of attenuation is largely 
undefined, highlighting the need for efficient, more targeted vaccine design. In addition, the 
process itself is quite inefficient, producing different vaccines in each batch. Achieving 
sufficient attenuation while retaining immunogenicity is also based entirely on trial and 
error, adding to overall inefficiencies (reviewed by Jordan, 2017).  
Numerous recombinant viruses have been investigated as an alternative method for vaccine 
generation, with the recombinant vaccines inducing protective immunity against IBV 
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challenge, including some expressing antigens from other pathogens (Yang et al., 2016, Wei 
et al., 2014). While the S gene has been the primary focus of vaccine development due to its 
immunogenic nature, some novel recombinant viruses with mutations elsewhere in the 
genome have been shown to induce protection. Deletions in the accessory genes in 
recombinant vaccine candidates are attenuated in vivo while still conferring protection 
against challenge (van Beurden et al., 2018). Further research is required to fine tune the 
process of generating sufficiently attenuated viruses which are still capable of inducing a 
protective immune response.  
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1.14 Thesis Aims and Objectives  
 
1. Characterise the glycosylation profile of the S protein of IBV. 
Objective 1: Use bioinformatics to identify potential glycosylation sites in the 
sequences of IBV S genes. Confirm glycosylation at these sites using mass 
spectrometry.  
Objective 2: Use deglycosylating enzymes and cellular inhibitors to identify glycan 
classes on the protein surface and assess their molecular weights through western 
blot.  Assess the effects of glycosylation inhibition on viral replication in vitro.  
Objective 3: Use reverse genetics to generate a recombinant virus with mutated 
glycosylation sites in the S glycoprotein. Characterise the virus in vitro to assess 
effects on replication and virus neutralisation.  
2. Use reverse genetics to investigate the role of the S protein in pathogenicity.  
Objective 1: Use reverse genetics to insert the S gene from a non-pathogenic strain 
of IBV into the genome of a pathogenic strain. Characterise the virus in vitro to assess 
changes in replication and tropism.  
Objective 2: Characterise the pathogenesis of the recombinant virus in vivo. Assess 
induction of clinical signs and ciliostasis. Use PCR to assess viral dissemination.  
3. Assess the effects of gene replacement on IBV pathogenicity.  
Objective 1: Use reverse genetics to insert the S gene from a pathogenic strain of 
IBV into the genome of a heterologous pathogenic strain. Rescue the virus in cells 
and characterise its replication patterns ex vivo.  
Objective 2: Assess the pathogenicity of the recombinant virus in vivo. Examine 
induction of clinical signs and ciliostasis and virus dissemination using PCR.  
4. Explore the cellular factors required for IBV infection.  
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Objective 1: Use exogenous trypsin to explore the potential for IBV infection in non-
permissive cells.  
Objective 2: Use recombinant viruses to assess the role of the S protein in 
temperature sensitivity.  
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Chapter 2: Materials and Methods 
 
2.1 Cell culture medium  
 
Table 2.1 CK cell culture medium  
Ingredient Volume Final concentration Supplier and catalogue 
number 
1XEagle’s minimum 
essential medium (EMEM) 
500ml 1X Sigma-Aldrich, M2279 
New-born bovine serum 
(NBBS) 50ml 10% v/v 
Sigma-Aldrich, N4762 
4-(2-hydroxyethyl)-1-
piperazineethanesulphonic 
acid 
(HEPES) 1M, pH 7.0-7.6  
5ml 1% v/v Sigma-Aldrich, H0887 
Penicillin/Streptomycin 
Solution (Pen/Strep) 
1ml Penicillin 10,000U 
Streptomycin 10mg 
Sigma-Aldrich, P4333 
Nystatin 2.5ml 25,000U Sigma-Aldrich, N1638 
 
 
Table 2.2: 1X N,N-bis[2-hydroxethyl]-2-Aminoethanesulfonic acid (BES) medium for 
culture of IBV in CK, DF-1 and Vero cells:  
 
Ingredient Volume Final concentration Supplier and catalogue 
number 
10X EMEM 50ml 1X Sigma-Aldrich, M0275 
Tryptose phosphate 
broth (TPB) 
50ml 10% v/v Sigma-Aldrich, T8159 
Bovine serum albumin 
(BSA) 
10ml 2% v/v Sigma-Aldrich, A7906 
BES (1M) 10ml 20 mM Sigma-Aldrich, B9879 
Sodium bicarbonate 
(NaHCO3) – 7.5% 
14ml 0.2% v/v 
Sigma-Aldrich, S8761 
L-Glutamine 5ml 2 mM Sigma-Aldrich, G7513 
Nystatin 2.5ml 25,000U Sigma-Aldrich, N1638 
Pen/Strep  0.5ml Penicillin 10,000U 
Streptomycin 10mg 
Sigma-Aldrich, P4333 
H2O 358ml ------ The Pirbright Institute Type 
II Endotoxin Free 
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Table 2.3: 2XBES for use in IBV plaque assays  
Ingredient Volume Final concentration Supplier and catalogue 
number 
10X EMEM 100ml 1X Sigma-Aldrich, M0275 
TPB 100ml 20% v/v Sigma-Aldrich, T8159 
BSA 20ml 4% v/v Sigma-Aldrich, A7906 
BES  20ml 40 mM Sigma-Aldrich, B9879 
NaHCO3 (7.5%) 28ml 0.4%  v/v Sigma-Aldrich, S8761 
L-Glutamine 5ml 2 mM Sigma-Aldrich, G7513 
Nystatin 2.5ml 25,000U Sigma-Aldrich, N1638 
Pen/Strep  1ml Penicillin 10,000U 
Streptomycin 10mg 
Sigma-Aldrich, P4333 
H2O 218.5ml ---- The Pirbright Institute Type II 
Endotoxin Free 
 
Table 2.4: Tracheal organ culture (TOC) growth medium  
Ingredient Volume Final concentration Supplier and catalogue 
number 
1XEMEM 500ml 1X Sigma-Aldrich, M2279 
HEPES 20ml 1% v/v Sigma-Aldrich, H0887 
Pen/Strep 1ml Penicillin 10,000U 
Streptomycin 10mg 
Sigma-Aldrich, P4333 
Nystatin 2.5ml 25,000U Sigma-Aldrich, N1638 
L-Glutamine  5ml  2mM Sigma-Aldrich, G7513 
 
Table 2.5: BHK-21 cell maintenance medium  
Ingredient Volume Final concentration Supplier and catalogue 
number 
1XGlasgow 
MEM (GMEM) 
500ml 1X Sigma-Aldrich, G5154 
Foetal bovine 
serum (FBS) 
5.5ml 1% w/v Sigma-Aldrich, F0926 
TPB  55ml 10% Sigma-Aldrich, T8159 
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Table 2.6: 1XGMEM for vaccinia virus (VV) infection of BHK-21 cells  
Ingredient Volume Final concentration Supplier and catalogue 
number 
1XGMEM 500ml 1X Sigma-Aldrich, G5154 
FBS 5.5ml 1% w/v Sigma-Aldrich, F0926 
TPB  55ml 10% v/v Sigma-Aldrich, T8159 
Pen/Strep 0.5ml Penicillin 5000U 
Streptomycin 5mg 
Sigma-Aldrich, P4333 
Nystatin 2.5ml 25,000U Sigma-Aldrich, N1638 
L-Glutamine  5ml 2mM Sigma-Aldrich, G7513 
 
 
Table 2.7: 1XEMEM for VV plaque purification in Vero cells 
Ingredient Volume Final concentration Supplier and catalogue 
number 
10XEMEM 50ml 2X Sigma-Aldrich, M0275 
FBS 25ml 10% v/v Sigma-Aldrich, F0926 
NaHCO3 (7.5%) 12.5ml 0.4% v/v Sigma-Aldrich, S8761 
Pen/Strep 1ml Penicillin 10,000U 
Streptomycin 10mg 
Sigma-Aldrich, P4333 
Nystatin 2.5ml 25,000U Sigma-Aldrich, N1638 
H2O 409ml ----- The Pirbright Institute Type II 
Endotoxin Free 
 
 
Table 2.8: 2XEMEM for VV plaque purification in Vero cells 
Ingredient Volume Final concentration Supplier and catalogue 
number 
10XEMEM 100ml 2X Sigma-Aldrich, M0275 
FBS 50ml 10% Sigma-Aldrich, F0926 
NaHCO3 (7.5%) 23ml 0.4% Sigma-Aldrich, S8761 
Pen/Strep 1ml Penicillin 10,000U 
Streptomycin 10mg 
Sigma-Aldrich, P4333 
Nystatin 2.5ml 25,000U Sigma-Aldrich, N1638 
H2O 311ml ----- The Pirbright Institute Type II 
Endotoxin Free 
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2.2 Cells and eggs 
All cells were provided by the Microbiological Services Unit at The Pirbright Institute 
(Compton Laboratory) or the Central Services Unit at The Pirbright Institute (Pirbright 
Laboratory).  
2.2.1 Primary chick kidney (CK) cells 
Chick kidney (CK) cells were prepared from 2-3 week old specific pathogen-free (SPF) Rhode 
Island Red (RIR) chickens using manual and trypsin disaggregation. CK cells were prepared 
and grown in CK growth medium (Table 2.1) and 1xBES medium (Table 2.2) during infections.   
2.2.2 Continuous cell lines 
 DF-1 cells are a continuous line of chicken embryo fibroblasts derived from 10 day 
old East Lansing eggs (Himly et al., 1998). Cells were maintained in Dulbecco’s 
modified essential medium (DMEM, Sigma) supplemented with 10% FBS unless 
otherwise stated.  
 Vero cells are a kidney epithelial cell line derived from the African green monkey. 
These cells were maintained in EMEM (Sigma) supplemented with 10% FBS.  
 Baby hamster kidney (BHK-21) cells are a cell line originally derived from 1 day old 
Syrian golden hamster kidneys and were maintained in BHK-21 cell maintenance 
medium or 1xGMEM (Table 2.6) during infection.  
2.2.3 Embryonated eggs 
VALO embryonated hens’ eggs (SPF) were delivered from VALO BioMedia GmbH and infected 
with IBV at 10 days old. SPF RIR eggs were provided by the Poultry Production Unit (PPU) at 
the Pirbright Institute, Compton Laboratory (2014-2015) and by the National Avian Research 
Facility (NARF) in Edinburgh (2015-2018).  
 
44 
 
2.3 Viruses 
Stocks of IBV were grown in embryonated hens’ eggs.  
2.3.1 IBV Strains:  
 M41-CK: pathogenic laboratory-adapted strain serially passaged in chick kidney cells 
(unknown number), replicates in CK cells, TOCs and embryonated eggs but not in 
continuous cell lines. 
 M41-K: Recombinant molecular clone of M41-CK, pathogenic, replicates in CK cells, 
TOCs and embryonated eggs but not in continuous cell lines.  
 M41-R: Recombinant molecular clone of M41-CK, non-pathogenic due to four point 
mutations in nsp10, 14, 15 and 16. Replicates in primary CK cells, TOCs and 
embryonated eggs but not in continuous cell lines.  
 Beau-R: Recombinant molecular clone of Beau-CK, non-pathogenic lab strain, 
replicates in CK cells, continuous avian cells (DF-1) and continuous mammalian cells 
(Vero) due to an extended host tropism (Casais et al., 2001, Bickerton et al., 2018) 
 QX L1148A: Pathogenic field strain originating from a Chinese isolate, infects 
oviducts in vivo causing fluid retention and penguin like stance in infected chickens. 
Obtained as a gift from Prof. Richard Jones, University of Liverpool (Worthington et 
al., 2008). Does not replicate in cell culture, only in tracheal organ cultures and 
embryonated eggs. 
 4/91: Pathogenic field strain originating in the UK, also known as 793B. Obtained as 
a gift from Intervet, UK. Does not replicate in cell culture, only in tracheal organ 
cultures and embryonated eggs.  
2.3.2 Fowlpox virus (FPV)  
 Stocks of FPV expressing the T7 RNA polymerase (FPV-T7) were propagated in 
chicken embryo fibroblast (CEF) cells.  
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2.3.3 Vaccinia viruses 
 rVV M41K-delS: a recombinant VV containing the entire M41-K genome cDNA with 
the S gene deleted. 
 rVV M41K-delS1: a recombinant VV containing the entire M41-K genome cDNA with 
the gene encoding the S1 subunit deleted.  
 
 
2.4 Infection of embryonated hens’ eggs with IBV  
Prior to infection with IBV, 10 day old embryonated hens’ eggs were candled using a lamp to 
check general embryo health. The air sac was marked using pencil and a small hole was 
drilled into the shell using a Bosch Dremel Engraver drill approximately 1cm above the air 
sac. Each egg was inoculated with 100 - 300µl of IBV using a 1ml syringe and a 25G needle. 
Post-inoculation the inoculation site was cleaned with 70% ethanol (in H2O) and the hole was 
sealed with nail varnish. Infected eggs were incubated at 37˚C for 24-48hrs depending on the 
predicted lethality of the virus. Embryos were monitored regularly by candling during this 
time to assess any decline in health. Eggs were chilled at 4˚C for at least 4 hours to cull the 
embryo before allantoic fluid was harvested. Allantoic fluid from the infected eggs was 
clarified by centrifugation at 500 x g for 5 minutes before storage at -80˚C.   
2.5 Ultracentrifuge purification of IBV  
IBV was purified by ultracentrifugation into a sucrose gradient (30-60%). At least 400ml of 
IBV-infected allantoic fluid was clarified by centrifugation at 1,200 x g for 15 minutes. The 
supernatant was layered onto a 30% sucrose cushion and centrifuged at 130,000 x g for 2 
hours. Supernatant was discarded and the pellet covered in 100µl phosphate buffered saline 
(PBS, supplied by Central Services Unit at The Pirbright Institute, recipe in Table 2.9). The 
pellet was left at 4˚C overnight. A 30-60% sucrose gradient was prepared using a gradient 
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maker and the pellet was added to the surface of the gradient before centrifugation at 
130,000 x g for 2 hours. After centrifugation, the top layers of sucrose were removed by 
pipetting and the band of virus was pipetted into another tube. The band was added to 30ml 
PBS, layered onto a 30% sucrose cushion and centrifuged at 130,000 x g for 2 hours. PBS and 
sucrose were discarded and the pellet was re-suspended in 100µl PBS containing 0.01% 
sodium azide (NaN3).  
Table 2.9: 1X Phosphate buffered saline (PBS) solution, provided by Central Services Unit 
at The Pirbright Institute 
Ingredient Final Concentration 
Sodium chloride 137mM 
Disodium phosphate  4.3mM 
Monopotassium phosphate 1.47mM 
Potassium chloride 2.7mM 
H2O (Dissolved in 8L) 
 
2.6 Glycosylation inhibitors and deglycosylation enzymes 
Kifunensine (Kif) (α-mannosidase I inhibitor, Sigma) stock solutions were prepared in PBS at 
2mM and diluted in 1xBES for use during infection. Initial stocks were donated as a gift from 
Dr Simon Spiro. Kif was used at 20µM, diluted in 1XBES and added at the time of infection.   
Swainsonine (SW) (α-mannosidase II inhibitor, Sigma) stock solutions were prepared in 
methanol (MeOH) at 1mg/ml and diluted to appropriate concentrations in 1xBES for use 
during infection.   
Endoglycosidase H (Endo H) and Peptide-N-Glycosidase F (PNGase F, New England Biolabs) 
digests were prepared as per the manufacturer’s instructions using purified M41-CK or Beau-
R and incubated at 37˚C for 1 hour. Digests were analysed by SDS-PAGE followed by western 
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blot (WB) using a monoclonal antibody against the S2 subunit of the S protein (26.1, 
Priomab). Digestion was confirmed by observation of a band shift compared to undigested 
samples.  
2.7 CellTiter-Glo cell viability assay (Promega) 
2.7.1 Inhibitor treatments 
 Cells were seeded in clear-bottomed 96 well plates with opaque sides and used at 80-90% 
confluency. Cells were washed once in PBS and appropriate media containing a range 
concentrations of Kif or SW was added to each well. Cells were incubated at 37°C. CellTiter-
Glo (CTG) reagents were added to cells as per the manufacturer’s instructions and data was 
generated using a GloMax plate reader.  
2.7.2 Temperature sensitivity 
Cells were seeded as described above. Confluent monolayers of cells were washed once in 
PBS and incubated at 37°C or 41°C. CTG reagents were added and data was generated as 
described above.  
2.8 RNA extraction and Reverse Transcription (RT)  
RNA from supernatant or allantoic fluid was extracted using QIAGEN RNeasy mini kits (based 
on column chromatography) following the RNA clean-up protocol according to the 
manufacturer’s instructions. RNA was eluted from columns in 35µl RNAse free water and 
stored at -20˚C.  
RNA from infected tissues was extracted according to the RNA clean-up protocol in the 
QIAGEN RNeasy mini-kit, following homogenisation in a TissueLyser II using a metal bead. 
Tissues were added to 500µl PBS and homogenised for 2-4 minutes until completely 
homogenous. Homogenised solutions were centrifuged for 3 minutes at 10,000 x g in a 
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benchtop refrigerated micro-centrifuge and 170µl of the supernatant was used for RNA 
extraction. The remainder was stored at -80°C and the pellets were discarded. 
cDNA was generated by reverse transcription (RT) using SuperScript III or IV (SSIII, SSIV, 
Invitrogen), according to manufacturer’s instructions. The thermocycler programs for use 
with SSIII and SSIV are detailed in Tables 2.10 and 2.11.  
Table 2.10: SuperScript III thermocycler program  
Temperature Time 
25°C 10 minutes  
50°C 60 minutes 
70°C 15 minutes 
18°C  Hold 
 
Table 2.11: SuperScript IV thermocycler program 
Temperature Time 
23°C 10 minutes 
55°C 10 minutes 
80°C 10 minutes 
18°C Hold 
 
 
2.9 Polymerase chain reaction (PCR) 
PCR was performed using Taq DNA polymerase (Invitrogen, product number 10342020) 
according to manufacturer’s instructions. The recipe for a standard PCR is detailed in Table 
2.12 and the thermocycler program in Table 2.13. Primers are detailed in Table 2.14.  
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Table 2.12: Standard PCR recipe 
Reagent Volume Final concentration 
10X PCR Rxn Buffer 5µl 1X 
MgCl2 2µl 2mM 
dNTPs 1µl 0.2mM 
(+) primer 1µl 0.2 pmol 
(-) primer 1µl 0.2 pmol 
Taq DNA polymerase 0.5µl 2.5U 
Template DNA 5µl --- 
Nuclease free H2O 34.5µl --- 
 
Table 2.13: Standard PCR Cycle 
Temperature Time Number of cycles 
95°C 3 mins 1 
95°C 45 seconds 
25 Annealing temp 30 seconds 
72°C Varied 
72°C 5 mins 1 
18°C Hold 1 
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Table 2.14 Oligonucleotides (custom synthesised by Sigma-Aldrich):  
Name Sequence Target 
region 
BG56 (5′ - 3′) CAACAGCGCCCAAAGAAG 3' UTR 
BG93/100 (3′ - 5′) GCTCTAACTCTATACTAGCCT 3' UTR 
BG42 (5′ - 3′) AATAATGGCAATGATGAC S1 
BG46 (5′ - 3′) CATCAAAATCACTAATGG S2 
BG136 (3′ - 5′) AACTGCCACAAACATACTGC S1 
BG142 (3′ - 5′) AGGGATCAAATACTTCTGTG S2 
M20 (5′ - 3′) GGAATGGGCATAATAAGG Nsp10 
M23 (3′ - 5′) CGGGTACGGGGTAGCAGTG Nsp10 
4/91 2+ (5′ - 3′) TGCCTTTAGGCCTGGTCAAG 4/91 S 
4/91 7- (3′ - 5′) TTCAAAGTATTGCGTTAGCT 4/91 S  
GPT F (5′ - 3′) ATGAGCGAAAAATACATCGTC GPT selection 
marker 
GPT R (3′ - 5′) TTAGCGACCGGAGATTGGC GPT selection 
marker 
Random primer GTTTCCCAGTCACGATCNNNNNNNNNNNNNNN ---- 
 
2.10 Sanger sequencing  
PCR products were generated using specific primers and the products were sent to Source 
Bioscience (Nottingham) for Sanger sequencing, as per the service provider’s requirements. 
4µl of PCR product was added to 20µl of H2O. Stock solutions (10µM) of forward and reverse 
primers were diluted 1:1 with H2O and sent separately alongside the diluted PCR product. 
Sequencing reads were processed and analysed using Staden Sequence Analysis Package 
(Staden, 1996). Alignments were generated using BioEdit (Hall, 1999).  
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2.11 NetNGlyc Server Prediction  
S gene consensus sequences generated by RT-PCR and Sanger sequencing were entered into 
the NetNGlyc 1.0 Server to identify potential N-linked glycosylation sites (PNGS). Predictions 
were made based on the server’s algorithms to provide a ranking of the sites most likely to 
be glycosylated at the identified asparagine residues. Scores above 0.5 generally indicate 
true glycosylation sites.  
 
2.12 Reverse genetics using vaccinia virus (VV) 
Recombinant IBVs were generated using a well-established reverse genetics system based 
on vaccinia virus (VV) (Casais et al., 2001, Britton et al., 2005). The first stage is homologous 
recombination between a recombinant VV and a plasmid containing the gpt gene and viral 
gene sequence containing the desired modification.  This is followed by six rounds of plaque 
purification before DNA extraction in preparation for rIBV rescue. The entire process is 
described in Figure 2.1. 
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Figure 2.1: Reverse genetics process for generation of recombinant IBVs (rIBVs). (A) Cells 
were infected with an rVV containing the rIBV M41-K cDNA and transfected with a vector 
containing the gpt gene and the desired sequence for insertion/mutation. (B) The first 
homologous recombination event between the IBV cDNA and the pGPT vector occurred due 
to the presence of identical flanking regions. (C) Selection for successful recombination 
events was achieved through three rounds of plaque purification in the presence of selection 
agents MPA, Xanthine and Hypoxanthine (MXH). (D) This resulted in the generation of an 
unstable intermediate rVV, containing the gpt gene between repeat sequences in the IBV 
cDNA. (E) The rVVs were then subjected to three rounds of plaque purification in the absence 
of selection agents (MXH), inducing a second recombination event and loss of the gpt gene 
but retention of the insertion/mutation, as a result of recombination between the repeat 
sequences. (F) Following the six rounds of plaque purification, ministocks were generated in 
Vero cells and each isolate was screened to check for the correct insertion and to verify the 
loss of the gpt gene. DNA was extracted from large stocks of rVV and used for virus rescue in 
CK cells, with the addition of rFPV-T7 and a plasmid expressing the IBV N gene.  
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2.12.1 pGPTNEB193 vectors 
The first stages of the reverse genetics process used a plasmid containing the guanine 
phosphoribosyl transferase (gpt) gene, which allows purine synthesis by an alternative 
pathway in the presence of xanthine and hypoxanthine. The plasmid also contained either 
the Beaudette S2 subunit sequence or the sequence of the ectodomain of the 4/91 S protein.  
pGPTNEB193 vectors were designed to include recombinant S genes to generate rIBVs 
M41K-BeauR(S) and M41K-4/91(S). DNA sequences were synthesised and cloned into 
pGPTNEB193 by GeneArt and used for homologous recombination. Two vectors were used 
for the generation of rIBVs M41K-BeauR(S) and M41K-4/91(S): pGPT-M41-BeauR-S1 and 
pGPT-M41-4/91-S, respectively.  
2.12.2 Homologous recombination: 
The first recombination event occurs between the pGPT plasmid and repeat sequences in 
the rVV (Figure 2.1A and B). Recombinant VV containing M41-K cDNA with a deletion or 
modification in the S gene (rVV M41K-del-S or rVV M41K-delS1-BeauR-S2) was sonicated for 
2 minutes (70% amplitude) and diluted in 500µl of EMEM to an approximate multiplicity of 
infection (MOI) of 0.2. Semi-confluent (50-60%) monolayers of Vero cells were infected with 
rVV M41K-del-S in duplicate and incubated for 2 hours at 37°C (5% CO2). After washing twice 
in OPTIMEM (Invitrogen), cells were transfected with 10µg of the relevant pGPT vector using 
Lipofectin (Life Technologies) as per the manufacturer’s instructions. Transfected cells were 
incubated at 37°C for 1 hour after which transfection solution was replaced with 1xEMEM 
(5ml). Cells were incubated at 37°C overnight. Selection agents (75µM mycophenolic acid 
(MPA), 165µM Xanthine, 184µM Hypoxanthine; MXH) were added to each well and cells 
were incubated at 37°C for a further 48 hours. After incubation, cells were scraped into the 
supernatant and harvested before storage at -20°C in a screw-cap vial.  
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2.12.3 Transient dominant selection (TDS) by plaque purification  
Confluent monolayers of Vero cells were infected with 500µl of sonicated rVV containing the 
desired rIBV cDNA diluted in 1xEMEM (10-1, 10-2 and 10-3). Cells were incubated for 1-2 hours 
at 37˚C. Virus inoculum was removed and replaced with 3 ml per well of an overlay solution 
of 1xEMEM containing 1% agar and selection agents MXH (Table 2.15). Overlay was left to 
set before cells were incubated at 37˚C for 72 hours. Cells were stained with 2ml per well of 
1xEMEM/1% agar overlay containing 0.01% Neutral Red and incubated for a further 24 hours 
at 37˚C until plaques were visible in the monolayer. Three plaques per virus isolate were 
picked using a cut pipette tip and added to 400µl of 1xEMEM. Each plaque was sonicated 
and used to repeat the plaque purification process three times in the presence of MXH 
(Figure 2.1C) and then 3 times in the absence of MXH (Figure 2.1E).  
Table 2.15: Overlay medium containing MXH selection agents 
Ingredient  Final concentration  Supplier and 
catalogue number 
2xEMEM 1X See Table 2.8 
2% Agar (in H2O) 1% w/v Sigma-Aldrich, A9539 
Mycophenolic acid (MPA) 75µM Sigma-Aldrich, M3536 
Xanthine Sodium Salt (X) 165µM Sigma-Aldrich, X3627 
Hypoxanthine (H) 184µM Sigma-Aldrich, H9636 
 
2.12.4 Generation of rVV ministocks in Vero cells  
Confluent monolayers of Vero cells were infected with the final plaques from the TDS 
process. Plaques were sonicated for 2 minutes and 150µl of supernatant was added to the 
cells with 350µl 1xBES. Infected cells were incubated at 37˚C for 2 hours before 2.5ml of 
1xBES was added to each well. Cells were incubated at 37˚C for 72 hours or until cytopathic 
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effect (cpe) was observed. Cells were scraped into supernatant and centrifuged at 5000 x g 
for 5 minutes. Supernatant was discarded and cell pellets were re-suspended in 700µl 1xBES. 
DNA was extracted from 200µl of each ministock following the DNA extraction from blood 
and tissue samples protocol in the QIAGEN DNA Extraction Kit according to the 
manufacturer’s instructions. DNA was eluted in 200µl nuclease-free H2O. PCR was carried 
out using primers covering the gpt gene to ascertain which ministocks had lost the selection 
marker. A second PCR was carried out using primers covering the S gene (Table 2.13) to verify 
that the insertion was correct (Figure 2.1E). Any ministocks with the correct insert which 
were negative for gpt presence were selected for generation of large stocks in BHK-21 cells.  
2.12.5 Generation of large stocks in BHK-21 cells  
rVV ministocks were diluted 1:200 in 1xGMEM and 2ml was used to infect BHK-21 cells 
seeded in T150 tissue culture flasks. Cells were washed once in PBS. Cells were incubated at 
37˚C for 2 hours before addition of 18ml of 1xGMEM to each flask. Flasks were incubated at 
37˚C until cells had completely detached from the surface of the flask (approximately 72 
hours). Supernatant and cells were pooled for each rVV and centrifuged at 500 x g for 15 
minutes. Supernatant was discarded and pellets re-suspended in 2ml Tris-EDTA (TE) buffer 
(Table 2.16) per flask and stored at -20˚C.  
Table 2.16: Tris-EDTA (TE) buffer, pH 9 
Ingredient Final concentration 
Tris-HCl (pH 9)  10mM 
EDTA (pH 9)  1mM 
 
2.12.6 Partial purification of rVV by ultracentrifugation  
Cells were freeze-thawed (dry ice/37˚C) three times and sonicated for 2 minutes to ensure 
adequate cell lysis. Cell lysates were centrifuged at 500 x g for 10 minutes (4˚C) to remove 
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the nuclei. TE buffer (pH 9) was added to the supernatant to make up a total volume of 13ml. 
This was layered onto 16ml of a 30% sucrose solution (in TE buffer, pH 9) and centrifuged at 
36,000 x g for 1 hour at 4˚C. Supernatant and sucrose were discarded and the pellet re-
suspended in 5ml TE buffer (pH 9). Partially purified rVVs were stored at -20˚C. 
2.12.7 Large-scale DNA extraction by phenol-chloroform  
Partially purified rVVs were thawed and an equal volume (5ml) of Proteinase K buffer (Table 
2.17) was added to each isolate along with 200µl of Proteinase K solution (Sigma, 20mg/ml). 
Solutions were incubated at 50˚C for 2.5 hours before DNA extraction by phenol-chloroform 
(Thermo Fisher). An equal volume of phenol-chloroform (10ml) was added to each sample 
and mixed thoroughly before centrifugation at 1,200 x g for 15 minutes. The upper aqueous 
phase was carefully transferred to a clean tube and the extraction was repeated once more 
to purify the DNA. A chloroform extraction was then performed where an equal volume of 
chloroform (Sigma-Aldrich/Merck) was added to the upper aqueous phase of the previous 
purification, mixed well and centrifuged for 15 minutes at 1,200 x g. Again, the upper 
aqueous phase of the solution was transferred to a fresh tube and 2.5 volumes of absolute 
ethanol (kept at -20˚C) and 0.1 volumes of 3M sodium acetate were added to precipitate the 
DNA. The solution was mixed by inversion and centrifuged at 2,300 x g for 45 minutes. 
Following centrifugation 10ml of 70% ethanol (in H2O, kept at -20˚C) was added to the pellet 
and incubated on ice for 5 minutes in order to dissolve any salts before centrifugation at 
2,300 x g for 45 minutes. The ethanol was carefully poured off and pellets were left to air-
dry for 10 minutes. Excess ethanol present on the inside of the tube was removed using 
paper towel and pellets were dissolved in 100µl H2O (nuclease-free). DNA was stored at 4˚C 
overnight then quantified using a Nanodrop 1000.  
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Table 2.17: 2X Proteinase K buffer  
 
Ingredient Final concentration 
Tris-HCl (pH 7.5)  200mM 
EDTA  10mM 
SDS 0.4% w/v 
NaCl 400mM 
 
2.12.8 Pulsed field gel electrophoresis (PFGE) of rVV DNA  
Approximately 1µg of rVV DNA was digested with SalI (Invitrogen) according to the 
manufacturer’s instructions.  The quality of the DNA was assessed by pulsed-field gel 
electrophoresis (PFGE). A 1% agarose (Bio-Rad, molecular grade) gel was prepared using 0.5X 
TBE buffer (Thermo Fisher, 10X stock). Gel solutions were heated for 2 minutes in a 
microwave and set in 12.7 x 14cm frames on a level surface. Buffer (0.5X TBE) was added to 
the CHEF-DR-II gel tank with the cooling unit switched on and left to cool to 4˚C. Loading dye 
was added to the digested DNA and the sample was heated to 65˚C for 10 minutes. Each 
sample was loaded onto the gel using cut tips to avoid shearing the DNA. The gel was run 
under the following conditions: initial pulse time = 0.1S, final pulse time = 1S, duration = 6-
16 hours, voltage (V) = 6.0 V/cm.   
Following electrophoresis the gel was removed from the tank, placed in a 0.1µg/ml solution 
of ethidium bromide and incubated at room temperature on an orbital shaker for 30 
minutes. The gel was washed in 400ml of H2O (Sigma) and incubated for a further 30 minutes. 
After washing, the gel was visualised using a Bio-Rad Gel Doc EZ, according to the 
manufacturer’s instructions.  
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2.12.9 Rescue of rIBVs in CK cells  
Semi-confluent monolayers of CK cells seeded onto 6 well tissue culture plates were infected 
with a recombinant fowlpox virus expressing the bacteriophage T7 RNA polymerase (rFPV-
T7) (Britton et al., 1996) at an MOI of 10 (500µl per well). Cells were incubated at 37˚C for 1 
hour then washed twice with OPTIMEM (Life Technologies). Cells were transfected with 10μg 
of rVV DNA and 5μg of a plasmid expressing the IBV M41 N protein (pCi-Neo-M41-N). The N 
protein is expressed in complement as it required for the synthesis of new virions (Siu et al., 
2008). The plasmid and rVV DNA were diluted in 1.5ml of OPTIMEM (per well) and then 
added to 30μl of Lipofectin in 1.5ml of OPTIMEM. Transfection solutions were added to the 
cells and then incubated overnight at 37°C.  
Following incubation, transfection media was removed, and 5ml of 1x BES added. The cells 
were then incubated at 37°C until extensive rFPV cpe was observed; this usually occurred at 
72 hours post-infection. Supernatant from each well was harvested and rFPV removed by 
filtering through a 0.22μm filter. Filtered supernatant was stored at -80°C. To determine 
whether rIBV was successfully rescued, rIBV M41K-BeauR(S) samples were serially passaged 
three times to increase viral titre. Confluent monolayers of CK cells were inoculated with 1ml 
of supernatant and incubated for 1 hour at 37°C followed by addition of 2ml of 1xBES. Cells 
were incubated for 48 hours at 37°C, until visible cpe was observed. The supernatant was 
removed and passaged a further two times. After the third passage, RNA was extracted from 
the viral samples and screened to confirm rescue of rIBV and to identify the presence of the 
desired mutation. 
IBV 4/91 does not replicate in cell culture and so for rIBV M41K-4/91(S) isolates, rescue 
supernatant was discarded and 500µl 1xBES was added to each well and plates were freeze-
thawed (-80˚/room temperature) in an attempt to lyse the cells and release the rIBV. After 
freeze-thaw, cells were scraped into the media and passed through a needle and syringe 
multiple times then filtered through a 0.22µm filter unit to remove the rFPV. The filtered cell 
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lysate was used to infect 10 day-old embryonated RIR eggs for passaging. Allantoic fluid was 
screened after each passage and stocks were generated at egg passage 2 (EP2).  
 
 2.13 Immunofluorescence (IF) staining for confocal microscopy 
Cells were seeded onto glass coverslips in 24 well tissue culture plates, infected with IBV and 
incubated for 24 hours at either 37˚C or 41˚C after which they were washed once with PBS 
and fixed in a solution of 4% paraformaldehyde (PFA) in PBS for 20 minutes on an orbital 
shaker. Cells were washed again in PBS and permeabilised using 0.1% Triton X-100 in PBS for 
10 minutes. Blocking solution consisted of 0.5% BSA in PBS and was also used to dilute 
primary and secondary antibodies. Cells were incubated in blocking solution for 1 hour then 
incubated in primary antibody for 1 hour. Primary antibody dilutions are listed in Table 2.17. 
Between primary and secondary antibody incubations, cells were washed 3 times in PBS for 
5 minutes per wash. Cells were incubated in secondary antibody solutions (Invitrogen 
AlexaFluor 488/568, diluted 1/500 in blocking solution) for 1 hour under foil and washed a 
further 3 times before counterstaining with DAPI, diluted 1/10,000 in type II endotoxin free 
water, for 5 minutes. Cells were washed once in water before coverslips were mounted onto 
glass microscope slides using VectaShield mounting medium (Vector Labs) and sealed with 
nail varnish before imaging using a Leica confocal microscope.  
Table 2.18 Primary antibodies  
Antibody  Target  Application Dilution  Source 
A13 S1 IF  1/200 Mockett et al, 
1984 
Anti-S2 (26.1) S2 IF/WB 1/500 Priomab 
Anti-dsRNA (J2) dsRNA IF 1/1000 Scicons 
Anti-β-actin β-actin IF/WB 1/1000 Cell Signalling 
Technologies 
Anti-α-tubulin  α-tubulin IF/WB 1/1000 Abcam 
Chicken anti-IBV 
(polyclonal) 
IBV  IF 1/500 Abcam  
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2.14 SDS-PAGE and western blot 
2.14.1 Western blot using cell lysate:  
Following infection with IBV as described previously, cells were washed once in cold PBS and 
350µl of cold RIPA lysis buffer (Table 2.19) containing 1X protease inhibitor cocktail (PIC, 
Thermo Fisher) was added to each well. Cells were incubated on ice for 20 minutes before 
being scraped into the buffer using a cell scraper. Buffer and cells were centrifuged at 10,000 
x g for 3 minutes to pellet cell debris. Cell lysate was mixed with Laemlli Sample Buffer 
(containing β-mercaptoethanol) at a ratio of 1:3 and heated to 80˚C for 10 minutes. 15µl of 
each sample was loaded onto a 4-20% Mini-PROTEAN TGX Precast protein gel (Bio-Rad) and 
run for 1 hour at 150V in running buffer (Table 2.20). Protein was transferred onto a 
nitrocellulose membrane using a Bio-Rad Trans Blot machine, according to the 
manufacturer’s instructions. Membranes were incubated in blocking solution (5% milk 
powder (Marvel) in PBS containing 0.1% Tween-20 (PBS-T)) for 1 hour at room temperature 
or overnight at 4˚C. Primary antibodies were diluted in blocking solution and applied to 
membranes for 1 hour at room temperature. Primary antibody dilutions are listed in Table 
2.18. Membranes were subjected to 3 x 5 minute washes in 0.1% PBS-T on an orbital shaker 
at room temperature. LI-COR secondary antibodies for western blot were diluted 1/15,000 
in blocking solution and applied to membranes for 1 hour at room temperature. Membranes 
were washed in PBS-T three times followed by one wash in H2O before visualisation on a LI-
COR Odyssey Scanner following the protocol for western blot imaging according to the 
manufacturer’s instructions.  
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Table 2.19 RIPA lysis buffer 
Ingredient  Final concentration  
Sodium chloride (NaCl) 5M 
Trisaminomethane hydrochloric acid (Tris-
HCl)  
1M 
Igepal 5% v/v 
Sodium deoxycholate  5% w/v 
Sodium orthanovate 1M 
Sodium fluoride  1M 
PIC (Thermo Fisher, 78430, 100X stock) 1X 
 
Table 2.20 SDS-PAGE Running buffer 
Ingredient  Final concentration  
Tris-HCl buffer (pH 7.4) 247mM 
SDS  34mM 
Glycine 1.92M 
 
2.14.2 Western blot using ultracentrifuge-purified IBV  
For purified samples, 3µl of purified virus was mixed with 2µl of Laemlli Sample Buffer 
containing β-mercaptoethanol and heated to 80˚C for 10 minutes. Heated samples were 
loaded onto protein gels and processed for western blot as described above.  It should be 
noted that the protein concentration in the purified virus samples was undetermined prior 
to western blot analysis. 
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2.15 Mass spectrometry (MS) methods: N-glycosylation 
mapping 
Methods provided and performed by Stuart Armstrong (University of Liverpool) 
2.15.1 Protein digestion 
The purified IBV sample was diluted with 50mM ammonium bicarbonate (NH4HCO3). 
Proteins were reduced by the addition of dithiothreitol (Sigma) (3mM final) and heated at 
60°C for 10 minutes. The samples were returned to room temperature, and iodoacetamide 
(Sigma) (9mM final) added for 30 minutes in the dark to alkylate the proteins. The sample 
was split and proteins were digested with either trypsin or chymotrypsin (Sigma) and left to 
incubate at 37°C overnight. The resulting peptide samples were then dried using a centrifugal 
vacuum concentrator (Eppendorf). Deglycosylation and H218O labelling was performed as 
described by Zhang et al (2016). Peptides were re-suspended in 50mM ammonium 
bicarbonate buffer prepared in H218O (97% 18O, Sigma Aldrich). The peptide samples were 
split and PNGase F (Sigma) added to only one of the samples and incubated at 37°C for 2 
hours. Samples were then acidified with trifluoroacetic acid (1% (v/v) final). Peptides were 
concentrated and desalted using C18 Stage tips (ThermoFisher Scientific) and then samples 
dried using a centrifugal vacuum concentrator (Eppendorf). Peptides were re-suspended in 
0.1% (v/v) trifluoroacetic acid and 5% (v/v) acetonitrile (Zhang et al., 2016).  
2.15.2 NanoLC MS ESI MS/MS analysis 
Peptides were analysed by on-line nanoflow LC using the Ultimate 3000 nano system 
(Dionex/Thermo Fisher Scientific). Samples were loaded onto a trap column 
(ThermoScientific, PepMap100, C18, 300μm × 5mm) then resolved on an analytical column 
(Easy-Spray PepMap® RSLC 50cm × 75μm inner diameter, C18, 2μm, 100Å) fused to a silica 
nano-electrospray emitter (Dionex).  The column was operated at a constant temperature of 
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30°C and the LC system coupled to a Q-Exactive HF mass spectrometer (Thermo Fisher 
Scientific). Chromatography was performed with a buffer system consisting of 0.1% formic 
acid (buffer A) and 80% acetonitrile in 0.1% formic acid (buffer B). The peptides were 
separated by a linear gradient of 3.8 – 50% buffer B over 90 minutes at a flow rate of 
300nl/min. The Q-Exactive HF was operated in data-dependent mode with survey scans 
acquired at a resolution of 60,000 and scan range 350-2000m/z. Up to the top 10 most 
abundant isotope patterns with charge states +2 to +5 from the survey scan were selected 
with an isolation window of 2.0Th and fragmented by higher energy collisional dissociation 
with normalized collision energies of 30. The maximum ion injection times for the survey 
scan and the MS/MS scans were 100 and 45ms respectively, and the ion target value was set 
to 3E6 for survey scans and 1E5 for the MS/MS scans. MS/MS events were acquired at a 
resolution of 30,000. Repetitive sequencing of peptides was minimized through dynamic 
exclusion of the sequenced peptides for 20s. 
2.15.3 Bioinformatic analysis 
Spectral data were analysed using the PEAKS studio 8.5 software (Bioinformatics Solutions 
Inc., Waterloo, ON, Canada). Tandem MS data were searched against the predicted protein 
sets of IBV (Uniprot, June 2015) and Gallus gallus (NCBI Refseq Feb 2016) (46255 sequences 
combined). Search parameters were as follows; precursor mass tolerance set to 10ppm and 
fragment mass tolerance set to 0.05Da. Two missed tryptic cleavages were permitted. 
Carbamidomethylation (cysteine) was set as a fixed modification and oxidation (methionine), 
HexNAcetylation (asparagine, + 203.08Da), deamidation of asparagine (+0.9840Da), and 
deglycosylated asparagine 18O labelling (+2.9890Da) were set as a variable modifications. The 
false discovery rate was set at 1%.  
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2.16 Mass spectrometry (MS) methods: Glycan analysis  
2.16.1 Protein digestion 
The purified IBV sample was diluted with 50mM ammonium bicarbonate (Sigma-Aldrich) and 
0.1% (w/v) Rapigest (Waters, Elstree, UK). Samples were then incubated at 80°C for 10 
minutes and reduced with 3mM dithiothreitol (DTT) at 60°C for 10 minutes then alkylated 
with 9mM iodoacetimde at room temperature for 30 minutes in the dark. The sample was 
split and proteins were digested with either trypsin or chymotrypsin (Sigma) and left to 
incubate at 37°C overnight. Samples were then acidified with trifluoroacetic acid (1% (v/v) 
final) and precipitated Rapigest removed. Peptides were concentrated and desalted using 
C18 Stage tips (ThermoFisher Scientific) and then samples dried using a centrifugal vacuum 
concentrator (Eppendorf). Peptides were re-suspended in 0.1% (v/v) trifluoroacetic acid and 
5% (v/v) acetonitrile.  
2.16.2 LC MS/MS 
LC-MS/MS analysis was performed on an Orbitrap Fusion Tribrid mass spectrometer 
(ThermoScientific), attached to an Ultimate 3000 nano system (Dionex). Peptides were 
loaded onto the trapping column (ThermoScientific, PepMap100, C18, 300μm × 5mm), and 
then resolved on an analytical column (Easy-Spray C18 75μm × 500mm 2μm bead diameter 
column) using a 30-min gradient from 96.2% A (0.1% FA) and 3.8% B (80% MeCN 19.9% H2O 
0.1% FA) to 50% B at a flow rate of 300nL min−1. The mass spectrometer was operated in 
data dependent mode to automatically switch between MS and MS/MS acquisition using 
HCD and EThcD. MS1 scan was acquired from 450–1800 m/z (60 000 resolution, 4e5 AGC, 
50ms injection time) followed by EThcD MS/MS acquisition of the precursors with the 
highest charge states in an order of intensity and detection in the Orbitrap.  HCD (30 000 
resolution, 3e5 AGC, 60ms injection time, collision energy (%) = 28). ETD scan range 120-
2000m/z (30 000 resolution, 1e5 AGC, 120ms injection time). The Fusion was run in product 
dependent acquisition mode (HCDpdETD), which generates a pair of HCD and ETD spectra. 
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Acquisition was triggered when fingerprint ions (m/z 204.0867(HexNac)), 138.0545(HexNac 
fragment), and 366.1396(HexNacHex) were detected within top 20 product ions. 
2.16.3 Data analysis 
The EThcD data was searched against the IBV spike glycoprotein (UniProt, P12651) using 
Byonic (v2.13.1, Protein Metrics, Inc.). The search parameters were as follows: Trypsin (RK) 
and Chymotrypsin (FLWY) cleavage sites. Initial precursor and fragment mass tolerances 
were set at 10 and 20 ppm, respectively, and up to two missed cleavages were allowed for 
enzyme digestion. Cysteine carbamidomethylation was set as a fixed modification, and 
methionine oxidation, asparagine deamination were set as ‘rare1’ modifications. EThcD was 
chosen as the fragmentation type. Glycan modifications were searched against a ‘narrow’ 
Byonic ‘N-glycan 50 common biantennery’ library and were set as ‘rare1’ modifications. Two 
common modifications and 1 rare modification were allowed to be included per peptide. All 
other settings were set at the default values. For glycopeptides, a Byonic score of >300 and 
a PEP2D score of <0.005 was considered a good score, which reflects the absolute quality of 
the peptide-spectrum match (Bern et al., 2012).  
 
2.17 Assessment of replication kinetics in primary and 
continuous cells 
Confluent monolayers of cells seeded in 6 well plates were washed once in PBS and infected 
with IBV at an MOI of 0.1 or 0.01 unless otherwise stated. Infected cells were incubated at 
37˚C or 41˚C for 1 hour. Following incubation, cells were washed twice with PBS and 3ml of 
1xBES was added to each well. Cells were incubated at 37˚C or 41˚C and supernatant was 
harvested at 1, 24, 48, 72 and 96 hours post-infection and stored at -80˚C.  
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2.18 IBV titration by plaque assay  
Virus titration by plaque assay was performed in 12 well plates of CK cells at 90-100% 
confluency. Viruses were diluted 10 fold in 1xBES and each dilution plated in triplicate. 
Infected cells were incubated for 1 hour at 37˚C after which virus was removed from cells 
and 1ml of overlay (1XBES containing 1% agar) was added per well. Infected cells were 
incubated at 37˚C for 72 hours before fixation with 10% formaldehyde (in PBS) and staining 
with 0.1% crystal violet (in H2O). An average number of plaques was calculated for each 
sample and used to determine the plaque forming units per ml (pfu/ml) for each sample.  
2.19 Virus neutralisation assay by plaque reduction  
Samples of IBV-infected CK cell supernatant were diluted to 2000pfu/ml in PBS. Monoclonal 
antibody A13 was diluted 1/10 in PBS then serially diluted two-fold with the pre-diluted virus 
samples. The final amount of virus in each solution was 103pfu/ml. Antibody-virus solutions 
were incubated for 30 minutes on an orbital shaker to ensure thorough mixing. Each dilution 
was used for plaque assay in CK cells (Section 2.18) and average pfu/ml values were 
calculated from three biological repeats.  
 
2.20 Infection of Vero cells in the presence of trypsin  
Confluent monolayers of Vero cells seeded in 6 well tissue culture plates were washed once 
in PBS. IBV was diluted in 1XBES medium containing tosyl phenylalanyl chloromethyl ketone 
(TPCK) treated trypsin (Sigma) at various concentrations. Each well was inoculated with 500µl 
of diluted virus and cells were incubated at 37°C for 1 hour. Cells were washed twice in PBS 
and 3ml of 1XBES (+TPCK-trypsin) was added to each well. Cells were incubated for 24 hours 
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at 37°C. Following incubation, IBV-induced cpe was assessed under a light microscope and 
supernatant from each well was harvested and stored at -80°C.  
2.21 Infection of ex vivo tracheal organ cultures (TOCs)  
Trachea from 19 day-old SPF RIR embryos were extracted and divided into sections using an 
automated microtome. Sections were separated by hand and individually placed into glass 
test tubes containing 1ml of TOC growth medium (Table 2.4). TOCs were incubated at 37˚C 
for 24 hours (no CO2) rotating at approximately 8 revolutions per hour (rph). TOCs were 
assessed 24 hours prior to infection; those exhibiting poor ciliary activity were discarded. 
Healthy TOCs were incubated for a further 24 hours at 37˚C (8rph). On the day of infection, 
TOCs were washed once in PBS.  
For ciliostasis assessments, 104pfu of IBV were added to each tube in 100µl of TOC growth 
medium. Ten replicates were infected for each virus. TOCs were incubated upright (no 
rotation) at 37˚C for 1 hour before addition of 900µl of TOC growth medium to each tube. 
TOCs were incubated at 37˚C (8rph) for a total of 96 hours. Ciliary activity in each TOC was 
assessed under a light microscope at the time of infection and then every 24 hours. Each TOC 
was assigned a score of 0-4 based on the proportion of visibly beating ciliated cells. A score 
of 1 indicates 25% of cilia visibly beating, a score of 4 indicates 100% visible beating. These 
scores were converted to percentages to provide an average ciliary activity score.  
For assessment of replication kinetics, TOCs were prepared in the same way. TOCs were 
infected with 1x104pfu of IBV in a total volume of 500µl and incubated upright for 1 hour. 
After this incubation TOCs were washed twice in PBS and 1ml of fresh TOC growth medium 
was added to each tube. TOCs were incubated at 37˚C (8rph). Supernatant from triplicate 
TOCs was harvested at 0, 24, 48, 72 and 96 hours post-infection.  
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2.22 Assessment of ciliostatic dose (CD50): titration in TOCs  
Embryonic TOCs were prepared as described above. For non-cell culture adapted strains of 
IBV, titration was achieved by calculation of the ciliostatic dose (CD50) for each sample. TOCs 
were washed once in PBS. Two-fold serial dilutions of virus samples were prepared in TOC 
medium. TOCs were washed once in PBS and infected with 500µl of each virus dilution in 
triplicate. Infected TOCs were incubated at 37°C (no CO2, 8rph) for 6 days. Each TOC was 
examined under a light microscope to assess ciliary activity and designated living or dead. 
Those exhibiting less than 25% ciliary activity or complete ciliostasis were deemed dead. CD50 
values were calculated based on the Reed-Muench method (Reed and Muench, 1938).  
2.23 In vivo methods:  
All in vivo methods were performed according to Home Office and ASPA regulations by 
trained individual licence holders in the Experimental Animal House at Compton or the 
Biological Services Unit at Pirbright.  
2.23.1 Infection of SPF RIR chickens with IBV  
8 day-old SPF RIR chicks were infected with IBV via the ocular-nasal route using a P200 
pipette to administer 100µl of diluted virus to the eyes and nares of each bird.  
2.23.2 Assessment of IBV-induced clinical signs  
Chickens were housed in colony cages in groups of 12-15 with various enrichments including 
pecking blocks, perches, mirrors and edible enrichment. From day 3 post-infection (rIBV 
M41K-BeauR(S)) and day 2 post-infection (rIBV M41K-4/91(S)), clinical signs were assessed 
for all groups. The total number of snicks observed in a 2 minute period was recorded by 
three individuals and an average was calculated for each group. Following this, each bird was 
assessed for respiratory and other signs of IBV infection including wheezing, rales, watery 
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eyes, nasal discharge and general lethargy. Any observed signs were recorded and monitored 
for the remainder of the experiment.  
2.23.3 Post-mortem harvesting of tissues  
Chickens were culled by an approved Schedule 1 method carried out by a trained member 
of Animal Services (Pirbright) and death was confirmed by cessation of heartbeat. Clean 
scissors, forceps and scalpels were used for each bird to collect tissue samples from the 
eyelid, beak, trachea, lung, kidney, gut, spleen and bursa. Sections of tissue were divided and 
stored in PBS and RNA Later (Thermo Fisher). Samples in RNA Later were stored at 4˚C 
overnight then transferred to -80˚C for storage before analysis.  
2.23.4 Assessment of IBV-induced ciliostasis  
Trachea were harvested from infected chickens as described above and cleaned to remove 
fat and debris using forceps and scalpels. Samples were sectioned into 10 rings of 
approximately 1mm thickness. Three sections were taken from the upper and lower parts of 
the trachea and four were taken from the middle. Sections were placed on a glass 
microscope slide and examined under a light microscope to assess the activity of the ciliated 
cells. Each section was assigned a score from 0-4 based on the proportion of visibly beating 
cells as described in Section 2.21. Scores were converted to percentages (4=100% visibly 
beating, 1 = 25% beating).  
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Chapter 3: Characterising the 
glycosylation profile in the IBV S 
protein   
 
3.1 Introduction 
N-linked glycosylation is an important modification of viral protein ectodomains that takes 
place in the ER and Golgi. Different classes of glycan are formed on the surface of a protein 
following attachment to the asparagine residue in the amino acid sequence Asn-X-Ser/Thr 
and subsequent trimming and processing by various cellular enzymes including 
mannosidases and glucosidases (Vigerust and Shepherd, 2007). Specific classes of glycan can 
be inhibited or removed either enzymatically or by use of enzyme inhibitors such as Kif and 
SW, both of which inhibit the formation of complex glycans through targeting mannosidase 
I and II, respectively (Elbein et al., 1990, Elbein et al., 1981).   
The S protein of IBV exhibits a high level of glycosylation, similar to other viral envelope 
proteins including HIV gp120 and influenza HA. Glycosylation has been shown to contribute 
towards correct protein folding and, in turn, function. In influenza, glycosylation of the HA 
protein has been shown to modulate the immune response, influence receptor binding and 
affect virulence and antigenicity (Tate et al., 2014).  
This aim of the work described in this chapter was to examine the glycan shield of the IBV S 
protein in more detail, identifying glycan structures on the protein surface and investigating 
the possible roles of specific classes of glycan in viral infectivity and immune evasion. The S 
proteins of four different strains of IBV, varying vastly in pathogenicity and tropism, were 
analysed to gain insight into the glycan profile of each strain. Two strains were analysed in 
more detail to define the role of specific glycans in viral infectivity and their interaction with 
antibodies.  
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3.2 Results 
3.2.1 Prediction and confirmation of N-linked glycosylation sites 
To assess the levels of variation in IBV S glycoprotein glycosylation, a range of IBV strains 
were used for the initial analyses of S gene sequences. Two laboratory-adapted strains with 
different levels of pathogenicity and two currently circulating pathogenic field strains were 
included in the analysis. The sequences of the Beau-R, M41-CK, QX and 4/91 S protein 
sequences were generated using strain specific primers during RT-PCR followed by Sanger 
sequencing and aligned using BioEdit (Hall, 1999). The alignment of the four sequences is 
included in Appendix A6. The S proteins shared between 82-96% amino acid homology. Table 
3.1 details the sequence comparison of the four IBV strains and highlights the differences 
between them. The S genes of M41-CK and Beau-R shared the greatest amount of sequence 
homology with 96.2% sequence identity between the amino acid sequences of each strain. 
Less homology was exhibited between the laboratory strains and the field strains, as M41-
CK and Beau-R exhibit approximately 82% homology with 4/91 or QX. These four strains were 
used for analysis of their N-linked glycosylation profiles as their sequences and tropisms are 
varied.  
Table 3.1: Spike (S) gene amino acid sequence homology of IBV M41-CK, Beau-R, QX and 
4/91.  
 M41-CK Beau-R QX 
Beau-R 96.2% --- --- 
QX 82.3% 82.1% --- 
4/91 82.4% 82.3% 84.0% 
 
BioEdit was used to generate identity matrices showing the percentage sequence identity between the S gene 
sequences of the four strains. 
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As a result of the cellular mechanisms and pathways by which they are produced, N-Linked 
glycans are present on glycosylated proteins in different forms. Simple or high mannose 
glycans contain a high proportion of mannose molecules compared to complex glycans which 
are subject to trimming by cellular enzymes including mannosidases. The amino acid 
sequence of a protein can be used to predict the location of N-linked glycosylation sites using 
the identification of the amino acid motif Asn-X-Ser/Thr. The presence of this sequence alone 
does not imply attachment of a glycan to this site; the identity of the central amino acid (X) 
influences the likelihood of glycan attachment. For example if a proline follows the Asn 
residue, the site is unlikely to be glycosylated. Other factors are known to influence 
glycosylation in this manner, including the surrounding sequence of amino acids and the 
folding and final conformation of the protein, as this may result in masking or distortion of 
the glycosylation site (Gavel and Heijne, 1990). Using the online server NetNGlyc 1.0, 
locations in the IBV S protein sequence with potential for glycosylation were identified. These 
sites consist of a specific amino acid sequence comprising Asn-X-Ser/Thr (N-X-S/T), where X 
can indicate any amino acid except Pro. The total number of sites present in each strain 
varies, with the most being present in the field strains QX (34 sites) and 4/91 (32 sites), 
compared to the two lab strains M41-CK and Beau-R which contain 29 and 28 potential sites 
across the S gene, respectively. This data is summarised in Table 3.2. Of the total sites in the 
S protein sequence of each strain, there is a higher proportion of N-X-T motifs compared to 
N-X-S. This is a common trait in N-linked glycosylation (Rao and Wollenweber, 2010). 
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Table 3.2: Number of PNGS in each of the selected strains M41-CK, Beau-R, QX and 4/91.  
Strain Total number of sites % N-X-S % N-X-T 
M41-CK 29 38 62 
Beau-R 28 39 61 
4/91 32 44 56 
QX 34 41 59 
 
To assess the conservation of the potential N-linked glycosylation (PNG) sites in the IBV 
genome, global analysis of all available published sequences of each subunit within the S 
gene (S1 and S2) was carried out and percentage conservation for each site was calculated. 
Sequences were obtained from UniProt Protein Database and analysed using Excel based on 
the amino acid positions in the M41-CK sequence. The results from this analysis are shown 
in Figure 3.1. Data are displayed for the S1 and S2 sequences separately. For S1 (Figure 3.1A), 
21 sites were included in the data analysis. Of these sites, 14 were conserved in 90% or more 
of the 834 analysed sequences. The least frequent site was identified at position 281, present 
in only 9.6% of sequences. The sites identified in the S2 region of the protein were more 
conserved across all strains, with 11 of the total 14 sites exhibiting close to 100% 
conservation across all analysed sequences (Figure 3.1B).  It was expected that the sites in 
the S2 sequences would be more conserved than those in the S1 segment, as S1 sequences 
are known to be more genetically diverse than S2 sequences (Gelb et al., 2005, Manswr et 
al., 2018). As the S1 subunit is responsible for attachment and is the main antigenic target 
during IBV infection, it can be postulated that the reason for the great sequence diversity is 
linked to avoidance of host immune responses (Bande et al., 2016, Kant et al., 1992).  
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Figure 3.1: Global analysis of PNGS conservation across all available IBV strains in the S 
gene sequence. Using 834 protein sequences available from GenBank, the predicted N-
linked glycosylation sites in the S1 segment of the IBV S gene were highlighted and assessed 
for conservation between strains (A). The same analyses were performed on 250 sequences 
for the S2 segment (B). The amino acid positions are based on the sequence of M41-CK, 
starting from the S gene start codon, including the signal sequence (amino acids 1-18 
(Promkuntod et al., 2014)).  
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A global analysis of the glycosylation sites was performed using all the available sequences 
from GenBank. Separately, the data from the online server predictions in each S gene 
sequence was used to generate tables of data that show the positions of the sites in each of 
the strains selected for deeper analysis. An alignment of these four gene sequences is 
displayed in Appendix A6. From the data shown in Figure 3.1 it was possible to identify sites 
that were present in the S gene sequences of the four IBV strains used for further analysis in 
this chapter (Beau-R, M41-CK, QX and 4/91). This analysis was also completed by identifying 
any suitable asparagine residues in Asn-X-Ser/Thr motif that are present in the sequences 
detailed in Appendix A6. This data is summarised in Table 3.3. The numbers in the table are 
in reference to the amino acid positions in each strain sequence, so where the numbers differ 
by only one or two positions, the glycosylation site is likely to be in the same place on the S 
protein. Where appropriate these have been grouped together for each strain. Notable 
regions of the S protein structure are labelled above each table including hypervariable 
regions (HVRs), the putative RBD (sourced from Promkuntod et al. 2014) and cleavage sites. 
The S2′ cleavage site is only present in the Beau-R S protein (Bickerton et al., 2018). Data is 
displayed for S1 (top) and S2 (bottom). Again, there seems to be more variation in the 
predicted sites among the four strains within the S1 subunit, compared to those located in 
the S2 subunit which are more conserved between all strains. There are also similarities 
between the field strains and the laboratory-adapted strains too, as there are no unique sites 
in the S2 subunit across the predictions for each virus. The sites present at amino acid 
positions 544 and 1060 (4/91) are not present in the laboratory-adapted strains and 
conversely the site at position 714 in M41-CK and Beau-R is not present in QX or 4/91. The 
differences in the patterns of glycosylation could be linked to the fact that the laboratory 
strains have been adapted to replicate in cell culture whereas the field strains can only be 
propagated in organ cultures, embryonated eggs or chickens.  
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Table 3.3: Amino acid positions of PNGS in IBV strains Beau-R, M41-CK, QX and 4/91. 
Numbering in each strain is based on the amino acid sequence of each protein, including the 
signal sequence. Hypervariable region (HVR) and cleavage sites (CS) are labelled. The S2′ CS 
is only present in the Beau-R sequence. 
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To further investigate the spatial locations of the potential sites, the S gene sequence was 
used to generate a model of the predicted 3D structure of the protein. Figure 3.2 shows the 
predicted structure of the protein, based on a model produced using the homology 
modelling Phyre2 server and PyMol for analysis and annotation. The models are based on 
the recently published IBV M41 S protein structure determined by cryo-electron microscopy 
(EM) (Shang et al., 2018) and demonstrate the spatial arrangement of the predicted 
glycosylation sites. M41-CK has been used to represent all strains as the differences in the 
spatial arrangement of the predicted sites are negligible. The models demonstrate that most 
of the predicted sites lie within the S1 subunit of the protein, quite evenly spread between 
the S1-NTD and S1-CTD. This is unsurprising as this subunit is responsible for attachment and 
N-linked glycans have been implicated in facilitating virus entry and receptor or co-receptor 
binding in related coronaviruses (Han et al., 2007).  
There are several glycosylation sites within the putative receptor binding motif in IBV M41-
CK S1, which has previously been mapped to amino acid residues 19-272 (Promkuntod et al., 
2014). Ten of the predicted sites detailed in Figure 3.2B lie within this putative receptor 
binding domain (RBD). There is evidence of surface oligosaccharides facilitating attachment 
and binding in other coronaviruses (Jeffers et al., 2004, Jeffers et al., 2006) so it is likely that, 
if glycosylated, these sites have some function in interactions with the cellular receptors or 
attachment factors with which the S protein interacts. The recent structural study by Shang 
at al. identified glycosylation at 20 sites in the S protein ectodomain, corroborating the 
predictions of those sites detailed in Figure 3.2B (Shang et al., 2018). All of the sites identified 
by Shang and colleagues were present in the 29 predictions (in M41-CK) described here.  
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Figure 3.2: IBV S modelling based on published M41-CK structure with labelled PNGS 
locations. Ribbon diagram of the putative S protein structure of IBV M41-CK. (A) Monomeric 
unit of the S protein coloured by rainbow from N (blue) to C terminus (red). S1 indicated in 
green/blue and S2 in red/yellow/orange. (B) Monomeric unit of the S protein with labelled 
Asn residues present in PNG sites (pink), generated using PyMol. (C) Trimeric formation of 
IBV M41-CK S from a side view and (D) from a top view, generated using SWISS Model. Each 
colour represents a monomeric unit.  
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In order to confirm the presence of glycans at the sites identified in Figure 3.1, mass 
spectrometry was performed on samples of IBV M41-CK purified by ultracentrifugation and 
chymotrypsin or trypsin digested. Samples of M41-CK containing allantoic fluid were purified 
at The Pirbright Institute by ultracentrifugation. Mass spectrometry sample preparation was 
performed by Dr Stuart Armstrong at the University of Liverpool. Figure 3.3 shows the 
combined results of two experiments performed to first confirm the presence of glycans at 
predicted sites in the amino acid sequence using NanoLC ESI MS/MS (Methods Section 2.15) 
then characterise the structure of the glycans present. Firstly, glycan sites were mapped by 
chymotrypsin or trypsin digestion followed by PNGase F treatment in presence of deuterium 
oxide, or heavy water (D2O). Any peptide modifications were highlighted using PEAKS 
software (BSI) and glycopeptides (chymotrypsin and trypsin digests) were analysed on a 
Thermo Orbitrap fusion instrument with EThcD mode (Methods Section 2.16). Data were 
analysed by using Byonic software (Protein Metrics) to generate cartoons representing the 
glycan composition.  
Glycosylation was confirmed at 18 of the possible 29 asparagine sites predicted by the 
NetNGlyc algorithms in the M41-CK protein sequence. The sample preparation did not allow 
for complete coverage of the S protein sequence so it is possible that more of the predicted 
sites are true glycosylation sites. Of the 18 detected glycans, 10 lie within the S1 subunit and 
8 in S2. The second set of MS experiments revealed the range of glycan structures present at 
6 of the 18 total sites. These are detailed at amino acid positions 144, 212, 425, 513, 947 and 
1014 in the S protein sequence. It is important to note the heterogeneity of the glycans at 
each site as this indicates that each individual S protein in the sample has a potentially 
different glycan profile. The majority of the glycans characterised here are high mannose 
glycans and are quite similar in their composition. Mass spectra for each structure are 
included in Appendix A1.  
81 
 
As described previously, the recent study by Shang et al. identified 20 sites at which the M41 
S protein was glycosylated. Of the sites described in Figure 3.3, nine are shared between the 
two data sets. Interestingly, the study by Shang et al. did not identify glycosylation at 
positions 425, 530, 960, 979, 1014, 1051 and 1074, all of which were confirmed as 
glycosylated by the MS methods described here. Another recent study involving the IBV S 
protein performed similar MS techniques to identify glycosylation sites within the Beaudette 
S protein. This study used a Vero-adapted strain of the virus and identified glycosylation at 
amino acid positions 212, 237, 247, 276, 513, 591, 1051 and 1074, all of which match with 
confirmed sites in Figure 3.3, except 237 and 276 (Zheng et al., 2018). There were differences 
in the strains and methods used in each study, offering some explanation for the differences 
in the results. Across all three studies, there were no differences in the predicted sites but 
those identified as true glycosylation sites differed slightly. 
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Figure 3.3: Confirmation of N-linked glycosylation and characterisation of glycan structures 
in the IBV M41-CK S protein. Purified samples of IBV M41-CK were subjected to trypsin and 
chymotrypsin treatment to separate the peptides followed by NanoLC ESI MS/MS mass 
spectrometry in the presence of heavy water (D2O) to determine the presence of glycans at 
each site.  Sites where the presence of a glycan was detected are indicated by coloured dots. 
Sites where the glycan structure has been predicted using LC MS with EThcD mode are 
indicated by cartoons (generated using Byonic software). Mannose molecules are indicated 
by green circles and N-acetylglucosamine (GlcNAc) molecules are represented by blue 
squares. Figure produced by Dr Stuart Armstrong (University of Liverpool).
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3.2.2 Assessment of the effects of S protein glycosylation inhibition in IBV 
Assessment of the types of glycans present in the IBV S protein profile was carried out using 
inhibitors and enzymatic treatments affecting the various classes of glycan. Kif was used to 
identify the presence of complex glycans on the surface of the protein. Endo H and PNGase 
F were used to cleave simple or high mannose glycans from closer to the glycan core, to 
achieve near complete or complete deglycosylation, respectively. Figure 3.4 describes the 
general structure of an N-linked glycan and indicates the action of the aforementioned 
inhibitors and enzymes. 
 
 
Figure 3.4: N-linked glycan structure and inhibitor action.  Schematic representation of 
possible glycan structures. GlcNac molecules are indicated by purple squares and mannose 
molecules are indicated by circles. PNGase F cleaves all glycans at the GlcNac core resulting 
in full deglycosylation of the treated protein. Endo H acts further downstream of the GlcNac 
core to remove high mannose and some hybrid glycans, resulting in near complete 
deglycosylation. Kif is an inhibitor which acts on the cellular ER enzyme α-mannosidase I to 
prevent the trimming and processing of the core glycans to result in complex glycans, 
inhibiting the formation of this class of oligosaccharide only, leaving simple and hybrid 
oligosaccharides intact.  
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In order to demonstrate the different actions of these inhibitors and therefore elucidate the 
range of glycans present on the surface of IBV S, samples of purified virus were treated with 
deglycosylating enzymes (Endo H and PNGase F) to remove high mannose and some hybrid 
glycans from the surface of the protein. Alongside these treatments, CK cells were infected 
with either M41-CK or Beau-R and treated with the α-mannosidase I inhibitor Kif, with the 
aim of producing viruses that expressed S without complex glycosylation. These treated 
samples were compared to purified wild-type M41-CK and Beau-R. Figure 3.5 shows a 
western blot using the monoclonal S2 antibody 26.1 to demonstrate the change in molecular 
weight when different classes of glycan are removed from the surface of the S protein. For 
both M41-CK and Beau-R, the samples were run in the order untreated purified IBV (UT), Kif-
treated cell lysate (Kif), Endo H treated purified IBV, PNGase F treated IBV. Molecular weights 
were compared to a Bio-Rad protein standard (M) to assess any changes following each 
treatment.  
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Figure 3.5: IBV S displays different classes of glycan. Ultracentrifuge-purified samples of IBV 
propagated in embryonated eggs were treated with deglycosylating enzymes that affect 
different types of glycan and protein size was compared to untreated (UT) virus samples. 
Endo H targets high mannose and some hybrid glycans while PNGase F targets all glycans. 
For inhibition of complex glycan formation, cells were treated with the mannosidase I 
inhibitor Kif at 20µM at the time of infection with IBV (MOI = 1). Protein lysates were 
harvested at 24hpi and used for western blot. S protein was detected using a monoclonal 
antibody against the S2 subunit (26.1, PrioMab). Changes in protein sizes indicate loss of 
glycan mass. Band sizes were compared to Bio-Rad Precision Plus All Blue Protein Standards. 
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In the untreated (UT), wild-type samples of purified M41-CK (left) or Beau-R (right), the S2 
antibody 26.1 produced a distinct band at approximately 80kDa, which indicates the S2 
subunit of the S protein. There was also a large smear of approximately 250kDa at the top of 
each of these lanes. This is thought to indicate uncleaved, glycosylated S protein. The 
additional smaller band of approximately 30kDa in the Beau-R samples is thought to indicate 
cleavage at the secondary cleavage site in the S2 subunit, known as the S2' site. This site is 
thought to contribute to the extended host range of Beau-R, allowing the virus to infect Vero 
cells as well as primary avian cells (Bickerton et al., 2018).  The Kif treated samples, to the 
right of the UT lanes, highlight an interesting difference between the two viral strains used 
for this experiment. In the M41-CK Kif samples, the staining was fainter compared to the 
untreated samples. While this could indicate a reduction in glycosylation levels in this 
sample, it could also indicate a smaller amount of protein in the sample. As this sample is 
derived from cell lysate rather than purified virus it is feasible that less protein was present 
and therefore a fainter band was produced by the S2 antibody. A loading control was not 
used for this experiment so exact conclusions concerning the levels of protein in each sample 
are difficult to draw. In the Kif-treated Beau-R sample, the effect of this inhibitor is more 
obvious, as there was no recognition of the S2 subunit or the putative S2′ cleavage product 
at all. The faint smear at the top of the lane indicates that S protein is still present, however 
the recognition of S2 has been lost following treatment with Kif. This presented an 
interesting line of investigation regarding the involvement of complex glycosylation and the 
S2 epitope recognised by 26.1, as the treatment with Kif had clearly interfered with the 
process of recognition by this monoclonal antibody.  
Different effects were observed in the enzymatically deglycosylated samples, located in the 
Endo H and PNGase F lanes in Figure 3.5. There were notable changes in the bands observed 
in the lanes for the samples treated with each enzyme. For both treatments, a band was 
recognised in both the M41-CK and Beau-R samples, indicated at approximately 70-75kDa. 
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The bands in the Endo H treated samples are slightly larger than the those in the PNGase F 
samples for both viruses, owing to the fact that PNGase F removes all glycans at the GlcNAc 
core, whereas complex glycans are resistant to Endo H treatment and would still have been 
present on the protein following treatment. In the Beau-R samples, the S2′ cleavage product 
was also still recognised following partial and complete deglycosylation. 
The 70-75kDa band in these samples could be indicative of several things. It is possible that 
this is the uncleaved S with partial glycosylation, and that the treatment has resulted in a 
notable shift in band size of the whole protein from approximately 250kDa to 75kDa. While 
glycans themselves do not exhibit a particularly heavy molecular weight, glycosylated 
proteins appear heavier than they are as a result of the bulky, branched nature of their 
attached glycans, so removing them could feasibly result in the dramatic size change 
observed here. It has been reported that glycan mass constitutes approximately half the 
molecular weight of HIV gp120, a similar glycoprotein to IBV S (Lasky et al., 1986, Leonard et 
al., 1990). This could explain the dramatic band shift observed in these samples. However, 
the absence of the S2 band between the uncleaved and S2′ bands cannot be explained in this 
context, unless S2 recognition has been lost entirely in all the Beau-R samples.  
Another explanation of the shift in band sizes is that the band at 70-75kDa is, in fact, the S2 
band, where the treatment with Endo H or PNGase F has resulted in a shift of only 5-10kDa. 
With this hypothesis it is also important to note the absence of the uncleaved S band at 
250kDa. One possibility for this loss is that the enzyme treatment has somehow increased 
cleavage of the S protein into its respective subunits, resulting in more distinct S2 susceptible 
to recognition by the antibody. This may explain the brighter band intensity in the M41-CK 
samples following enzymatic treatment.  
Overall, these results clearly demonstrate a range of glycan structures present on the surface 
of the IBV S protein in both M41-CK and Beau-R samples. While there are some unanswered 
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questions regarding the changes in band recognition in some of the samples, it can be 
assumed that treatment with the α-mannosidase inhibitor Kif has affected the binding 
capacity of the monoclonal antibody 26.1 to the S2 subunit of the protein, indicating a 
potential role for complex glycosylation in this process.  
During glycan processing, several different enzymes act on the oligosaccharides to create 
different classes of glycan. The α-mannosidases I and II are involved in the generation of 
complex glycans and are located in the ER and Golgi, respectively (Aebi et al., 2010, Stanley, 
2011). To confirm that the loss of S2 recognition in Beau-R was specific to Kif treatment and 
inhibition of α-mannosidase I, another mannosidase inhibitor, SW was used to disrupt the 
processing of hybrid glycans in both M41-CK and Beau-R. SW specifically acts on α-
mannosidase II to inhibit glycan trimming and processing in the Golgi.  
Western blot was used to assess whether the S protein could still be detected by mAb 
following SW treatment in IBV-infected cells. CK cells were infected with either Beau-R or 
M41-CK and treated with SW. Cell lysates were processed and analysed by western blot using 
the S2 monoclonal antibody 26.1. Figure 3.6 shows that there was no change in mAb 
recognition of the S2 subunit by the 26.1 antibody following SW treatment, demonstrating 
that the effect seen in Figure 3.5 can be attributed to the inhibition of complex glycan 
formation by Kif. The additional S2′ band at 30kDa was not seen in this experiment. This is 
thought to be due to the nature of the samples, as those used for deglycosylation in Figure 
3.5 are purified IBV and are, as such, much more concentrated than the cell lysates analysed 
during cellular inhibitor treatments. There is also a more general reduction in the band 
intensity in the Beau-R samples compared to the M41-CK samples in this experiment, 
indicating that either there are less cells in the Beaudette samples due to more extensive 
IBV-induced cpe, or that the S2 antibody is less reactive with the Beau-R protein compared 
to M41. This is an important consideration when interpreting these results given the lack of 
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loading control, however the levels of protein recognition between the treated and 
untreated samples shows that in this experiment SW had no effect on S2 binding by 26.1.  
 
 
 
 
 
 
 
 
Figure 3.6: SW has no effect on mAb recognition of S2 in M41-CK or Beau-R infected CK 
cells. CK cells were mock-infected or infected with M41-CK or Beau-R at an MOI of 1. SW was 
added to cells at the time of infection. Cells were lysed using RIPA lysis buffer after 24 hours 
incubation at 37°C and proteins were separated by SDS-PAGE followed by western blot. S2 
was detected using the mAb 26.1 followed by incubation with LI-COR IRDye 700CW 
secondary antibody diluted in blocking solution. Membranes were visualised using the LI-
COR Odyssey.  
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To assess whether the effects observed by western blot were reflected in conformational 
protein as opposed to linear, infections in CK cells in the presence of Kif were carried out to 
investigate whether a similar reduction in antibody recognition would be observed in M41-
CK infected/Kif-treated cells compared to Beau-R infected/Kif-treated cells. The results from 
these infections and IF staining are shown in Figure 3.7. As expected, there is no difference 
in the α-tubulin staining between the mock untreated and Kif-treated cells, indicating that 
the cell viability has not been affected by the inhibitor treatment. There was a marked 
reduction in the signal observed for S2 staining in the Beau-R infected/Kif-treated samples; 
however S2 was still clearly detected by the mAb 26.1 following M41-CK infection with Kif 
treatment. Interestingly this again suggests that complex glycans are involved in allowing the 
mAb to recognise the specific epitope required for binding in Beau-R but not M41-CK. There 
could be a slightly different conformation or sequence in M41-CK where the complex glycans 
are not required for recognition. There could also be differences in the class of glycan 
attached to the sites present in this epitope in M41-CK; complex glycans may not even be 
present here and so the protein may remain unaffected by Kif treatment.  
It is also imperative to note the quality of the staining in the Beau-R infected, Kif-treated cells 
in the bottom right panel of Figure 3.7. The tubulin staining appears to be fainter than in 
these cells than in the other samples, indicating that the treatment has affected the overall 
health of the cells. In contrast, data from cell viability assays suggests that there is no effect 
on CK cell viability following treatment with Kif (Appendix A2), so this could be an anomalous 
result.  
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Figure 3.7: Kif treatment reduced monoclonal antibody binding of S2 during Beau-R but 
not M41-CK infection in CK cells. CK cells on coverslips were infected with M41-CK or Beau-
R at an MOI of 1. Kif (20µM) was added to the media (1xBES) at the time of infection. Cells 
were incubated for 24 hours at 37°C before fixation in 4% paraformaldehyde in PBS. Cells 
were permeabilised using 0.1% Triton in PBS and blocked in 0.5% BSA in PBS. A monoclonal 
antibody against S2 (26.1) was used to detect the S protein. Cells were also stained for α-
tubulin. Cells were stained with secondary antibodies AlexaFluor 568 IgG2a (S2, red) and 488 
IgG1 (α-tubulin, green) and nuclei were counterstained with DAPI (blue).  
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The pattern of glycosylation present on a given protein can differ depending on the cell type 
in which it is produced (Goh and Ng, 2018). Beau-R exhibits an extended host tropism 
compared to M41, in that it is able to infect and successfully replicate in continuous cell lines 
as well as primary CK cells, due to the additional cleavage site present in the S2 subunit as 
recently described (Bickerton et al., 2018). To assess whether the antibody recognition loss 
seen in CK cells was reflected in other cell types, chicken fibroblast (DF-1) cells were seeded 
onto coverslips, infected with Beau-R and treated with Kif before staining for IF. M41-CK is 
unable to infect DF-1 cells and so was excluded from the experiments.  
Figure 3.8 shows the images taken from these experiments. As expected, no S2 was detected 
in either of the mock samples. The α-tubulin staining is also unchanged following treatment 
with Kif. In the Beau-R infected samples, there was a loss of S2 recognition by the monoclonal 
antibody 26.1 following Kif treatment for 24 hours, compared to the untreated samples. 
Again, the signal for the S2 antibody was severely depleted in the treated cells compared to 
the infected control, confirming the results observed by western blot and indicating that 
removal of complex glycans from the protein has removed or distorted the epitope 
recognised by the antibody.  
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Figure 3.8: Kif treatments cause monoclonal antibody recognition loss for Beau-R S2 in DF-
1 cells. DF-1 cells seeded onto coverslips were infected with Beau-R (MOI = 1) or mock 
infected with 1xBES. At the time of infection, Kif was added to the supernatant (20µM). Cells 
were incubated for 24 hours at 37°C before fixation in 4% paraformaldehyde in PBS. Cells 
were permeabilised using 0.1% Triton in PBS and blocked in 0.5% BSA in PBS. A monoclonal 
antibody against S2 (26.1) was used to detect the S protein. Cells were also stained for α-
tubulin. Cells were stained with secondary antibodies AlexaFluor 488 IgG2a (S2) and 568 IgG1 
(α-tubulin) and nuclei were counterstained with DAPI (blue).  
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The effects seen in Figures 3.5-8 indicate a potential role for complex glycans in protein 
folding and antibody recognition, however a role for these glycans in infection and 
replication has not been defined. To address whether inhibiting the formation of these 
glycans had any effect on viral infectivity and to confirm that the Kif treated samples were, 
in fact, infected, supernatant from IBV-infected/Kif-treated CK cells was used for plaque 
assay in CK cells. The average viral titres for M41-CK and Beau-R following treatment with Kif 
are shown in Figure 3.9. For both M41-CK and Beau-R, no significant change in viral titre was 
observed following treatment with Kif. There is a reduction in Beau-R titre following 
treatment but it is not statistically significant (p = 0.1499). Taken together these results 
suggest that complex glycans are non-essential for IBV infection but may have some function 
in contributing to the proper conformation of the protein and arrangement of its epitopes.  
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Figure 3.9: Treatment with Kif does not affect viral titre in CK cells. Cells were infected with 
either M41-CK (black) or Beau-R (grey) at an MOI of 1 for 24 hours either in the presence (+) 
or absence (-) of Kif (20µM). Supernatant was harvested and used for titration by plaque 
assay in CK cells. Infections were repeated 3 times and mean values for each treatment are 
displayed with standard deviation (SD). Statistical analysis of untreated and treated values 
for each virus were completed using unpaired t-test.  
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Further investigations were carried out to provide a more comprehensive understanding of 
the role of complex glycans in antibody recognition of the S protein using another 
monoclonal antibody, known as A13, directed against the S1 subunit. Again, recognition of 
the S protein was assessed by infection of CK cells with IBV in the presence of Kif, followed 
by IF to assess any changes in S protein detection following the inhibition of complex glycan 
formation. Figure 3.10 shows the confocal images from these infections using the A13 
antibody and a polyclonal antibody recognising a range of IBV proteins (chIBV). This antibody 
was used as a control to confirm infection in the cells.  
No staining was observed in the mock cells, bar the nuclei (DAPI), as expected. There was no 
change in S1 recognition by A13 following Kif treatment in either M41-K or Beau-R infected 
cells, indicating that the removal of complex glycans has not impacted the structure or 
formation of the epitope recognised by this antibody and that the effects observed with 26.1 
are antibody specific. The chIBV staining was diffuse throughout the cytoplasm of the 
infected cells in both the treated and untreated samples. 
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Figure 3.10: Recognition of S1 by monoclonal antibody A13 is not affected by Kif treatment. 
CK cells were seeded onto glass coverslips and infected with Beau-R or M41-K at an MOI of 
1 and incubated for 24 hours either in the presence (+) or absence (-) of Kif (20 µM). Cells 
were fixed in 4% PFA and stained using a monoclonal antibody against S1 (A13) and a 
polyclonal antibody against IBV (chIBV). Cells were stained with AlexaFluor Goat anti-Mouse 
IgG 488 (S1, green) and AlexaFluor Donkey anti-chicken IgG 568 (IBV, red). Nuclei were 
counterstained using DAPI (blue).  
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The involvement of surface glycans in evasion of the immune response and neutralising 
epitope shielding is well known (reviewed by Vigerust and Shepherd, 2007). As antibody 
binding to Beau-R S2 was clearly reduced following Kif treatment, effects on virus 
neutralisation were assessed using an antibody against the IBV S1 subunit (A13) by plaque 
reduction assay. Beau-R and M41-K were used to infect CK cells and those treated with Kif 
were compared to untreated infected samples of CK cell supernatant in their susceptibility 
to neutralisation by monoclonal antibody. Figure 3.11 shows the average viral titre of 
untreated and Kif-treated samples, in the presence of decreasing concentrations of A13. This 
allows identification of the concentration at which the antibody becomes neutralising to the 
virus.  
The data clearly show that A13 did not neutralise Beau-R even at the highest concentration 
of antibody. This result was expected as published data has shown Beaudette strains to be 
resistant to A13 neutralisation (Mockett et al., 1984). M41-K was susceptible to 
neutralisation by A13. The dilution at which neutralisation occurred was between 1/64 and 
1/128 for the UT samples. Kif treatment resulted in some slight variations in the data for 
M41-K neutralisation, with the suggestion of a trend towards a minor reduction in its 
susceptibility to A13 neutralisation, however the differences were very small and not 
statistically significant. Kif treatment had no effect on Beau-R, which remained resistant to 
neutralisation in the presence of the inhibitor. The inhibiting action of Kif in these samples 
was confirmed by western blot on the cell lysates from these samples to show loss of 
Beaudette S2 recognition by 26.1 (Figure 3.12). 
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Figure 3.11: Kif treatment does not affect A13-mediated virus neutralisation in M41-K or 
Beau-R infections. Infected CK cell supernatant (untreated (UT) and Kif-treated) was diluted 
to 2000pfu/ml and incubated with decreasing concentrations of the S1 monoclonal antibody 
A13. Virus-antibody solutions at each dilution were used for plaque assay in CK cells. The 
average viral titres (log10) of three biological repeats are shown in pfu/ml and are displayed 
with SEM. Each set of data was analysed by unpaired t-test.  
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Confirmation of the effects of Kif in the experiments detailed in Figure 3.11 was achieved 
through analysis of cell lysates by western blot. The S1 antibody A13 is incompatible for use 
in western blot and so anti-S2 (26.1) was used to verify the inhibitor action in these samples 
through loss of S2 subunit recognition. Figure 3.12 shows the western blot confirming this 
effect in the cell lysates from the original infections used for Figure 3.11. The cell supernatant 
was used for the plaque reduction assay and the cell lysates were harvested and used for 
western blot with 26.1. The 80kDa band indicating S2 recognition was present in both the 
untreated and the Kif-treated M41 samples, again demonstrating that Kif treatment had no 
effect on the recognition of the M41 S2 subunit by 26.1. In the Beau-R samples, the S2 band 
was visible only in the untreated sample and recognition was lost in the Kif-treated sample. 
The bands indicating the presence of β-actin in the Beau-R samples appeared slightly fainter 
than those seen in the M41-infected samples. This may be due to the nature of the strains, 
as Beau-R is known to cause more extensive cpe in infected cells compared to M41 strains, 
meaning a proportion of the cells may have been lost during washing steps as they may have 
become detached during infection.  
This result consolidates previous results, further demonstrating that inhibition of complex 
glycan formation by Kif treatment affects recognition of the S2 subunit by 26.1 by some 
mechanism. It also confirms that the effect is only seen in Beau-R infected cells and that the 
inhibition has no effect on M41 S2 recognition.  
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Figure 3.12: S2 subunit binding by 26.1 is reduced following Kif treatment. CK cells were 
infected with IBV or mock-infected in the presence (+) and absence (-) of Kif and incubated 
for 24 hours at 37°C. Cell lysates were harvested using RIPA lysis buffer and used for SDS-
PAGE followed by western blot using a monoclonal S2 antibody (26.1) and anti-β-actin 
(Sigma). The S2 subunit is indicated at approximately 80kDa. Band sizes were compared to 
Bio-Rad Dual Colour Standards.  
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Using the PNGS predictions detailed in Figures 3.1 and 3.2, attempts were made to generate 
a mutant virus with a modified S protein removing 9 of the PNGS highlighted by the NetNGlyc 
algorithms. These nine sites were chosen for modification based on the scores assigned to 
each site indicating the likelihood of glycan attachment and thus utilisation by the virus. The 
plasmid detailed in Figure 3.13 was synthesised by GeneArt and used in attempts to generate 
the virus through vaccinia virus-based reverse genetics. The plasmid was designed to include 
N to A mutations in each of the nine sites (Figure 3.13B), hence removing the glycosylation 
sequences from the gene. The plasmid was used for homologous recombination followed by 
plaque purification to isolate a virus containing the correct mutations. The reverse genetics 
process is described in detail in Methods Section 2.12. After numerous attempts at virus 
rescue using recombinant vaccinia virus (rVV) DNA containing full length IBV cDNA with the 
modified S gene in both CK and Vero cells, it can be concluded that rescue of this virus (M41-
delPNGS) is not possible. This suggests an essential role for the combination of these specific 
glycan sites most likely in protein folding and virus assembly. While a positive control was 
not specifically included for the rescue attempts, other recombinant viruses were rescued 
successfully at the same time, indicating that the rescue system was not the issue in 
recovering M41-delPNGS. 
It is likely that the virus could not be rescued in CK cells due to incorrect protein folding. 
While each glycan is unlikely to be crucial for virus replication individually, the collective 
mutations may have affected protein folding pathways in the ER and Golgi during protein 
synthesis to a degree where the virus cannot incorporate correctly folded S proteins and thus 
becomes non-viable.  
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Figure 3.13: Rescue of rIBV M41-delPNGS with 9 mutations in PNGS is not possible.  (A) The 
plasmid (generated by GeneArt) detailed was used to generate a recombinant vaccinia virus 
(rVV) containing full length IBV cDNA with a modified S protein containing 9 mutations in 
each glycosylation site. (B) Schematic representation of the modified M41CK-S-PNGS S gene. 
Mutations were introduced at 7 PNGS in the S1 subunit and 2 in the S2 subunit. Asn positions 
are indicated by black arrows.  
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3.3 Discussion 
The N-linked glycosylation profile of IBV, until recently, has remained relatively understudied 
compared to other coronaviruses, where its importance has been proposed in processes 
such as virus entry and immune evasion (Han et al., 2007, Walls et al., 2016b). Four strains 
of IBV were chosen for analysis based on their differences in virulence and pathogenicity. 
Three pathogenic strains (M41-CK, QX and 4/91) and one non-pathogenic strain (Beau-R) 
were selected for sequence analysis to characterise the levels of glycosylation present in 
each strain. M41-CK and Beau-R were selected for more in-depth analysis based on their 
feasibility of propagation in cell culture and the differences in their in vitro tropisms.  
To begin the assessment of N-linked glycosylation in the IBV S protein, the sequences of four 
strains of IBV were analysed to identify any PNGS with the amino acid sequence N-X-S/T. The 
results from this analysis show a high level of potential glycosylation in each strain with 
similar numbers of suitable Asn sites present in each sequence (Table 3.2). The results 
highlight a difference between the lab-adapted strains and the field strains in that the field 
strains QX and 4/91 contain more PNGS than M41 or Beau-R. There is some variation in the 
numbers of potential sites present in the S proteins of other coronaviruses; for example the 
S glycoproteins of the betacoronaviruses SARS and MERS contain far fewer potential sites 
than any of the IBV strains selected for analysis, with 22 and 25 potential sites, respectively 
(Yuan et al., 2017). However across all coronaviruses the S protein exhibits a generally high 
level of glycosylation. In some viruses the presence of such a high density of glycans on the 
surface of the protein has been implicated in epitope masking and immune evasion (Walls et 
al., 2016b).  
The S1 subunit of the IBV S glycoprotein was shown to contain the majority of the N-X-S/T 
sequences. To assess the global conservation between a wider range of IBV strains, the S 
gene sequences were analysed and percentage conservation for all available gene sequences 
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was calculated (Figure 3.1). The majority of the sites identified in the S1 subunit are highly 
conserved among IBV strains, being present in between 80 and 100% of the 834 analysed 
sequences. The high level of conservation among all strains indicates a definite role for 
glycosylation in coronaviruses, otherwise the sites would have been lost through evolution. 
The sheer number of potential sites present in these viruses shows that they must play an 
important part in the success of these viruses.  
Recently published structures of IBV S proteins, elucidated by cryo-EM, have allowed more 
accurate modelling of the strains described here to assess the spatial positioning of the 
glycosylation sites in relation to the whole protein conformation. M41-CK was used here as 
a representative strain to show the positioning of each site on the 3D models generated using 
PyMol and SWISS Model. The recently published structure of IBV M41-CK provided a basis 
for the models detailed in Figure 3.2, with 100% confidence in the sequence identity (Shang 
et al., 2018). The models further demonstrate the higher density of glycosylation sites 
present in the S1 subunit of the protein. As this subunit constitutes the globular head of the 
protein and is responsible for attachment to host cells, this is unsurprising. In other RNA 
viruses with similar glycoproteins such as influenza, glycosylation has been shown to be 
involved in binding to receptors on host cells, facilitating virus entry (Londrigan et al., 2011).  
The number of potential sites present in a given protein sequence does not indicate 
attachment of an oligosaccharide to this site. Many factors influence the likelihood of glycan 
attachment, including the amino acid sequence surrounding the asparagine, not just the N-
X-S/T motif itself. Purified samples of IBV M41-CK were used for analysis by MS to further 
investigate which sites showed evidence of oligosaccharide attachment and which were 
unlikely to be utilised by the virus. The results from the MS experiments in Figure 3.3 indicate 
a high proportion of sites with evidence of glycan attachment; at least 18 of the 29 sites 
present in the sequence are utilised by the virus for glycosylation. There could be a higher 
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number of utilised sites as the coverage of the protein sequence achieved during the 
experiments was not complete. Improvements could be made in future repeats of the 
experiment with more concentrated samples, however this may not be ethically viable due 
to the number of embryonated eggs required to produce the quantities of virus used for 
purification. A recent study using MS techniques to analyse the S protein of a Vero-adapted 
strain of Beau-R showed far fewer utilised sites following their analysis of the glycosylation 
profile. Only 8 sites were identified as being positive for glycan attachment out of a potential 
29 (Zheng et al., 2018). It is possible that the Vero adaptation process has reduced the 
number of utilised sites in the glycoprotein, or that the LC-MS/MS technique used is less 
sensitive than the EThcD techniques used in this analysis. Two separate instruments were 
used for analysis of the M41-CK strain described here, providing a more robust analysis. 
Another recent study investigating the structure of the M41 S protein ectodomain identified 
20 glycosylation sites, similarly to the numbers identified in Figure 3.3 (Shang et al., 2018). 
Comparing the two sets of data reveals that of the 20 sites identified by Shang et al., 9 are 
consistent with sites identified on the S protein M41-CK by MS methods in this study. More 
sites were identified in the S2 subunit of the protein in Figure 3.3 compared to the published 
results. This is not to say that either list is exhaustive. There are differences in the methods 
for each dataset which may have altered the results slightly. For instance, the protein studied 
by Shang and colleagues was expressed in insect cells whereas the protein studied here was 
wild-type as the material used for the experiment was derived from purified virus particles 
propagated in embryonated eggs. The differences in these production methods may have 
influenced the conformation and glycan profile of each protein, resulting in the detection of 
different glycosylation sites. Nonetheless the identification of 9 sites across both methods 
validates the results shown in Figure 3.3, indicating that these sites may be conserved even 
after the high number of passages in CK cells to which M41-CK has been subjected.  
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MS techniques were also used to begin to characterise the structures of the glycans present 
at these sites. Structures were elucidated at six of the sites present in the S glycoprotein, 
with relatively similar oligosaccharide compositions consisting of mainly simple high 
mannose glycans. The heterogeneity of the structures present at each site implies that the 
glycosylation profile varies between individual glycoproteins within a sample of virus. Other 
studies have used the same MS techniques to provide detailed characterisation of the glycan 
shield in other coronaviruses such as HCoV-229E (Walls et al., 2016b). More detailed results 
were obtained from these experiments, including a more diverse range of glycan classes, 
possibly due to sample preparation method using protein expression in human cell lines 
compared to the purification of infected allantoic fluid described here. It is important to note 
that a more diverse range of glycans was detected during the MS experiments but their 
detection fell below the limit of significance compared to the other structures and so were 
not included in the final results. Overall it appears that protein expression systems in human 
and insect cell lines may provide better coverage of the protein compared to the purification 
methods described here. However the data described are more likely to be accurate and 
relevant to the natural host of IBV, as the virus was propagated in embryonated eggs. 
While not fully characterised using MS techniques, a diverse range of glycans has been 
detected on the S glycoproteins of both M41-CK and Beau-R using other techniques. PNGase 
F treatment demonstrates the contribution of N-linked glycosylation to the overall molecular 
weight of the protein, possibly suggesting that more than half the protein’s weight is 
attributed to N-linked glycans. Endo H and Kif were used to demonstrate the presence of 
different classes of glycan present on the protein surface. Taken together the results show 
that the IBV S glycoprotein displays all three major classes of glycan: high mannose, complex 
and hybrid (Figure 3.5). Treatment with the α-mannosidase I inhibitor Kif (Elbein et al., 1990) 
highlighted an important difference between M41-CK and Beau-R; following inhibition of 
complex glycan formation, recognition of the S2 subunit by the mAb (26.1) was completely 
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lost in Beau-R but not in M41-CK. This indicates that the epitope recognised by this mAb has 
been either distorted or lost following removal of complex glycans from the surface of the 
protein. The mAb 26.1 has been shown to bind to residues 546-725 in S2 (Kusters et al., 
1989). There are five PNGS in this epitope, three of which were confirmed by MS (Figure 3.3), 
so it is likely that interference with the attachment and processing of glycans at these sites 
in Beau-R is the reason for the loss in mAb recognition, most likely through epitope 
distortion. These sites are also present in the M41-CK sequence however they may not be 
affected by complex glycan removal. The differences in S recognition by 26.1 in the M41-CK 
samples was also of interest. With a visibly stronger S2 band intensity observed in the M41-
CK-Kif samples, it appeared that the recognition of the uncleaved proportion of S was lost, 
indicating that potentially more cleaved S2 was present in the sample. This could be linked 
to the glycosylation site present just before the S1/S2 cleavage site at M41 position 530 
(confirmed by MS in Figure 3.3). Perhaps the change in glycosylation status at this position 
altered the cleavage rates of the protein within this sample. Further investigation into the 
action and mechanisms involved in Kif treatment would be required to add proof to this 
hypothesis.  
Treatment with another inhibitor (SW) was used to confirm that the effect observed here 
was Kif specific (Figure 3.6). SW treatment did not result in a change in mAb recognition by 
western blot, showing that the results observed with 26.1 were due to Kif treatment and 
inhibition of complex glycan formation. This raises an interesting point about the different 
pathways involved in protein synthesis and folding affected by these inhibitors. The greater 
effects observed with Kif treatment compared to SW treatment could indicate that the action 
of ER α-mannosidase I may be more crucial to the proper synthesis and folding of the protein. 
The ER modifications are more likely to affect the fundamental folding processes in protein 
synthesis, related to the involvement of glycosylation in the calnexin cycle and ERAD 
pathways. SW acts on α-mannosidase II which resides in the Golgi. This enzyme acts after 
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processing in the ER has been completed and the protein has been transported to the Golgi, 
having already achieved an adequate conformation. While modifications that occur in the 
Golgi are important, they may play a less crucial role in the proper folding and epitope 
presentation of the glycoprotein compared to those that occur in the ER.  
Further investigation into Kif-induced mAb recognition loss was carried out using 
immunofluorescence in avian cells. Figures 3.7 and 3.8 both reiterate the loss of S2 
recognition following Kif treatment, showing the effect is not cell type-specific. There was no 
change in viral titre following Kif treatment in CK cells, indicating that complex glycans are 
not required for infection (Figure 3.9). Glycosylation has also been shown to be non-essential 
for viral infectivity in HIV glycoprotein gp120, supporting the data described here (Rathore 
et al., 2017). Further investigations would be required to assess more specific effects of the 
inhibitor in different processes during viral replication. These experiments were also only 
performed after 24 hour treatments. Passaging the virus in the presence of Kif could provide 
more information on how the virus would compensate for the lack of complex glycans, if an 
effect would be seen at all. Similar effects in loss of antibody recognition following 
glycosylation site deletions have been observed in HIV, with the presence of glycan-
dependent epitopes dictating binding to the gp120 envelope protein (Doran et al., 2014).  
In related studies, Kif has mainly been used for investigations into the glycosylation of the 
HIV-1 surface glycoprotein gp120, in which there were notable effects on virus neutralisation 
with monoclonal antibodies following Kif treatment (Walker et al., 2010). The data from the 
plaque reduction assays (Figure 3.12) indicate that Kif treatment has not had an effect on 
Beau-R neutralisation by the monoclonal antibody A13, which has been shown not to 
interact with other Beaudette strains in past studies (Mockett et al., 1984). The data for M41-
K neutralisation are slightly more variable following Kif-treatment, but the differences in 
neutralisation between the treated and untreated samples are not significant. It would be 
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beneficial to study this in more detail using a range of antibodies targeting different epitopes 
on the S protein, to assess which were most affected by the removal of complex glycans. 
Other inhibitors could also be used to disrupt the formation of other classes of glycan to 
elucidate their role in susceptibility to virus neutralisation.  
Another important consideration regarding experiments involving Kif concerns the location 
of the mannosidases on which the inhibitor has an effect within the cell. As mentioned 
previously, mannosidases are important players in the ERAD pathways, which regulate the 
protein folding process in the ER. Interference with these pathways can not only lead to 
altered glycosylation profiles in glycoproteins but also the accumulation of incorrectly folded 
proteins, due to the suppression of the regulation mechanisms. In-depth analysis of these 
pathways is beyond the scope of the project however this may be important to remember 
when analysing future experiments with Kif, taking into account any off-target effects that 
may have arisen as a result of disruption of these critical cellular pathways.  
Assessment of the role of individual glycans in viral replication would be beneficial to start 
to target specific sites for vaccine development, in order to render the virus more susceptible 
to the host immune response, for example. Attempts were made to generate a recombinant 
virus containing a modified S glycoprotein with mutations in the individual glycosylation 
sites, based on the information generated by the NetNGlyc 1.0 Server. The combination of 
mutations included in the modified S protein was not compatible with virus rescue, indicating 
that these glycosylation sites are essential for virus viability. It is unclear whether all the 
mutated sites are individually important to the virus or whether the effect is cumulative. 
Given the crucial involvement of glycosylation in protein folding pathways in the ER and 
Golgi, it is likely that the mutated protein was not able to achieve a native conformation and 
was targeted to for degradation. The protein could also have been misfolded and 
incorporated into virions in the wrong conformation, leading to altered or reduced function. 
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Mutations in N-linked glycosylation sites have been shown to impact rescue in other viruses 
due to interference in protein folding. It has also been suggested that mutations in the PNGS 
closer to the N-terminus of the protein are more likely to impact folding and hence virus 
rescue (Shi et al., 2005, Herbert et al., 1997, Helenius and Aebi, 2001), providing a possible 
explanation for the failure of M41K-delPNGS rescue. It could also be true that the mutant 
virus was, in fact, recovered with the modified S protein, but was then incapable of 
productive infection on subsequent passages and amplification. In any case, this 
recombinant virus could not be detected in any of the amplification attempts and so it can 
be concluded that this amount of mutations is incompatible with rIBV rescue.  
It has been shown that IBVs with fewer mutations can be rescued and characterised in vitro. 
Recently, Zheng et al. demonstrated notable effects in cell-cell spread and fusion activities 
following N to D mutations in individual N-linked glycosylation sites in the IBV Beaudette S 
protein (Zheng et al., 2018). As this data is all based on a Vero-adapted strain of Beaudette, 
it would be highly beneficial to study the effects of PNGS mutation in a more relevant 
pathogenic virus such as M41, where the mutations could be studied in an in vivo setting as 
well as in vitro. As there is now a more robust set of data surrounding the IBV glycosylation 
profile, individual glycosylation sites can be selected for mutation in the M41 S glycoprotein 
based on information from the MS experiments described in Figure 3.3. These experiments 
will provide more insight into the role of specific glycans in protein function and the virus 
lifecycle.  
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Chapter 4: Generation and characterisation of rIBV 
M41K-BeauR(S) to assess the role of the S protein 
in IBV pathogenesis 
 
4.1 Introduction:  
The spike (S) protein of IBV is involved in several parts of the virus lifecycle including 
attachment to an unknown receptor and fusion of viral and cellular membranes. The protein 
is cleaved into two subunits, S1 and S2. Previous work has shown that the S1 subunit is 
involved in viral entry into host cells as it contains the putative receptor binding domain 
(RBD) whereas S2 is responsible fusion of viral and cellular membranes and has been shown 
to determine cell tropism (Wickramasinghe et al., 2011, Bickerton et al., 2018). However, the 
role of the S protein in IBV pathogenicity has remained relatively unexplored. This is largely 
due to a lack of reverse genetics system for modifying genes in a pathogenic virus. In previous 
studies, the ectodomain of the S protein from a pathogenic strain of IBV was inserted into a 
non-pathogenic genome but this was not sufficient to confer pathogenicity to the 
recombinant virus (Hodgson et al., 2004). Since this study, another reverse genetics system 
based on a pathogenic IBV strain has been developed to better understand IBV pathogenesis.  
The pathogenic molecular clone known as M41-K was generated from a pathogenic lab strain 
of IBV, M41-CK.  
Here, the genome of M41-K has been altered using reverse genetics to replace the S protein 
with that of a non-pathogenic strain, Beau-R (a non-pathogenic molecular clone of the Beau-
CK lab strain). The replication and pathogenicity of the resultant recombinant virus rIBV 
M41K-BeauR(S) have been assessed both in vitro and in vivo to further elucidate the S 
protein’s role in the virus lifecycle and disease pathogenesis.  
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4.2 Results 
4.2.1 Generation and rescue of rIBV M41K-BeauR(S)  
The rIBV M41K-BeauR(S) was generated by reverse genetics using VV as a vector for the IBV 
full length cDNA. TDS was used to modify the IBV cDNA using the plasmid detailed in Figure 
4.1, containing the Beaudette S1 sequence flanked by a section of the sequence of the M41 
replicase gene at the 5' end and a section of the Beaudette S2 sequence at the 3' end. The 
recombinant S gene sequence detailed in Figure 4.1 was inserted into an rVV containing full 
length M41-K cDNA comprising the Beaudette S2 gene sequence and a deleted S1 sequence 
(rVV M41K-delS1-BeauR-S2), thus generating full length rVV M41K-BeauR(S).  
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Figure 4.1: (A) Plasmid map of pGPT-M41-BeauR-S1 used to generate rIBV M41K-BeauR(S) 
containing the recombinant S sequence comprising the Beaudette S1 subunit with flanking 
regions of the M41 replicase gene at the 5' end and Beaudette S2 at the 3' end within the 
pGPT plasmid vector. The AmpR gene and the lac promoter sequence are highlighted along 
with the pUC origin of replication site (ori). The S1 gene is indicated. The plasmid map was 
generated from the plasmid sequence using SnapGene. (B) Schematic diagram detailing the 
structure of the chimeric S gene in the recombinant virus rVV M41K-BeauR(S), comprising 
the Beaudette-derived ectodomain flanked by the M41 transmembrane domain and 
cytoplasmic tail.  
S1 
pGPT-M41-BeauR-S1 
6456bp 
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Following the completion of six rounds of plaque purification as part of the TDS process 
(Methods Section 2.12.3), two rVV isolates were chosen based on PCR verification of the loss 
of the selection gene (gpt) and the presence of the correct insertion – the Beaudette-derived 
S gene. Large stocks of these two rVV M41K-BeauR(S) isolates were propagated BHK-21 cells. 
DNA was extracted from the cells by phenol-chloroform extraction and the quality of the 
DNA used to rescue the recombinant virus was assessed using PFGE. A SalI digest was 
performed to separate a fragment containing the rIBV DNA from the rVV DNA.  
Figure 4.2 shows the PFGE image analysing the rVV DNA extracted from infected BHK-21 
cells. The band at approximately 33.5kb indicates the full length IBV cDNA in both isolates (1 
and 2). The presence of this fragment demonstrates the successful generation of rVV M41K-
BeauR(S) and that the DNA is of sufficient quality to attempt rIBV rescue in CK cells.  
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Figure 4.2: Analysis of full length rIBV M41K-BeauR(S) cDNA within vaccinia virus (VV) 
vector DNA. VV DNA was extracted from BHK-21 cells infected with stocks of two isolates (1 
and 2) of recombinant VV containing IBV M41K-BeauR(S) cDNA. The DNA was digested using 
SalI (Invitrogen) to produce a fragment of approximately 33.5kb. 1µg of DNA from each 
isolate was analysed by PFGE. The SalI fragment containing full length IBV cDNA is indicated 
by a band at approximately 33.5kb. Band sizes were compared to a BioRad 8-48kb DNA 
Standard (M).  
 
 
 
 
 
 
rVV M41K-BeauR(S) DNA  
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After several attempts, rIBV M41K-BeauR(S) was successfully rescued in CK cells using FPV-
T7 with the addition of a plasmid containing the IBV M41 nucleocapsid (N) gene, to package 
the genomic RNA. Following rescue, the virus was passaged in CK cells and embryonated eggs 
to amplify the amount of virus present. Figure 4.3 shows an agarose gel of the positive PCR 
from the first egg passage (EP) indicating IBV presence and a successful virus rescue. A band 
of approximately 500bp was present in each of the three M41K-BeauR(S) lanes (1, 2 and 3). 
This showed that IBV was present in all of the rescue isolates. A previously analysed sample 
of cDNA, known to be positive for IBV QX, was used as a positive control for the PCR. The size 
of the band in this lane (+) was slightly larger than the band for the M41K-BeauR(S) isolates, 
due to the longer PCR product generated by this set of primers in QX samples.  
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Figure 4.3: Confirmation of rIBV M41K-BeauR(S) rescue. RNA was extracted from allantoic 
fluid from the first passage of M41K-BeauR(S) in three replicate embryonated hens’ eggs 
(EP1) and used for RT-PCR (Invitrogen SuperScript IV, Invitrogen Taq DNA Polymerase) with 
primers covering the 3' UTR of the IBV genome (BG56 and BG93/100). A DNA band of 
approximately 500bp indicates presence of IBV in the samples. + = IBV QX cDNA, - = H2O.  
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In order to verify the identity of the rescued virus, cDNA generated from infected allantoic 
fluid was analysed by RT-PCR and Sanger sequencing using primers covering the overlap 
between the M41-K backbone and the Beaudette-derived S gene. Figure 4.4 shows an 
example of the sequence analysis, confirming the presence of the Beau-R sequence within 
the M41-K genome. The recombinant S protein comprises the Beaudette ectodomain with 
the cytoplasmic tail and transmembrane domain of M41-K. Inclusion of the M41 sections of 
the gene sequence preserves the interactions of S with other viral proteins.  
The rescued virus was confirmed to be positive for the correct recombinant S gene. As shown 
in Figure 4.4A, the viral genome sequence of M41K-BeauR(S) is homologous to M41-K until 
position 483 (within the recombinant S gene sequence), at which point the gene is then 
homologous to the Beau-R S sequence, thus conserving the signal sequence of the M41 S 
gene. The S sequence of the recombinant virus matches the Beau-R sequence until position 
3357, at which point it becomes homologous to M41-K, thus conserving the CT and TM 
domains at the end of the recombinant S gene.  
This shows that the entire process of generation and virus recovery for rIBV M41K-BeauR(S) 
was successful and that the intended recombinant sequence was not altered as a result of 
rescue passaging.  
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Figure 4.4: Example sequence alignment of M41K-BeauR(S), M41-K and Beau-R stocks. 
Stocks of M41K-BeauR(S) were propagated in embryonated hens’ eggs and the allantoic fluid 
containing the virus was used for RT-PCR followed by Sanger sequencing using primers 
covering the S gene sequence and the flanking regions. Differences between the consensus 
sequences are highlighted. The S gene start codon is highlighted in yellow at position 428. 
Arrows indicate M41K-BeauR(S) sequence homology to the M41-K genome (orange) or the 
Beau-R genome (blue).  Numbers indicate the nucleotide position within the recombinant S 
gene including flanking regions of the M41 signal sequence (A) or the cytoplasmic tail at the 
3′ end of the gene (B).  
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4.2.2 In vitro characterisation of rIBV M41K-BeauR(S) 
From the three successfully rescued isolates of M41K-BeauR(S), two were randomly selected 
for the propagation of virus stocks in embryonated eggs. These stocks were used to 
characterise the virus in vitro. Figure 4.5 shows the replication kinetics of M41K-BeauR(S) in 
primary CK cells (Fig. 4.5A) and cpe caused by the virus in CK cells after 48 hours (Fig. 4.5B). 
M41K-BeauR(S) follows the same replication pattern as Beau-R and causes similar levels of 
cpe in the infected cells, indicating that it has adopted the characteristics of the S protein 
donor strain. All viruses used for this experiment reached peak titre at 24 hpi. There was no 
statistically significant difference between any of the peak viral titres.  
The similarities in the cpe induced by Beau-R and M41K-BeauR(S) shown in Figure 4.5B 
indicate that the virus infection and spread through the cell monolayer occurred in a similar 
manner. This was expected as both viruses contain the same S ectodomain. Again, this 
demonstrates that M41K-BeauR(S) adopted the in vitro tropism of the S donor strain, Beau-
R.  
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Figure 4.5: rIBV M41K-BeauR(S) replicates in primary chick kidney (CK) cells. (A) Cells were 
infected with M41-K, Beau-R or M41K-BeauR(S) at an MOI of 0.1 and incubated at 37˚C for 
96 hours. Supernatant was harvested at 1, 24, 48, 72 and 96 hours post-infection and titrated 
by plaque assay on CK cells. Average viral titre at each time point is displayed with standard 
SEM in pfu/ml. Data were analysed by One-Way ANOVA to compare replication of the three 
viruses (B) IBV-induced cytopathic effect (cpe) in CK cells at 48 hpi infected at an MOI of 0.1 
with M41-K, Beau-R or M41K-BeauR(S) compared to mock infected cells.  
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Due to the presence of the Beaudette S protein ectodomain, it was hypothesised that M41K-
BeauR(S) would be capable of replicating in both avian and mammalian continuous cell lines, 
exhibiting an extended host tropism compared to M41-K which can only infect primary CK 
cells. To test this hypothesis, continuous cell lines were infected with M41K-BeauR(S) and 
the viral replication kinetics were assessed. Figure 4.6 shows the replication kinetics of 
M41K-BeauR(S), Beau-R and M41-K in Vero cells (Fig. 4.6A) and DF-1 cells (Fig. 4.6B).  
In Vero cells the recombinant virus was unable to reach the same titre as Beau-R but did 
exhibit similar replication kinetics over 96 hours. Given that the stock of M41K-BeauR(S) used 
to infect the Vero cells was propagated in embryonated eggs and was not adapted to Vero 
cells, it is unsurprising that there was some difference between the titres. Differences 
between the titres of Beau-R and M41K-BeauR(S) at both 72 and 96 hpi were statistically 
significant. M41-K is unable to replicate in Vero cells due to its restricted tropism. Both M41K-
BeauR(S) and Beau-R replicated to significantly higher titres from 24 hpi onwards.  
DF-1 cells are a chicken fibroblast cell line which also support Beaudette replication (Himly 
et al., 1998). Replication of M41K-BeauR(S) in these cells is significantly lower than Beau-R at 
24 and 48 hpi, but the virus is able to replicate to significantly higher titres than M41-K, 
further demonstrating that the recombinant virus M41K-BeauR(S) has adopted the extended 
host tropism of the Beaudette strain. This characteristic is conferred by the Beaudette S 
gene, demonstrating that the ectodomain of the Beau-R S protein is sufficient to alter viral 
tropism.     
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Figure 4.6: Demonstration of extended host tropism: in vitro replication characteristics of 
rIBV M41K-BeauR(S) in continuous cell lines. Confluent monolayers of Vero cells (A) and DF-
1 cells (B) were infected with M41-K (green), Beau-R (blue) or M41K-BeauR(S) (orange) at an 
MOI of 0.1 and incubated at 37°C for 96 hours. Supernatant was harvested at 24 hour 
intervals and titrated by plaque assay in CK cells in triplicate. Log10 values of average viral 
titres are shown in pfu/ml with SEM. Infections were performed in triplicate and average 
values were analysed by One-Way ANOVA for each time point. Comparisons between each 
virus are indicated by coloured asterisks above the relevant line, matched to the colour of 
each group in the key (* indicates p < 0.02, ** p < 0.01, *** p < 0.001, **** p < 0.0001).  
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Distribution of the recombinant S protein in infected primary CK cells was assessed using 
indirect immunofluorescence with a monoclonal antibody against the S2 subunit of the 
protein. Figure 4.7 shows the distribution of the protein in CK cells infected with M41K-
BeauR(S) compared to the parent viruses M41-K and Beau-R. Cells were also stained for α-
tubulin as a cellular control. There was no S2 staining visible in the mock infected cells, as 
expected. In the Beau-R infected cells, staining of the S protein was diffuse throughout the 
cytoplasm. There appeared to be less Beau-R infected cells compared to the M41-K samples, 
however this may have been due to image frame variance rather than true infection rate. In 
the M41-K infected samples, staining was again diffuse throughout the cytoplasm, similar to 
what was observed in the M41K-BeauR(S) infected cells, in which there was also a visibly 
higher proportion of infected cells.  
Taken together these results show that the S protein is diffuse throughout the cytoplasm of 
all infected cells independent of the virus strain. M41K-BeauR(S) was able to infect and 
replicate in CK cells to similar levels as both the parent viruses M41-K and Beau-R. It also 
demonstrates that the recombinant nature of the S protein in M41K-BeauR(S) had no effect 
on the binding ability of the monoclonal S2 antibody 26.1.  
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Figure 4.7: rIBV M41K-BeauR(S) exhibits the same S protein distribution as M41-K and 
Beau-R in infected CK cells. CK cells were infected with Beau-R, M41-K or M41K-BeauR(S) at 
an MOI of 1 and distribution of the S protein was compared to mock infected cells using a 
monoclonal antibody against the S2 subunit (26.1). Nuclei were stained with DAPI (blue). 
Alpha-tubulin is stained in red (AlexaFluor 568 Goat anti-mouse IgG1) and S2 is stained in 
green (AlexaFluor 488 Goat-anti-mouse IgG2a).  
 
 
 
 
Mock  Beau-R  
M41-K M41K-BeauR(S))  
128 
 
As the primary site of IBV replication in vivo is the epithelial cells of the trachea, M41K-
BeauR(S) replication was also characterised in ex vivo tracheal organ cultures (TOCs). Figure 
4.8 shows the replication kinetics of the recombinant virus and the two parent viruses in 
tracheal organ cultures. All three viruses reached peak titres at 24 hpi, with very little 
variance between the values. After this point, virus titres began to decrease steadily in M41K-
BeauR(S) infected TOCs. Both M41-K and Beau-R exhibited a small increase in titre from 48 
to 72 hpi. There was a small difference in titre at 72hpi between the two parent viruses and 
the recombinant M41K-BeauR(S) which is of statistical significance.  
 This demonstrates that M41K-BeauR(S) followed the same pattern of replication in ex vivo 
cultures as well as in primary cells and reached the same peak titres as the parent viruses 
M41-K and Beau-R. It also shows that the insertion of the Beaudette sequence into the M41-
K genome has not affected the ability of the recombinant virus to replicate in tracheal 
epithelial cells.  
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Figure 4.8: Viral replication kinetics of M41K-BeauR(S) in ex vivo tracheal organ cultures 
(TOCs) compared to M41-K and Beau-R. TOCs were infected with 1x104pfu/ml of either 
M41-K (green), Beau-R (blue) or M41K-BeauR(S) (orange) and incubated at 37˚C rotating at 
8rph for 96 hours. Supernatant was harvested from each TOC at 24 hour intervals and 
titrated by plaque assay in chick kidney (CK) cells. Infections were replicated 3 times and 
average viral titres are displayed with standard error of the mean (SEM). Values at each time 
point were analysed by One-Way ANOVA (* indicates p < 0.01). At 72hpi the difference 
between M41-K and Beau-R titres is not significant but the difference between the parent 
viruses and M41K-BeauR(S) is significant.  
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During in vivo infections, pathogenic strains of IBV infect and destroy the ciliated epithelial 
cells of the trachea in infected birds. This destruction leads to ciliostasis and cessation of 
ciliary activity, resulting in secondary bacterial infections and increased mortality. In 
industrial studies for vaccine development, IBVs are usually predicted to be pathogenic if 
they cause extensive (more than 50%) reductions in ciliary activity during infection in vivo. 
Beau-R is an exception to this general rule, as it causes ciliostasis ex vivo but is non-
pathogenic in vivo. 
As an indicator of pathogenicity, the ability of M41K-BeauR(S) to cause ciliostasis was 
assessed ex vivo. TOCs were infected with M41K-BeauR(S), M41-K or Beau-R and ciliary 
activity was recorded over 96 hours. Figure 4.9 shows the effects on ciliary activity over the 
course of the experiment. While ciliary activity on the mock infected cultures remains close 
to 100% throughout the experiment, it is almost completely ablated in those infected with 
M41K-BeauR(S) by 48 hours post-infection. The majority of ciliary activity is diminished in all 
infected groups by 72 hours post-infection. From 48 hours post-infection, values for ciliary 
activity in M41-K and M41K-BeauR(S) infected TOCs were significantly different to the mock 
and from 72 hours post-infection, this was true for all infected groups. The statistical analysis 
displayed in this figure indicates that each group was compared to the mock. From 48 hours 
post-infection, ciliary activity values for each of the infected groups is significantly different 
from the mock-infected group. 
These results further demonstrate that the recombinant virus M41K-BeauR(S) can infect and 
maintain replication in tracheal epithelial cells and is also capable of causing ciliostasis in 
these cells at 37°C. 
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Figure 4.9: rIBV M41K-BeauR(S) induced ciliostasis is comparable to M41-K ex vivo. TOCs 
were infected with 1x10
5
pfu of each virus in replicates of 10. Ciliary activity of each TOC was 
assessed under a light microscope at 24 hour intervals. TOCs were given a score from 1-4 
(0=ciliostasis, 1=25% beating, 2=50% beating, 3=75% beating, 4=100% beating). The average 
values are displayed as percentages with standard deviation (SD). Data were analysed by 
One-Way ANOVA followed by Tukey’s multiple comparison test, allowing comparison 
between viruses at each time point. Significance is indicated (* indicates p < 0.04, ** indicates 
p < 0.005).  
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4.2.3 In vivo analysis of rIBV M41K-BeauR(S) pathogenesis 
The results displayed in Figures 4.5 – 4.9 show that the recombinant virus M41K-BeauR(S) is 
able to replicate efficiently in both primary and continuous cells, indicating that the inserted 
S gene did not impair viral replication or infectivity. They also clearly demonstrate that the 
virus has adopted the in vitro tropism of Beau-R. The effect of the S gene modification on 
replication in vivo, however, remained to be assessed. 
Pathogenicity of M41K-BeauR(S) was investigated and compared to the pathogenic parent 
viruses M41-K (molecular clone) and M41-CK (population). Groups of 12 SPF RIR chickens 
were infected with IBV or mock-infected with PBS at 8 days of age via the ocular-nasal route, 
according to the protocol outlined in Methods Section 2.23.1. Clinical signs, including 
snicking and rales, were assessed daily from day 3 pi and recorded for each bird. Post-
mortem (PM) tissue samples were taken from three randomly selected birds in each group 
on days 4 and 6 pi. Ciliary activity in the trachea of these birds was also assessed on days 4 
and 6 pi. On day 7 pi, the remaining six birds in each group were culled and tissues were 
harvested. Details of the experimental plan are shown in Figure 4.10.    
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Figure 4.10: Experimental plan for M41K-BeauR(S) pathogenicity assessment. Groups of 12 
SPF RIR chicks were infected at 8 days old with 1x104 pfu of either M41-K, M41K-BeauR(S) or 
M41-CK by the ocular-nasal route. A mock group was inoculated with PBS by the same 
method. Clinical signs were recorded from day 3 to 7 pi. Three birds from each group were 
selected at random on days 4 and 6pi and tissues were extracted for PM analysis. All 
remaining birds were culled on day 7pi.  
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As described, any IBV-induced clinical signs in the infected birds were assessed every day 
from day 3 to day 7 pi. The breathing of each bird was assessed to identify any infected 
animals exhibiting rales. The number of snicks in each group on each day was also calculated. 
Clinical signs from the infected birds are shown in Figure 4.11.  
The percentage of birds exhibiting rales in each group is shown in Figure 4.11A. The mock 
infected birds displayed no rales on any of the observation days pi. Similar observations were 
made in the M41K-BeauR(S) infected group. Conversely, the percentage of birds exhibiting 
rales in the M41-K and M41-CK infected groups increased over the course of the experiment 
to peaks of approximately 90% and 70%, respectively. Again, the number of snicks in the 
M41-K and M41-CK infected groups increased over the course of the experiment, with the 
peak values occurring on days 6 and 7, respectively. Very few snicks were recorded in the 
M41K-BeauR(S) infected group on any of the observation days. Even fewer still were 
observed in the mock infected group (Fig.4.11B).  
Overall, few respiratory signs were observed in the M41K-BeauR(S) infected group compared 
to the M41 infected birds (Fig. 4.11A and Fig. 4.11B). This indicates that the recombinant 
virus is non-pathogenic as it was unable to cause clinical disease in infected chickens.  
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Figure 4.11: rIBV M41K-BeauR(S) causes mild clinical signs in vivo. (A) From day 3 pi, the 
breathing of each bird was assessed daily and those exhibiting rales were noted. The number 
of birds exhibiting rales is shown expressed as a percentage of the total number of birds in 
each group. (B) The average number of snicks per bird per minute was recorded daily for 
each group.  
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Tracheal ciliary activity in the infected birds was measured under a light microscope on days 
4 and 6 pi, according to the protocol outlined in Methods Section 2.23.4. A percentage ciliary 
activity was calculated for the birds in each group in order to assess the ciliary damage 
induced by infection with IBV (Figure 4.12). Ciliary activity in the mock infected group 
remained close to 100% in all birds on both days pi. Similar results were seen in the M41K-
BeauR(S) infected birds, where, again, there appeared to be no effect on ciliary activity on 
either day pi. In the M41-K and M41-CK infected groups, ciliary activity was ablated by day 4 
pi. By day 6 pi the ciliary activity had recovered slightly but was still significantly reduced 
compared to the both the M41K-BeauR(S) and mock infected groups. This indicated that 
infection with the recombinant virus M41K-BeauR(S) had no effect on the ciliary activity in 
the trachea. There were no statistically significant differences between the values for ciliary 
activity in the M41-K and M41-CK control groups.  
The chickens infected with M41K-BeauR(S) showed very few respiratory signs of infection 
and ciliary activity in the trachea was largely unaffected by infection. Taken together the 
results from Figures 4.11 and 4.12 indicate that rIBV M41K-BeauR(S) is attenuated in chickens 
and unable to cause ciliostasis in vivo. Clinical signs and ciliary activity observed in the M41K-
BeauR(S) infected birds were similar to those observed previously in experiments assessing 
Beau-R pathogenicity. Previous studies demonstrated that Beau-R did not cause clinical signs 
and so, in line with the principles of the 3Rs, it was not chosen as a control for this experiment 
(Hodgson et al., 2004).  
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Figure 4.12: rIBV M41K-BeauR(S) does not affect ciliary activity in vivo. Trachea from the 
three birds culled on days 4 and 6 was divided into 10 x 1mm sections (3 from the dorsal 
section, 4 from the medial section and 3 from the terminal section) and ciliary activity was 
assessed under a light microscope. Ciliary activity for each group on each day pi is expressed 
as a percentage with SEM. Average values of percentage ciliary activity for each day were 
analysed by One-Way ANOVA followed by Tukey’s multiple comparison test to compare 
mean values in each group (*** indicates p <0.0004, **** indicates p < 0.0001). Significance 
between the mock, and M41-K and M41-CK groups is indicated as well as significance 
between M41-K and M41-CK compared to M41K-BeauR(S). Differences between the mock 
group and M41K-BeauR(S) were not significant, nor were the differences between M41-K 
and M41-CK. 
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Assessment of virus dissemination from the sites of infection was performed by RNA 
extraction from a panel of homogenised tissues extracted on days 4 and 6 pi followed by RT-
PCR using primers covering the 3' UTR of the IBV genome (BG56 and BG93/100). Isolation of 
viable virus from the trachea was achieved by infection of embryonated eggs with tracheal 
homogenate followed by screening of the infected allantoic fluid by RT-PCR. The results from 
these experiments are summarised in Table 4.1. The PCR results from each of the three 
individual birds on days 4 and 6 are detailed alongside clinical signs for each bird and any 
observations noted during the PM examinations.  
The pattern of dissemination for the two pathogenic control viruses is very similar, with the 
viruses reaching the trachea by day 4 and remaining present to day 6 pi. Both M41-K and 
M41-CK appear to have been cleared from the beak and eyelid by day 6 pi. M41K-BeauR(S) 
is present in the beak and eyelid on day 4 pi but only in the eyelid on day 6 pi. Virus can be 
detected in the trachea of 1 of the 3 birds on day 4 and day 6 pi by standard RT-PCR and in 
two of the three virus isolation samples on day 6 pi. This difference can be attributed to the 
increased sensitivity of the virus isolation technique, as any virus present in the sample is 
likely to have been amplified during the infection in the embryonated egg. IBV was not 
detected in any of the remaining tissues for any of the groups.  
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Samples positive for detection of IBV genome are indicated by shaded boxes. Homogenate from the trachea was 
also used for virus isolation (V.I.) in embryonated eggs. M41K-BeauR(S) group = F, M41-K group = G, M41-CK 
group = H. 
Table 4.1: Assessment of in vivo virus dissemination by RT-PCR. 
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Results from the PCR screening shown in Table 4.1 indicated that there was a lot of variation 
in the presence of each strain in the eyelid and trachea. To quantify the amount of virus 
present in these tissues of each bird, samples of trachea and eyelid were taken on days 4 and 
6 pi from 3 birds selected at random from each group. Ex vivo TOCs were infected with 
homogenised trachea or eyelid samples from each day. Viral load in each sample was 
calculated by ciliostatic dose (CD50) using the Reed-Muench method (1938).  
Figure 4.13 shows the quantities of virus present in each sample on each day post-infection 
for eyelid (Fig. 4.13A) and trachea (Fig. 4.13B). On day 4 pi, average viral load in the M41K-
BeauR(S) infected group was significantly lower than in the group infected with M41-CK in 
the trachea (p < 0.05). By day 6 viral load in the M41 infected groups was more similar to the 
M41K-BeauR(S) group, which remained relatively low on both days. There was some 
variation between individual birds in the M41K-BeauR(S) infected group, with almost no 
detectable virus in the trachea on either day pi.  
In the eyelid samples at day 4pi, viral load is significantly lower in the M41K-BeauR(S) and 
M41-K infected birds compared to the M41-CK infected birds (p < 0.01). Each group contains 
data from 3 individual birds apart from M41-CK day 4pi which contains data from 2 birds. 
The viral load in the third sample was greater than the dilutions measured and can be 
assumed to be greater than 3 log10CD50/ml. On day 6, there are no significant differences 
between the viral loads in the eyelid in any of the infected groups.  
The data displayed here indicate that M41K-BeauR(S) is able to disseminate from the sites of 
infection to the trachea in the infected birds but is present at significantly lower levels than 
the pathogenic parent viruses (M41-K and M41-CK).  
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Figure 4.13: Quantification of viral load in extracted tissues measured by ciliostatic dose 
(CD50). (A) Homogenate from sections of trachea from three birds culled on day 4 (left panels) 
and day 6 (right panels) pi was titrated in ex vivo tracheal organ cultures (TOCs). Homogenate 
was serially diluted in TOC growth medium and 500µl of each dilution was used to infect 
TOCs in replicates of 5. TOCs were incubated for 6 days at 37˚C (8rph) after which each TOC 
was assessed under a light microscope for ciliary activity. Those exhibiting ciliostasis were 
recorded as positive for IBV presence. Ciliostatic dose (CD) was then calculated using the 
Reed-Muench method (1938). Log10 CD50 values are displayed for each bird. Data were 
analysed by One-Way ANOVA using multiple comparisons (* indicates p < 0.05). (B) Viral load 
in samples of eyelid homogenate was measured by the same method as in the trachea  
(* indicates p < 0.01).  
* 
A: Trachea 
B: Eyelid 
*
*
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4.3 Discussion:  
A recombinant IBV has been generated using a VV based reverse genetics system where the 
S gene from a non-pathogenic IBV was inserted into the genome of a pathogenic strain. The 
resulting virus is known as M41K-BeauR(S) and was successfully rescued and characterised 
both in vitro and in vivo to compare replication and pathogenicity with the parental viruses 
M41-K and Beau-R.  
The recombinant virus M41K-BeauR(S) has adopted the in vitro replication characteristics of 
the S donor strain Beau-R. The virus replicates to similar titres as both parent viruses in CK 
cells (Figure 4.5A) but exhibits the extended host tropism of Beau-R, where it is able to infect 
and replicate in mammalian (Vero) cells (Figure 4.5 and Figure 4.6A). At present, there are 
several hypotheses concerning the extended host tropism of Beau-R. Certain studies have 
attributed it to an additional cleavage site present in the S2 segment of the S protein which 
allows cleavage by cellular proteases, allowing entry into Vero cells (Belouzard et al., 2012, 
Yamada and Liu, 2009, Bickerton et al., 2018). Other groups have identified the presence of 
a heparan sulphate (HS) binding site as a selective binding factor for IBV in Vero cells (Madu 
et al., 2007). The replacement of the S gene in M41K-BeauR(S) allows the virus to be 
propagated in continuous cell lines, conferring a huge advantage for vaccine development. 
Having already been approved for vaccine production, Vero cells provide a good system for 
producing vaccines on an industrial scale. As the current vaccine production process involves 
the use of hundreds of embryonated hens’ eggs per batch, a platform to produce rationally 
attenuated viruses in cell culture would be extremely beneficial to the vaccine industry, both 
financially and ethically. With further investigation this virus could be used for a vaccine-
challenge experiment to assess the level of protection conferred by M41K-BeauR(S).  
S genes in other coronaviruses have been shown to alter viral tropism, in line with the results 
described here. One example is MHV, the tropism of which is dependent on the S gene. 
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Studies have shown that replacing the S gene in MHV alters the ability of the virus to infect 
and replicate in hepatocytes (Navas et al., 2001). Other parts of the MHV genome have also 
been implicated in tropism, however, suggesting that the S gene is not the sole determinant 
(Zhang et al., 2015).  
The results from the pathogenicity experiment show that M41K-BeauR(S) did not cause any 
IBV related respiratory clinical signs in the infected chickens (Figure 4.11A and B), indicating 
that the Beaudette-derived S gene has attenuated the virus. Previous work described the 
insertion of the M41 S gene into the Beaudette genome, to determine whether this would 
generate a pathogenic virus (BeauR-M41(S)) (Casais et al., 2003). While the resultant virus 
did adopt the tropism of M41 in vitro, it was completely attenuated in vivo (Hodgson et al., 
2004). The results from that study showed that the ectodomain from a pathogenic virus was 
not sufficient to alter the pathogenicity of Beau-R. In contrast, the experiments described 
here demonstrate that modifying the ectodomain of the M41 S protein can attenuate this 
pathogenic virus. Taken together this shows that the Beaudette genome is too attenuated 
to support changes in its genome which should alter pathogenicity and that the M41 based 
reverse genetics system is a useful tool for studying IBV pathogenesis.  
Through ex vivo and in vivo comparisons, it is clear that M41K-BeauR(S) is unable to induce 
ciliostasis in the natural host (Figures 4.9 and 4.11C, respectively). As the exact process of 
ciliostasis in the host is unknown, we cannot conclude that the S gene is responsible for 
ciliostasis in pathogenic IBV infections. It is likely that the virus itself does not cause ciliostasis 
directly but rather the host immune response to the infection. It has been shown that IBV 
infection induces the innate immune response, increasing expression of TLRs and 
downstream signalling molecules. Macrophage numbers in the trachea of infected birds are 
also increased during infection (Kameka et al., 2014). Induction of pro-inflammatory 
cytokines has also been demonstrated in the trachea of IBV infected birds. It is suggested 
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that the excessive immune response induced by infection with certain strains of IBV leads to 
inflammation in the infected tissues causing the pathology associated with the disease (Jang 
et al., 2013). Investigating the immune response to infection in the bird could elucidate the 
reasons why there is a lack of ciliostasis in the M41K-BeauR(S) infected birds. The lower viral 
load in the tissues (Figure 4.12) may have resulted in an altered immune response to the 
infection, thus altering the pathogenesis and development of disease. Assessing the 
populations of immune cells attracted to the sites of infection and what effect this has on 
the tissues would be beneficial in the elucidation of the involvement of the host response to 
IBV infection.  
It is also possible that the gene replacement in M41K-BeauR(S) has disrupted the interactions 
of the other viral proteins which may be responsible for influx of immune cells. For other 
coronaviruses, interactions between the S and M proteins have been studied. One study 
looked at the interaction of chimeric M proteins with the other structural proteins of MHV. 
They noted a reduction in the number of S proteins incorporated into the virions, indicating 
a disrupted interaction with the S protein (Kuo et al., 2016). This could be the case for the 
recombinant virus described here; the chimeric nature of the recombinant S protein may 
have disturbed interactions with M and hence disrupted viral replication in the bird. An 
interesting line of future investigation would be to generate a recombinant virus including 
Beaudette M and S genes in an M41 genome to assess what effect this would have on 
replication and dissemination in vivo.  
While M41K-BeauR(S) is completely non-pathogenic, it has retained the ability to 
disseminate from the sites of infection, demonstrated by the fact that the virus was detected 
in the trachea from day 4pi (Figure 4.12A). Beau-R cannot disseminate through the bird 
during infection as shown in previous pathogenicity studies where it could not be detected 
in the trachea by PCR (Armesto et al., 2009). Having assessed the viral load in the extracted 
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tissues from the infected birds, it is clear that the recombinant virus was present in the 
trachea but in much lower levels compared to the pathogenic control viruses (Figure 4.12A). 
Lower levels of the virus in the trachea may also be responsible for the lack of ciliostasis in 
these tissues. The virus is also present in lower levels in the eyelid (Figure 4.12B), indicating 
that M41K-BeauR(S) replication is not as efficient as M41-K in vivo. The reason for this 
disparity is likely to be multifactorial however one hypothesis for the differences in virus 
levels is that M41K-BeauR(S) may be sensitive to the higher body temperature of a bird 
compared to the in vitro incubation temperature of 37°C (discussed in detail in Chapter 6).  
Overall, M41K-BeauR(S) has adopted both in vitro and in vivo characteristics of Beau-R, with 
the exception of the recombinant virus’s ability to disseminate from the sites of inoculation 
to the trachea. This implies that the S protein is a factor in IBV pathogenicity. The differences 
between in vitro and in vivo results highlight an interesting area of investigation, 
demonstrating that the results from in vitro studies are not always reflected in the natural 
host.  
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Chapter 5: Generation and 
characterisation of M41K-4/91(S) to 
assess the effect of IBV genome 
modification on pathogenesis  
 
5.1 Introduction   
Previous studies have generated viruses where S genes from pathogenic viruses have been 
inserted into the genome of Beau-R (Hodgson et al., 2004, Armesto et al., 2011). These 
viruses did not adopt a pathogenic phenotype despite the insertion of a pathogenic S protein, 
most likely due to the extreme attenuation of Beau-R. With the development of a reverse 
genetics system based on the pathogenic M41 strain, it is possible to modify and replace 
genes within the context of a pathogenic virus, therefore examining the involvement of 
specific genes in IBV pathogenesis. M41K-BeauR(S) (described in Chapter 4) was generated 
to elucidate the influence of the S gene on IBV pathogenicity. This virus demonstrates that 
the S gene is a factor in IBV pathogenicity and that a recombinant virus will adopt the tropism 
of the S donor strain.   
To demonstrate that the observed alterations on pathogenicity can be solely attributed to 
the insertion of the Beaudette-derived S protein ectodomain, another recombinant IBV was 
generated in which the genome of M41-K was modified to include the S protein of a 
pathogenic field strain of IBV 4/91 (also known as 793B). The resultant virus is known as 
M41K-4/91(S) and has been characterised both ex vivo and in vivo to assess the effects of 
inserting the S ectodomain from a pathogenic virus into the genome of another, 
heterogeneous pathogenic virus.  
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5.2 Results: 
5.2.1 Generation and rescue of rIBV M41K-4/91(S)  
The recombinant IBV (rIBV) M41K-4/91(S) was generated by reverse genetics using VV-based 
reverse genetics. The reverse genetics system is described in more detail in Chapter 4 and 
Methods Section 2.12. The ectodomain of 4/91 S was inserted into the M41-K genome using 
the plasmid detailed in Figure 5.1A. The plasmid includes a selection marker and a 
recombinant S gene sequence comprising the ectodomain of 4/91 S with the signal 
sequence, transmembrane domain and cytoplasmic tail of M41-K to maintain interactions 
between the S protein and other viral proteins such as the M protein (Figure 5.1B).  
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Figure 5.1: (A) Plasmid map of pGPT-M41-4/91(S) used to generate rIBV M41K-4/91(S) 
containing the recombinant S sequence comprising the 4/91 ectodomain with flanking 
regions of the M41 signal sequence at the 5′ end and cytoplasmic tail at the 3′ end within the 
pGPT plasmid vector. The ampicillin resistance gene (AmpR) and the lac promoter sequence 
are highlighted along with the pUC origin of replication site (ori). The recombinant 4/91 gene 
is indicated. The plasmid map was generated from the plasmid sequence using SnapGene. 
(B) Schematic diagram detailing the structure of the chimeric S gene in the recombinant virus 
rVV M41K-4/91(S), comprising the 4/91-derived ectodomain flanked by the M41 signal 
sequence and cytoplasmic tail.  
4/91 S 
pGPTM41-4/91-S 
8008bp 
A 
B 
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Following the successful generation of recombinant vaccinia virus DNA containing M41K-
4/91(S) cDNA by reverse genetics, attempts to recover the virus were made in CK cells. As 
previously described, the virus rescue system involved infection of CK cells with FPV-T7 and 
transfection with rVV DNA and a plasmid containing the IBV N protein (Methods Section 
2.12.9).  
After numerous attempts, the recombinant virus M41K-4/91(S) was successfully generated 
in primary CK cells. As recombinant IBVs have previously adopted the cell tropism of the 
strain from which their S gene was derived, M41K-4/91(S) should be refractory for replication 
in CK cells (Armesto et al., 2011). Therefore alternative techniques for harvesting and 
completing the virus rescue were employed. Several lysis methods were used to extract 
potential viable virus from the cells. The cells used for virus rescue were subjected to freeze-
thawing followed by homogenisation through a needle to allow the virus to escape the cells. 
This material was immediately used for passage in embryonated eggs in order to amplify any 
potential infectious virus. Allantoic fluid was screened by RT-PCR to check for virus presence 
using primers covering the 3' UTR of the IBV genome. IBV was detected in the first passage 
in the allantoic fluid of embryonated eggs (Fig. 5.2) and this fluid was used to generate stocks 
of the recombinant virus to use for further experiments.  
This demonstrates that it is possible to recover a recombinant IBV containing an S gene that 
exhibits only 82.4% amino acid sequence homology to the backbone strain M41.  
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Figure 5.2: rIBV M41K-4/91(S) was successfully rescued in CK cells. Three replicate wells of 
CK cells (1, 2 and 3) were infected with FPV-T7 and transfected with VV DNA containing IBV 
M41K-4/91(S) cDNA along with a plasmid expressing the N protein of M41. After 96 hours 
incubation, cells were subjected to freeze-thaw (-80/37°C) followed by lysis using a needle 
and syringe. The resulting cell lysate was used to infect embryonated eggs and RNA from the 
allantoic fluid of each egg was extracted and used for screening by RT-PCR using primers 
BG56 and BG93/100. Band sizes were compared to Invitrogen 1kb Plus DNA Ladder (L). H2O 
was used as a negative control for both the RT and PCR (-). Known Beaudette-positive RNA 
and DNA samples were used as positive (+) controls for the RT reaction and PCR, respectively. 
A band of approximately 500bp is indicative of IBV presence. The PCR product generated by 
this primer set is slightly shorter in M41 compared to Beau-R, hence the PCR product for the 
M41K-4/91(S) sample is smaller (approximately 400bp) than those observed in the + 
samples.  
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Stocks of M41K-4/91(S) were propagated in embryonated eggs for use in all subsequent 
experiments. The sequence identity was confirmed by Sanger sequencing across the entire 
S gene to verify that the recombinant gene contained the M41 signal sequence and 
cytoplasmic tail and the ectodomain sequence of 4/91. An example of the DNA sequence 
alignment for the three viruses is displayed in Figure 5.3. The sequence of the recombinant 
S gene in M41K-4/91(S) was homologous to the M41 S gene sequence up to position 55 in 
the nucleotide sequence after which it matched the sequence encoding the 4/91 S 
ectodomain until position 3363. At this point the sequence was again homologous to M41.  
This confirmed that the recombinant virus contained the correct S gene sequence and that 
no point mutations had occurred in the S gene throughout the virus generation and rescue 
process.  
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Figure 5.3: Example of alignment of IBV M41K-4/91(S), M41-K and 4/91 amino acid 
sequences. Stocks of 4/91, M41K-4/91(S) and M41-K were propagated in embryonated eggs 
before RNA extraction from allantoic fluid followed by RT-PCR and Sanger sequencing to 
obtain sequences for the S gene in each virus. Nucleotide sequences were aligned using 
BioEdit. Nucleotide positions are indicated from the first base of the S gene. (A) The M41K-
4/91(S) sequence matches M41 until position 55 (indicated by the black box and arrow), after 
which it matches the 4/91 ectodomain sequence. (B) From position 3363, the M41K-4/91(S) 
sequence matches the CT and TM domain sequence of M41.  
  
 
A 
B 
153 
 
5.2.2 In vitro and ex vivo characterisation of rIBV M41K-4/91(S)  
As previously discussed, the S protein is a determinant of in vitro tropism for IBV and as such 
it was expected that rIBV M41K-4/91(S) would lose the capacity to replicate in cell culture 
with the insertion of the 4/91-derived S protein. To test this hypothesis, CK cells were 
infected with M41-K, 4/91 or M41K-4/91(S) and incubated at 37°C for 48 hours. Signs of IBV-
induced cpe were assessed under a light microscope. Figure 5.6 shows the microscope 
images from these infections.  
Extensive cpe was observed in the M41-K infected cells, with numerous clearings in the 
monolayer and patches of rounded cells throughout. As expected, no signs of IBV-induced 
cpe were seen in the 4/91 infected cells, which remained healthy and comparable to the 
mock infected cells. The M41K-4/91(S) infected cells did not exhibit any signs of infection 
and were also comparable to the mock infected cells. This indicates that M41K-4/91(S) is 
unable to infect and successfully replicate in CK cells, having adopted the tropism of 4/91, 
the strain from which the recombinant S gene was derived.  
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Figure 5.4: rIBV M41K-4/91(S) does not cause cpe in CK cells. CK cells were infected with 
M41-K, 4/91 or M41K-4/91(S) and incubated at 37°C for 48 hours. Cells were assessed for 
any signs of IBV-induced cpe, including rounded cells and clearings in the monolayer, 
compared to mock-infected cells. Images were taken on an EVOS Light Microscope, 10X 
objective.  
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The S protein has been shown previously to be a determinant of cell tropism (Casais et al., 
2003). As indicated in Figure 5.4, the recombinant virus M41K-4/91(S) is unable to replicate 
in cell culture, exhibiting a similar tropism to the previously generated rIBV BeauR-4/91(S) 
(Armesto et al., 2011) and so replication kinetics were assessed in ex vivo TOCs alongside the 
two parent viruses M41-K and 4/91. TOCs were infected with each of the three viruses and 
samples of supernatant were harvested at 24 hour intervals from the time of infection. The 
samples of supernatant from each time point were titrated in TOCs in order to calculate the 
ciliostatic dose (CD50) values for each virus. The results from these experiments are shown in 
Figure 5.5.  
All three of the viruses were able to replicate in these cultures. M41-K and 4/91 followed 
fairly similar patterns of replication over the course of the experiment, with the peak titres 
occurring at 48 hpi in both cases.  M41K-4/91(S) replicated as well, if not slightly better than 
either of the parent viruses, with the peak titre occurring at 72 hpi. There was no significant 
difference between the replication kinetics of any of the viruses, but M41K-4/91(S) appeared 
to replicate to higher titres than M41-K and 4/91 at 24, 48 and 72 hpi. Overall, the data 
described here demonstrate that the presence of a heterologous S protein has not impaired 
virus replication in ex vivo TOCs.  
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Figure 5.5: rIBV M41K-4/91(S) replicates well in ex vivo TOCs. TOCs from 19 day old RIR 
embryos were infected in triplicate with either M41K-4/91(S), M41-K or 4/91 and incubated 
at 37°C (rotating). The titre of each virus was determined by titration in TOCs prior to the 
assessment of replication kinetics. TOCs were infected with the equivalent of 1x104 pfu in 
500µl. Supernatant was harvested at 24 hour intervals and used for titration in embryonic 
TOCs. Serial dilutions of supernatant from each time point was used to infect TOCs. After 6 
days incubation at 37°C, TOCs were assessed to identify the dilution at which 50% of the 
TOCs were exhibiting ciliostasis. Average data are displayed with SEM at each time point. 
Data were analysed by One-Way ANOVA followed by Tukey’s multiple comparison test. 
There was no statistically significant difference between the replication kinetics of any of the 
viruses.  
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Induction of ciliostasis is used as a marker of pathogenicity in IBV infection in vivo, with a 
virus being considered pathogenic if infection reduces ciliary activity by more than 50%. To 
compare the progression of ciliostasis in TOCs infected with M41K-4/91(S), 4/91 and M41-K, 
changes in ciliary activity were measured over 96 hours. The results are shown in Figure 5.6. 
M41-K, 4/91 and M41K-4/91(S) all induce dramatic reductions in ciliary activity by 48 hours 
pi with a gradual decline to 96 hours pi. The lowest levels of ciliary activity are observed in 
the 4/91-infected TOCs. There is a slight reduction in the ciliary activity in the mock-infected 
TOCs but the average remains above 80% throughout the experiment. The values for ciliary 
activity observed in the infected TOCs at all time points from 48 hpi onwards are significantly 
reduced compared to the mock-infected TOCs (**** indicates p < 0.0001). There is no 
significant difference between the values for ciliary activity in any of the infected groups. In 
general, all three viruses induce similar reductions in ciliostasis but M41K-4/91(S) appears to 
act more slowly than the two parental viruses M41-K and 4/91.  
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Figure 5.6: M41K-4/91(S) induces ciliostasis in ex vivo TOCs. Embryonic TOCs were infected 
with M41K-4/91(S), M41-K and 4/91 in replicates of ten, or mock infected with TOC 
maintenance medium. TOCs were incubated at 37°C and ciliary activity was assessed under 
a light microscope at the time of infection and then every day from 48 hpi. Each TOC was 
given a percentage score of ciliary activity and the averages for each virus are displayed with 
SEM. Data were analysed by One-Way ANOVA followed by Tukey’s multiple comparison test 
to compare the average values at each time point (*** p < 0.002, **** p < 0.0001). 
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5.2.3 In vivo analysis of rIBV M41K-4/91(S) pathogenesis 
The results from the in vitro and ex vivo experiments outlined in Figures 4-6 demonstrate 
that the recombinant virus M41K-4/91(S) is able to replicate efficiently in TOCs and cause 
significant reductions in ciliary activity. It is also clear that the virus has adopted the restricted 
tropism of 4/91, in that it cannot cause cpe in primary CK cells.  
To investigate the effects of the insertion of the recombinant S gene in vivo, pathogenicity 
of the rIBV M41K-4/91(S) was assessed in SPF RIR chickens and compared to the parent 
viruses M41-K and 4/91. Groups of 15 chickens (12 in the mock-infected group) were infected 
at 8 days old via the ocular-nasal route with IBV or PBS. Clinical signs were assessed from day 
2 to day 7 pi. Five birds from the IBV-infected groups or 4 birds from the mock-infected group 
were culled on days 4 and 6 pi. Tissues were harvested PM from each of these birds for 
analysis. Details of the experimental plan are included in Figure 5.7.  
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Figure 5.7: Experimental plan for in vivo pathogenicity assessment. RIR chicks were infected 
at 8 days old by the ocular-nasal route with either M41-K, 4/91 or M41K-4/91(S) or mock 
infected (PBS). IBV-induced clinical signs were observed from day 2 to day 7 pi. Five birds 
from each group were culled on days 4 and 6 and tissues were harvested for post-mortem 
analysis. On day 14pi, clinical signs were checked, the remaining birds in each group were 
culled and blood and tissues were harvested for analysis.  
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Clinical signs were observed from day 2pi. Figure 5.8 shows the collated data for the 
observations made on each day post inoculation for birds exhibiting snicking and rales. The 
peak clinical signs for the recombinant virus M41K-4/91(S) occur much earlier than the two 
pathogenic control groups (M41-K and 4/91). Until day 5, there was a similar level of snicking 
observed across all three IBV-infected groups. From day 5 onwards there are considerably 
more snicks in the two control groups compared to the M41K-4/91(S) group, with the peak 
occurring on day 4 followed by a steady decrease to day 14 (Fig. 5.8A). A similar pattern is 
seen for the number of birds exhibiting rales, with the peak in the M41K-4/91(S) group 
occurring at day 5, with no rales observed on subsequent days. The rales patterns observed 
in the control groups are quite different. For the M41-K infected group, there is a steady 
increase with a plateau of 60% exhibiting rales on day 5. For the 4/91 infected birds however, 
there is a more dramatic increase from day 2 to day 3, after which it increases steadily to day 
5pi and then decreases again with no birds exhibiting rales on day 14pi (Fig. 5.8B). As 4/91 is 
a field strain and is not laboratory adapted in the same way as M41, the enhanced clinical 
signs in this group were expected.  
While the patterns differ somewhat between all the infected groups, it is still clear that the 
recombinant virus M41K-4/91(S) is inducing classical symptoms of IBV infection, showing 
that the modification of the S gene has not altered the virus’ ability to cause disease. 
Interestingly, it appears that M41K-4/91(S) may be cleared earlier than M41-K and 4/91, 
indicated by the earlier decrease in observed clinical signs in this group. 
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Figure 5.8: rIBV M41K-4/91(S) induces respiratory clinical signs. From day 2 pi, the number 
of snicks in each group was recorded and the average number per bird per minute was 
calculated for each day (A). The breathing of each bird was assessed daily from day 2 pi and 
those exhibiting rales were noted. The percentage of birds exhibiting rales was calculated for 
each group (B).  
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Another assessment of pathogenicity measured during the infections is the effect of IBV on 
tracheal ciliary activity. This is an important consideration for the poultry industry as loss of 
ciliary activity can result in fatal secondary bacterial infections. In this experiment, ciliary 
activity in the trachea of the birds culled on days 4 and 6pi was measured under a light 
microscope and a percentage score was calculated for each group. These scores are 
displayed in Figure 5.9. The observed effects on ciliary activity are similar across the infected 
groups, with all three viruses causing a significant reduction in ciliary activity on both days 4 
and 6 pi compared to the mock infected birds. On day 4 pi there is some variation between 
the average percentage ciliary activities in each of the groups. The most dramatic decrease 
is seen in the 4/91 infected group, where complete ciliostasis has been induced by day 4pi 
with no recovery observed on day 6 pi. As mentioned, this is unsurprising due to the nature 
of this field strain. There is no statistical difference between the reductions in ciliary activity 
in each of the IBV-infected groups on either day pi, despite the considerable variation in the 
values of the M41-K infected birds on day 4 pi and the M41K-4/91(S) infected birds on day 6 
pi.  
The ciliary activity in the M41K-4/91(S) group however was comparable to the two control 
groups, with the values falling somewhere between that of M41-K and 4/91. M41K-4/91(S) 
caused near complete ciliostasis by day 4 pi with only a slight recovery on day 6 pi. 
Interestingly, the virus appears to have induced comparable damage in the trachea to the 
two control viruses, without having caused the extensive clinical signs observed in the 
control groups. Ciliary damage induced by M41K-4/91(S) occurs slightly earlier than the 
damage observed in the M41-K infected trachea, with a slower decline in ciliary activity from 
day 4 to day 6 pi.  
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Figure 5.9: rIBV M41K-4/91(S) causes significant reductions in ciliary activity in infected 
chickens. Trachea were extracted from 5 birds in each group on days 4 and 6pi. Trachea were 
sectioned, examined under a light microscope and the average percentage ciliary activity 
was calculated for each group. Average values are displayed with SEM. Data were analysed 
by One-Way ANOVA followed by Dunnett’s multiple comparison test to compare mean 
values in each group to the mock (** indicates p = 0.0013, *** indicates p = 0.001, **** 
indicates p < 0.001).  
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There are marked differences between IBV strains in their ability to disseminate from the 
sites of infection and their replication in different tissues. For example Beau-R is unable to 
disseminate from the eyes/nares to the trachea and is unable to cause disease in the infected 
chicken (Hodgson et al., 2004). To identify any differences in the dissemination patterns of 
M41K-4/91(S), M41-K and 4/91, RNA was extracted from post-mortem trachea samples and 
used for RT-PCR to detect IBV present in the sample. The results from the virus detection are 
summarised in Table 5.1. As expected, none of the trachea samples from the mock infected 
group were positive for IBV presence. IBV was detected in all day 4 pi trachea samples from 
the M41K-4/91(S) infected birds and the 4/91 infected birds. Four out of five birds in the 
M41-K infected group were positive for IBV.  
Table 5.1: Assessment of virus dissemination in vivo  
Tissue Group Mock M41K-4/91(S) M41-K 4/91 
Trachea 0/5 5/5 4/5 5/5 
 
Taken together the results show that the recombinant virus M41K-4/91(S) was capable of 
inducing clinical symptoms of IBV infection as well as causing dramatic reductions in ciliary 
activity. In terms of reaching the trachea, the dissemination pattern of the M41K-4/91(S) was 
the same as the parent viruses M41-K and 4/91, indicating that the ability of the virus to 
spread from the sites of infection to the primary replication sites was not altered as a result 
of the S protein modification.  
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5.3 Discussion 
The recombinant IBV M41K-4/91(S) has been generated using VV-based reverse genetics and 
has been characterised both ex vivo and in vivo to analyse the effects of gene replacement 
on replication and pathogenesis in IBV. The virus has been successfully rescued in CK cells 
and amplified in TOCs before characterisation of both replication in ex vivo TOCs and in vivo 
pathogenesis.  
The successful rescue of M41K-4/91(S) further demonstrates the possibility of generating 
recombinant IBVs containing S glycoproteins of significant sequence divergence compared 
to the viral backbone, as shown with other recombinant viruses such as M41K-BeauR(S), 
BeauR-M41(S) and BeauR-4/91(S) (Armesto et al., 2011, Hodgson et al., 2004). While the 
M41 and Beau-R S genes exhibit 96% amino acid sequence homology, M41 and 4/91 
similarity is closer to 82%. This shows that both the M41-K and Beau-R genomes can support 
the insertion of divergent S genes in vitro.  
The in vitro assessment of M41K-4/91(S) shows that the virus replicates well in embryonic 
TOCs (Figure 5.5) and has adopted the tropism of the S donor strain 4/91, in that it has lost 
the ability to replicate in cell culture, indicated by its inability to cause cpe (Figure 5.4). As 
previously discussed, the S gene has been shown to play an important role in determining 
the cellular tropism of IBV (Casais et al., 2003). M41K-4/91(S) is therefore expected to 
replicate in ex vivo cultures and embryonated eggs but not in cell culture, mirroring the 
tropism of 4/91. This does however limit the in vitro characterisation of M41K-4/91(S) to 
assessment of replication kinetics and induction of ciliostasis due to the nature of the 4/91-
derived S protein. The analysis of M41K-4/91(S) replication is therefore confined to studies 
in embryonated eggs and TOCs.  Assessment of M41K-4/91(S) replication in TOCs revealed 
that the insertion of the 4/91 S protein did not impact the replication capacity of the virus as 
it remained able to replicate successfully in these cultures. There were some slight 
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differences between the replication patterns of the three viruses in TOCs. M41K-4/91(S) was 
able to replicate in TOCs to similar titres as M41-K and 4/91 and followed the same pattern 
of replication as the S donor strain 4/91. M41-K exhibited a slightly different pattern of 
replication, but the differences are not significant. While the protocols involved in ex vivo 
characterisation are extremely labour intensive and expensive compared to cell culture 
techniques, this type of characterisation does provide a more relevant insight into replication 
in the host.  
The increased titres of M41K-4/91(S) compared to the other viruses may be linked to the 
progression of ciliostasis in these cells. In ex vivo cultures, M41K-4/91(S) induced ciliostasis 
occurs at a slower rate than that induced by 4/91 (Figure 5.6). This means that more cells are 
susceptible to virus infection for a longer period of time, extending the period in which 
infectious virus can be produced.   
Adoption of the S donor strain cell tropism has been demonstrated previously with the 
generation of BeauR-4/91(S), where the recombinant virus lost the ability to grow in cell 
culture and exhibited a restricted tropism profile compared to Beau-R (Armesto et al., 2011). 
The extended host tropism of Beau-R could be applied to M41K-4/91(S) with the insertion of 
the S2′ cleavage site, which may allow the virus to infect in vitro cell cultures (Bickerton et 
al., 2018). Insertion of this small modification could provide a platform for propagating 
M41K-4/91(S) in cell culture to allow more in depth characterisation and a possible system 
for rational vaccine development against pathogenic field strains.  
As previously discussed, there have been investigations into the role of the S gene in IBV 
pathogenicity where S genes from pathogenic viruses have been inserted into the genome 
of Beau-R (BeauR-M41(S) and BeauR-4/91(S)), to assess whether the resultant viruses would 
adopt a pathogenic phenotype. However these viruses remained attenuated despite the S 
gene modifications and so it was concluded that the S gene was not a pathogenicity 
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determinant for IBV. At the time, these findings were contrary to research with other, related 
coronaviruses, in which the S gene had been shown to dramatically alter the virulence and 
in vivo tropism of MHV and TGEV (Phillips et al., 1999, Navas et al., 2001, Sanchez et al., 
1999). In contrast, the generation of M41K-BeauR(S) showed that a recombinant IBV can be 
attenuated following the insertion of the Beaudette S ectodomain, suggesting that the S gene 
is a pathogenicity factor in IBV infection. Taking the results from previous studies into 
account, the S gene cannot be termed a pathogenicity determinant as its replacement in a 
non-pathogenic virus (Beau-R) did not result in an altered pathogenicity. The contradiction 
in these studies raised an interesting question regarding the effects of gene replacement in 
IBV and whether it was this process that caused the attenuation in M41K-BeauR(S) rather 
than the presence of the S gene. The generation of M41K-4/91(S) described here has 
demonstrated that the process of gene modification does not interfere with pathogenicity 
and that the S gene does contribute to the virulence of a recombinant IBV. This is evident in 
the clinical signs and ciliostasis induced by the virus, which are comparable to those induced 
by the pathogenic parent viruses M41-K and 4/91 (Figures 5.8 and 5.9).  
There are some differences in the patterns of clinical signs induced by each virus. For 
example, the peak in clinical signs induced by M41K-4/91(S) occurs earlier in the course of 
infection than 4/91 or M41-K (Figure 5.8). This is followed by a dramatic decrease in 
respiratory symptoms, possibly indicating that the virus is cleared by the birds more quickly 
than the control viruses. This could be due to the recombinant nature of the virus; although 
M41K-4/91(S) has remained pathogenic following the S gene modification, the chimeric 
nature of the virus may have rendered it more susceptible to the host immune response and 
thus less able to sustain infection for as long as either M41-K or 4/91. Without further 
investigation into the immune responses induced following M41K-4/91(S) infection it is 
difficult to draw conclusions on the reasons for the early-onset clinical signs observed here. 
Future investigations following these experiments will include assessment of neutralising 
169 
 
antibody induction following infection with M41K-4/91(S) using the serum collected on day 
14pi. Antibody responses to 4/91 (793B) and M41 have been measured in other IBV 
pathogenicity studies but detectable levels of neutralising antibody were not found until day 
21pi for either virus (Benyeda et al., 2009). It would be interesting to compare the responses 
following M41K-4/91(S) infection to identify any differences in the host response to infection 
with a pathogenic recombinant IBV.  
Without further modifications there would not be scope to use M41K-4/91(S) as a vaccine 
due to the extensive clinical signs and ciliary damage induced by the virus. However this work 
demonstrates that a heterologous S gene from a different serotype can be inserted into the 
genome of a pathogenic IBV without affecting the pathogenicity of the resultant virus and 
further reiterates that the M41-based reverse genetics system can be used to effectively 
study IBV pathogenicity, demonstrating that the M41 genome can support insertion of large, 
heterologous gene sequences. 
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Chapter 6: Investigation into cellular 
factors influencing IBV tropism 
 
6.1 Introduction  
There are multiple factors that influence viral tropism which originate from both the virus 
and the host cell. In order for a cell to be infected it must express the correct receptors with 
which the surface proteins of the virus can interact. It must also provide the correct 
environment for the virus to attach and enter successfully, allowing its proteins to be 
properly processed. The local temperature and protease composition are both well studied 
conditions that can contribute to the intracellular environment required to allow virus 
interaction/replication within host cells. 
IBV strains exhibit a wide range of tropisms both in cell culture and in the infected host. Some 
strains are capable of infecting a wider range of host cells in vitro, thought to be due to the 
presence of extra receptors on the host cell and/or different sequences in the viral 
attachment protein, spike (S).  The S protein of the virus is thought to be solely responsible 
for in vitro tropism. It has been shown for other coronaviruses that the S protein determines 
hepatotropism in vivo (Navas et al., 2001). Mutations in the coronavirus S protein have been 
implicated in the acquisition of additional tissue tropisms, as demonstrated with feline 
coronaviruses (Rottier et al., 2005). The Beaudette S2 subunit is responsible for the extended 
host tropism observed with this strain of IBV in vitro (Bickerton et al., 2018), although this 
strain is incapable of maintaining replication in vivo (Hodgson et al., 2004).  
The work described in this chapter aimed to examine the environmental requirements of the 
S protein necessary for IBV infection and maintenance of replication in a range of cell types, 
including protease requirements for proper cleavage events and the effects of temperature 
variation on viral replication.  
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6.2 Results  
6.2.1 Protease requirements  
It is well established that Beaudette strains of IBV exhibit an extended host tropism 
compared to M41 strains. This feature is thought to be due to the presence of a secondary 
cleavage site, located downstream of the S1/S2 furin site, in the S2 subunit which may be 
subject to further cleavage by cellular proteases (Bickerton et al., 2018). To demonstrate the 
presence of the S2' site in IBV Beau-R, purified IBV was used for analysis by SDS-PAGE, under 
reducing conditions, followed by western blot using the 26.1 monoclonal antibody against 
the S2 protein (PrioMab). The presence of the S2' cleavage product is indicated in Figure 6.1 
by the presence of a band of approximately 30kDa. The 80kDa bands detected in both the 
M41-CK and Beau-R sample indicate the presence of S2. The large smear of approximately 
250kDa+ is thought to be present as a result of S glycoprotein glycosylation.  
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Figure 6.1: Demonstration of secondary cleavage site (S2′) in Beau-R. Samples of purified 
M41-CK and Beau-R were analysed by SDS-PAGE followed by western blot using the 26.1 
monoclonal antibody against the S2 subunit of the S protein. The indicated band at 
approximately 30kDa is thought to be a degradation product of the S2' cleavage site, only 
present in Beaudette samples.  
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Previous evidence suggests that the addition of exogenous proteases can expand viral 
tropism in coronaviruses, allowing entry into usually non-permissive cells (Park et al., 2016). 
To ascertain whether this theory applied to IBV infection, M41-K and M41-CK were used to 
infect Vero cells in the presence of exogenous tosyl phenylalanyl chloromethyl ketone 
(TPCK)-treated trypsin (Sigma). At 24 hours post-infection, the supernatant was used for 
titration by plaque assay on CK cells to assess quantities of infectious virus produced in the 
presence of trypsin. Figure 6.2 shows the viral titres of each virus in the presence of 
increasing concentrations of trypsin. Unlike M41-K, M41-CK is able to infect Vero cells at a 
very low level in the absence of trypsin. This may be due to the nature of the viruses, as M41-
CK is a mixed population and M41-K originated from a viral clone. Viral titres of both M41-K 
and M41-CK are significantly higher in the presence of exogenous trypsin at all 
concentrations (0.2µg/ml - 2µg/ml).  For M41-K, the lowest concentration of trypsin yielded 
variable results and there was a significant difference in viral titre between the two viruses. 
However increase in viral titre is still significant for M41-K with the addition of trypsin at 
0.2µg/ml. Taken together these results show that the addition of exogenous trypsin allows 
these M41 strains to enter non-permissive Vero cells at relatively low concentrations.  
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Figure 6.2: Addition of exogenous trypsin significantly increases replication of M41 strains 
in Vero cells.  Vero cells were infected with M41-K or M41-CK at an MOI of 1, diluted in 
serum-free media containing varying amounts of TPCK-treated trypsin. After 1 hour 
incubation at 37°C, cells were washed in PBS and the media was replaced with fresh media 
containing TPCK-treated trypsin. Cell supernatant was harvested after 24 hours incubation 
at 37°C and used for titration by plaque assay on CK cells. Mean viral titres of three biological 
repeats are displayed for each virus at each concentration, with SEM. Data were analysed by 
Two-Way ANOVA followed by multiple comparison tests to compare each concentration. 
Significant differences are indicated (* indicates p = 0.01, ** indicates p = 0.001 and *** 
indicates p < 0.001).  
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Figure 6.2 demonstrates that M41 is capable of producing infectious virus in non-permissive 
cells in the presence of exogenous protease. The induction of cpe in infected cells is indicative 
of IBV infection in cell culture, with observations including cell rounding and clearings in the 
monolayer. To assess whether the addition of trypsin has affected the virus’ ability to induce 
cpe, Vero cells were infected with IBV in the presence of TPCK-treated trypsin at a dose of 
1µg/ml, diluted in 1XBES medium. This dose was chosen based on the results shown in Figure 
6.2, where this was the lowest concentration that provided consistent results, in order to 
minimise cytotoxicity.  
Both M41-K and M41-CK caused visibly higher levels of cpe compared to the mock-infected 
cells. This shows that M41-K and M41-CK are both able to cause cpe in a non-permissive cell 
line with the addition of exogenous trypsin. The images from these infections compared to 
the mock-infected cells are shown in Figure 6.3. The observation of cpe indicates that IBV is 
spreading from cell to cell during infection due to the presence of exogenous trypsin in the 
cell culture medium. 
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Figure 6.3: M41 causes extensive cpe in Vero cells in the presence of trypsin. Vero cells 
were infected with M41-K and M41-CK (MOI=1) in the presence (+) or absence (-) of TPCK-
trypsin (1µg/ml). After 24 hours incubation at 37°C, signs of IBV-induced cpe, including 
clearings in the monolayer and rounded cells, were observed under an EVOS light microscope 
at 10X magnification. 
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To confirm IBV infection in the presence of trypsin, Vero cells were infected with M41-K or 
M41-CK and the presence of dsRNA was assessed by IF. The presence of dsRNA is thought to 
be indicative of a replicative intermediate and is found in the DMVs of coronavirus-infected 
cells (Knoops et al., 2008). Figure 6.4 shows confocal images of infected cells in the presence 
or absence of exogenous trypsin.  Compared to untreated (-) cells, there is more dsRNA 
present in the M41 infected samples when trypsin is added, indicating an increase in the 
levels of infection. The distribution of dsRNA in the trypsin-treated infected cells is the same 
between M41-K and M41-CK.  
Taken together these results show that it is possible to extend the host range of IBV using 
exogenous proteases such as trypsin, allowing virus entry and replication in usually non-
permissive cell types.  
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Figure 6.4: Exogenous trypsin allows infection of Vero cells by M41-K and M41-CK. Vero 
cells were seeded onto coverslips and infected with M41-K or M41-CK diluted in trypsin-
containing media (0.00125%) and incubated for 24 hours at 37˚C. Cells were fixed in 4% PFA 
in PBS and permeabilised with 0.1% Triton X-100 in PBS. Cells were incubated in blocking 
solution (0.5% BSA in PBS) before staining with primary antibodies against dsRNA (red) and 
α-tubulin (green). Cells were incubated in secondary antibodies AlexaFluor Goat anti-Mouse 
IgG1 (α-tubulin) and IgG2a (dsRNA). Nuclei were counterstained with DAPI (blue).  
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The data described above clearly show that the addition of exogenous trypsin allowed M41 
entry and replication in non-permissive cells over 24 hours. To assess whether this infection 
could be maintained, Vero cells were infected with M41-K and M41-CK in the presence of 
trypsin for 24 hours and the resulting supernatants were passaged a further three times on 
Vero cells in the presence of TPCK-trypsin. Figure 6.5 shows the viral titres from each passage 
with two different concentrations of trypsin (0.2µg/ml and 2µg/ml). Overall, there is a 
downward trend in the titres as the passage number increases for both concentrations, 
showing that the presence of trypsin over multiple passages does not aid M41 infection and 
replication in Vero cells. This indicates that trypsin is not the only factor required to maintain 
M41 replication in Vero cells. It should be noted that each passage was repeated only once 
and so further replicates should be completed before any definite conclusions are drawn. 
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Figure 6.5: M41 replication is not maintained over passage in Vero cells in the presence of 
TPCK-trypsin. Vero cells were infected with M41-K and M41-CK diluted in media containing 
TPCK-trypsin at 2µg/ml or 0.2µg/ml for 24 hours at 37°C (Passage 1). Supernatant was 
harvested and infections were repeated for a further three passages with trypsin-containing 
media at the same concentrations. Supernatant from each passage was used for titration by 
plaque assay in CK cells. Viral titres (log10) are displayed for each virus (n = 1).    
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Propagation of field strains of IBV is challenging as most strains do not replicate in cell 
culture. To assess whether the addition of exogenous trypsin would affect field strain 
replication in the same way as M41 strains, Vero cells were infected with QX in the presence 
of TPCK-trypsin. Infected supernatant was used for plaque assay in CK cells and viral titres 
between treated and untreated samples were compared. Figure 6.6 shows that the addition 
of trypsin does allow QX to enter and replicate in Vero cells. It is important to consider that 
these infections were only conducted once and so further replicates would be required to 
confirm the result, however it is clear that there was a dramatic increase in the replicative 
capacity of QX in these cells following TPCK-trypsin addition.  
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Figure 6.6: Addition of exogenous TPCK-trypsin facilitates QX infection of Vero cells. 
Confluent monolayers of Vero cells were washed once in PBS and infected with QX at an 
approximate MOI of 1, diluted in 1XBES containing TPCK-trypsin (1µg/ml). Cells were 
incubated for 24 hours at 37°C before supernatant was harvested and used for plaque assay 
in CK cells in triplicate.  
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6.2.2 Temperature sensitivity  
There are major differences in the clinical disease caused by the different strains of IBV used 
in a laboratory setting. M41 is highly pathogenic and causes numerous respiratory symptoms 
associated with infection as well as complete destruction of the ciliated cells in the trachea. 
In contrast, Beau-R causes no clinical disease or ciliostasis in infected birds (Hodgson et al., 
2004). In fact, during previous pathogenicity studies, Beau-R was never detected in the 
trachea, indicating that it cannot disseminate through the bird. In vitro, however, Beau-R 
replicates very well and can cause ciliostasis in ex vivo TOCs. 
As part of a wider study, possible reasons for this disparity between in vitro and in vivo 
replication capacities of Beau-R have been investigated. One factor that was noted was the 
difference in incubation temperature used in the two types of study. All in vitro and ex vivo 
investigations were carried out at 37°C, whereas the core body temperature of a chicken is 
approximately 40-42°C. It was hypothesised that perhaps this was the limiting factor in the 
inability of Beau-R to cause clinical disease, as maybe the virus was unable to replicate and 
function at the higher temperature, due to being temperature sensitive. 
To test this hypothesis some preliminary experiments were performed by Sarah Keep to 
compare replication of IBV at 41°C compared to 37°C. Figure 6.7 shows the average titres of 
M41-CK and Beau-R at 37°C and 41°C over a 96 hour time course. A summary of the statistical 
analyses is detailed in Table 6.1. At each time point post-infection, both M41-CK and Beau-R 
replicate to significantly higher titres at 37°C compared to Beau-R at 41°C, which remains 
below 101pfu/ml throughout the experiment. M41-CK follows the same pattern of 
replication at both 37 and 41°C, although titres at 37°C are significantly higher (p < 0.0001) 
from 48 hours post-infection onwards. Average titres for Beau-R at 41°C are significantly 
lower than M41-CK at 41°C at every time point pot-infection, showing that Beau-R replication 
is highly sensitive to temperature compared to M41-CK. 
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Figure 6.7: Replication of rIBV Beau-R is temperature sensitive in vitro. Confluent 
monolayers of CK cells were infected with IBV Beau-R or M41-CK at an MOI of 0.1 and 
incubated at either 37°C or 41°C for 96 hours. Supernatant was harvested at 1, 12, 24, 48, 72 
and 96 hours post-infection and titrated by plaque assay in CK cells. The average viral titres 
from three biological repeats are displayed with SEM. Data were analysed by Two-Way 
ANOVA followed by Tukey’s multiple comparisons test, summarised in Table 6.1. 
Experiments and statistical analyses were completed by Sarah Keep.   
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Table 6.1: Statistical analyses of M41 and Beau-R temperature sensitivity comparisons at 
12, 24, 48, 72 and 96 hours post-infection in CK cells.  
 
A Two-Way ANOVA was used to analyse the data displayed in Figure 6.7 in order to compare each virus at each 
time point post-infection. *** indicates a p value of 0.0001 and **** indicates a p value of <0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 Hours post-infection 
Comparison 12 24 48 72 96 
BR 37 BR 41 **** **** **** **** **** 
BR 37  M41 37 *** **** ns *** **** 
BR 41  M41 37 **** **** **** **** **** 
BR 41 M41 41  **** **** **** **** **** 
BR 37 M41 41 *** **** **** ns ns 
M41 37 M41 41 ns ns **** **** **** 
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Parts of the entry and fusion process in other viruses including Sendai virus are known to be 
dependent on several external factors including, in some cases, temperature (Wharton et al., 
2000). Following the initial investigations into temperature sensitivity shown in Figure 6.7, 
the involvement of the S gene in replication at 41°C was examined using a range of 
recombinant viruses with different S genes. As the S gene is responsible for viral attachment 
and fusion, characterising the replication of these recombinant viruses allows us to establish 
whether the processes affected by temperature sensitivity included virus entry. M41K-
BeauR(S) and BeauR-M41(S) contain the ectodomain of the reciprocal S gene (either M41 or 
Beaudette-derived). The replication kinetics of these rIBVs at both temperatures were 
assessed and compared to that of the parent viruses M41-K and Beau-R.  
Figure 6.8 shows the replication kinetics of the four strains of IBV at 37°C (Fig. 6.8A) and 41°C 
(Fig. 6.8B). At 37°C, all four viruses can establish and maintain replication over 96 hours. At 
41°C, M41-K and M41K-BeauR(S) replicate to significantly higher titres than Beau-R and 
BeauR-M41(S). A summary of the statistical analyses for these data is displayed in Table 6.1. 
M41K-BeauR(S) replication has been slightly hindered by the insertion of the Beaudette-
derived S gene but the virus is still capable of replication at 41°C, following a similar pattern 
of replication to M41-K. This shows that replacing the S gene from a virus that replicates 
efficiently at 41°C cannot rescue Beaudette replication at this temperature, indicating that 
the molecular basis of this sensitivity lies within a different viral gene. 
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Figure 6.8: Insertion of the M41 S gene cannot rescue Beaudette replication at 41°C. 
Confluent monolayers of CK cells were infected with IBV at an MOI of 0.01 and incubated at 
37°C (A) or 41°C (B). Supernatant was harvested at 1, 24, 48, 72 and 96 hours post-infection 
and used for titration by plaque assay on CK cells. The mean viral titres of three biological 
repeats are displayed with SEM. Data were analysed by Two-Way ANOVA followed by 
Tukey’s multiple comparisons test (see Table 6.1).  
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Table 6.1: Summary of the overall statistical differences in replication kinetics at 37°C and 
41°C.  
Comparison Significance P-value 
Beau-R  
37 
Beau-R  
41 
**** <0.0001 
M41-K  
37 
M41-K  
41 
* 0.0345 
M41K-BeauR(S)  
37 
M41K-BeauR(S)  
41 
** 0.0023 
BeauR-M41(S) 
37 
BeauR-M41(S)  
41 
**** <0.0001 
M41-K 
41 
M41K-BeauR(S) 
41 
* 0.0142 
Beau-R  
41 
BeauR-M41(S) 
41 
ns --------- 
Beau-R 
41 
M41-K 
41 
**** <0.0001 
M41K-BeauR(S) 
41 
BeauR-M41(S)  
41 
** 0.0018 
 
Data were analysed by Two-Way ANOVA followed by Tukey's multiple comparisons test to compare each virus 
at each temperature. 
 
To further investigate the mechanisms of replication at 41°C, the presence and distribution 
of dsRNA (a marker of IBV infection) in infected cells was assessed by IF using monoclonal 
antibodies against dsRNA (Scicons) and α-tubulin (Abcam). Figure 6.9 shows the confocal 
images from these infections. Again, a range of recombinant viruses was used to investigate 
the potential of the S gene to alter infection at different temperatures. M41-K and Beau-R 
are both capable of infecting CK cells at 37°C and swapping the S gene from these two viruses 
has no effect on their ability to replicate in these cells, as demonstrated with M41-BeauR(S) 
and BeauR-M41(S). At 41°C however, only M41-K and M41K-BeauR(S) are able to establish 
infection, as indicated by the presence of dsRNA in infected cells. There is no visible dsRNA 
in the cells infected with Beau-R or BeauR-M41(S) at 41°C, further implicating that the S gene 
does not dictate the temperature-dependent tropism of an IBV, but rather this phenotype is 
determined by other parts of the genome.  
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Figure 6.9: Detection of dsRNA in infected Vero cells is not dictated by the S gene at 41°C. 
CK cells on coverslips were infected with Beau-R, M41-K, M41K-BeauR(S) or BeauR-M41(S) 
and incubated at 37°C or 41°C for 24 hours. Cells were fixed in 4% PFA in PBS and 
permeabilised with 0.1% Triton X-100 in PBS before staining using primary antibodies anti-
dsRNA and anti-α-tubulin. Cells were incubated in secondary antibodies AlexaFluor Goat 
anti-Mouse 488 IgG1 (α-tubulin, green) and AlexaFluor Goat anti-Mouse 568 IgG2a (dsRNA, 
red). Nuclei were counterstained with DAPI (blue).  White bars = 25µm scale. 
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As previously mentioned, Beaudette strains of IBV exhibit an extended host tropism, dictated 
by specific amino acids in the S2 subunit of the S protein (Bickerton et al., 2018). In order to 
assess whether this tropism was affected by changes in temperature, Vero cells were 
infected with IBV and incubated at 41°C before assessment of dsRNA presence by IF.  
Figure 6.10 shows the confocal images from the infections at 41°C compared to those at 37°C 
in Vero cells. As shown in Figures 6.7-6.9, M41-K is capable of replicating at 41°C in 
permissive CK cells. M41-K cannot replicate in Vero cells due to its restricted host tropism. 
The viruses used here containing M41-derived S genes (M41-K and BeauR-M41(S)) have not 
replicated successfully in these cells, as demonstrated by the absence of dsRNA (Fig. 6.10). 
Beau-R is only able to replicate in Vero cells at 37°C, not 41°C. The insertion of the S gene 
into the M41-K genome allowed M41K-BeauR(S) to infect and replicate in Vero cells at 41°C; 
its in vitro tropism was not affected by the increased temperature. This demonstrates that 
IBV requires both a permissive S gene and a competent virus backbone (i.e. M41-K) to 
successfully replicate in Vero cells at 41°C. 
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Figure 6.10: IBV requires more than a permissive S gene to extend host tropism at 41°C. 
Vero cells were infected with IBV Beau-R, BeauR-M41(S), M41-K or M41K-BeauR(S) and 
incubated at 37°C or 41°C for 24 hours before fixation with 4% PFA in PBS. Cells were 
permeabilised with 0.1% Triton X-100 in PBS and blocked in 0.5% BSA in PBS before 
incubation with primary antibodies against dsRNA and α-tubulin. Cells were incubated with 
secondary antibodies AlexaFluor Goat anti-Mouse 488 IgG1 (α-tubulin, green) and 
AlexaFluor Goat anti-Mouse 568 IgG2a (dsRNA, red). Nuclei were counterstained with DAPI 
(blue).  
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6.3 Discussion  
Viral infection of a given cell is dependent on several factors. Some of these factors are virus-
dependent and some are external environmental factors. The virus must possess the correct 
genetic composition and the cell must provide the correct environment for all the steps of 
the infection cycle to take place in a proper manner. The scope of this chapter included initial 
assessments of the protease requirements for IBV infection and the effects of the external 
environment on viral replication, with a focus on temperature. 
6.3.1 Protease requirements of the IBV S protein  
In some coronaviruses, proteolytic cleavage of the S protein by host cell proteases is an 
essential requirement for virus entry (reviewed by Millet and Whittaker, 2015). In IBV, the 
classical furin cleavage site present at the S1/S2 junction is required for entry into host cells. 
There is an extra site present in the Beaudette strains, known as the S2′ site. Cleavage at this 
site is thought to allow these strains to enter a wider variety of cells in vitro, including Vero 
cells. The presence of the S2′ site in Beau-R compared to M41-CK is demonstrated in Figure 
6.1.  
A large proportion of the strains of IBV are unable to be cultured in vitro, exhibiting a 
restricted tropism. These strains are often only able to replicate in whole organ cultures or 
in embryonated hens’ eggs. Previous work with MERS-CoV showed that the tropism of a 
coronavirus could be extended with the addition of exogenous proteases (Millet and 
Whittaker, 2015, Park et al., 2016). Here, M41 was used as a tool to assess whether this was 
true for IBV. The addition of exogenous trypsin significantly increased the capacity of both 
M41-K and M41-CK to replicate in usually non-permissive Vero cells (Figure 6.2).  
Trypsin is known to cleave only at exposed Arginine (R) and Lysine (K) residues in protein 
sequences (Olsen et al., 2004). Comparing the amino acid sequence of the Beaudette and 
M41 S genes highlights cleavage sites susceptible to action by trypsin. The sequence of the 
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Beaudette S2′ site is RRKRR whereas the corresponding M41 sequence is missing the central 
lysine, potentially preventing the cleavage of this site in M41 by furin but still allowing its 
cleavage by trypsin. There are two further R residues in M41 present at positions 689 and 
691 that could also theoretically be susceptible to cleavage by trypsin. To further elucidate 
the mechanisms behind the trypsin-mediated entry into non-permissive cells, the cleavage 
products of the S protein following trypsin cleavage could be examined by western blot and 
compared to cleavage products produced in permissive cells, such as CK cells. This would 
provide more information on the location of target regions for cleavage events in the 
coronavirus S protein. 
Initial investigations into the maintenance of replication in Vero cells in the presence of 
trypsin show that this treatment does not increase replication over passage. In fact, the 
observed effect is quite the opposite. The viral titre over three passages in Vero cells 
decreased quite dramatically in the majority of the samples. These results are contradictory 
to observations in other coronaviruses such as PEDV, where passaging in the presence of 
trypsin resulted not only increases in viral titre, but also in the generation of trypsin-
independent mutants able to replicate efficiently in cell culture (Park et al., 2011, Wicht et 
al., 2014).  
With further investigation it would also be prudent to repeat these infections in a more 
relevant cell type such as avian DF-1 cells, which are also non-permissive to M41 infection. 
In this case Vero cells were used as a proof of principle to demonstrate that the tropism of a 
given IBV strain could be extended by altering the cellular environment. In addition, Vero 
cells are already licensed for vaccine production so propagation in this cell type is extremely 
relevant to the vaccine industry.  
IBV is notoriously difficult to culture in a laboratory setting, with many strains only able to 
infect embryonated eggs or ex vivo organ cultures. The addition of exogenous proteases has 
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been shown here to allow infection of classically non-permissive cells. There is also potential 
for this work to be applied to more relevant, circulating field strains, such as QX and 4/91, 
both of which only replicate in ex vivo tracheal organ cultures (TOCs) and embryonated eggs. 
Initial investigations into the application of this technique to field strains (demonstrated with 
QX) showed that the addition of trypsin causes a considerable increase in the viral titres 
produced in CK cells (Figure 6.6). Replicates of these experiments are required to verify the 
result but the initial assessments are promising. Other non-cell culture adapted strains such 
as 4/91 should also be included in the analysis. 
Generation of a platform for vaccine virus/field strain production in cell culture would 
dramatically reduce the numbers of embryonated eggs used in this field. The benefits would 
also extend to basic research as this would reduce animal costs required for studying 
economically important viruses, providing a potential method for in vitro investigations 
without the use of whole organs, embryos or adult birds.  
 
6.3.2 Temperature sensitivity in IBV 
Observations from previous studies with Beau-R have shown that this virus is extremely 
attenuated in vivo. The virus cannot cause clinical signs and has not been recovered from the 
trachea of infected birds, indicating that the virus is incapable of spreading from the sites of 
inoculation (eyes and nares) (Hodgson et al., 2004). To elucidate the potential mechanisms 
behind this attenuation, investigations were carried out into the replication of different 
strains of IBV at biologically relevant temperatures. The core body temperature of a chicken 
is between 40-42°C, therefore 41°C was chosen as a comparison to the standard in vitro 
incubation temperature of 37°C. 
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The initial studies carried out by Sarah Keep (Figure 6.7) revealed a stark difference in the 
replication capacities of Beau-R and M41-CK, with Beau-R completely unable to sustain 
infection and replication at 41°C. This difference corresponds to the variance in pathogenicity 
between the two strains, as M41-CK is highly pathogenic. Temperature sensitivity has been 
observed in other coronaviruses and has been linked to virus dissemination in vivo 
(Christianson et al., 1989), indicating a possible reason for the attenuation of Beau-R in 
chickens.  
To further investigate the genetic basis of this temperature sensitivity, the replication 
kinetics of rIBVs with modified S genes was assessed at each temperature. The data from the 
assessment in CK cells (Figure 6.8) show that the S gene is not responsible for the potential 
of a virus to replicate at 41°C, indicating that the limiting step in this process is not virus 
entry, as M41K-BeauR(S) is only slightly hindered by the foreign S gene. The presence of 
dsRNA in these cells at 41°C consolidates this finding, as dsRNA is a marker of IBV replication 
(Figure 6.9). Overall the results indicate that the background genome, rather than the S 
protein ectodomain, is responsible for conferring sensitivity to temperature. In related 
coronaviruses, temperature sensitivity has been attributed to proteins encoded in the 
replicase gene, including nsp3 and nsp5. Studies with the Betacoronavirus MHV have shown 
that decreases in replication efficiency can be linked to the protease activities of both these 
proteins (Stobart et al., 2012, Stokes et al., 2010). This has also been observed in various 
strains of influenza, where the introduction of mutations in the polymerase genes have 
resulted in the generation of temperature sensitive mutants (Meyer et al., 2016). This 
principle has been used to investigate the use of these viruses as live-attenuated vaccines 
(Nogales et al., 2017). It is therefore likely that the replicase gene of Beau-R is responsible 
for the temperature sensitivity observed in the experiments described here. It can be 
hypothesised that the pathogenicity is linked to temperature sensitivity, as the replicase 
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gene has previously been identified as a pathogenicity determinant in IBV (Armesto et al., 
2009).  
Tropism has previously been shown to be dictated by the S protein of various coronaviruses, 
so viral tropism at higher temperatures was investigated using IF for the detection of dsRNA. 
The confocal images of IBV infection in Vero cells (Figure 6.10) clearly demonstrate that two 
factors are required to achieve the extended tropism at 41°C; the virus requires both a 
competent replicase gene and a permissive S gene. For this reason, the recombinant virus 
M41K-BeauR(S) is capable of replicating in Vero cells at 41°C, as it contains the replicase gene 
from M41-K and the S gene (ectodomain) from Beau-R.  
There are limitations associated with using Vero cells at 41°C; as they are a primate cell line, 
they are adapted to growth at 37°C. Data from cell viability assays (Appendix) showed that 
Vero cell viability cannot be maintained for long periods of time at 41°C. These experiments 
must therefore be interpreted as a proof of principle and further investigations should be 
carried out in a more suitable cell line such as the continuous avian fibroblast cell line DF-1 
cells. The replication kinetics in these cells post 24 hours should be assessed and compared 
to replication in CK cells at 41°C.  
Other aspects to consider for future investigations include the assessment of replication at 
intermediate and lower temperatures. While 41°C is biologically relevant to the core body 
temperature of a chicken, the temperature in the upper respiratory tract is likely to be lower. 
Therefore investigations into viral replication at temperatures which better reflect the 
natural host environment may be beneficial to fully understanding the mechanisms behind 
IBV replication at different temperatures.  
Taken together the data described here show that IBV tropism is dictated by more than the 
virus itself and that the cellular environment must be considered. The addition of proteases 
during infection can dramatically alter the tropism of IBV, potentially providing a platform 
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for in vitro propagation of field strains only capable of replication in organs or embryos. The 
temperature sensitivity experiments show that the S protein is not sufficient to rescue 
replication at higher temperatures. Further investigation into identifying the regions 
responsible for the temperature sensitivity observed in Beau-R infections could lead to 
rationally designed vaccines.  
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Chapter 7: Discussion  
The overall aims of this thesis were to characterise the glycan profile of the IBV S gene and 
to further elucidate the role of the protein in viral pathogenicity and in vitro tropism. The 
aims have been achieved using a range of techniques to identify glycosylation sites on the S 
protein and assess the impacts of disrupting the patterns of glycosylation during protein 
synthesis and modification. The relationship between the IBV S gene and pathogenicity has 
been defined using recombinant viruses expressing heterologous S proteins. These viruses 
have also been used to investigate the involvement of the S protein in cellular tropism, 
focussing on temperature sensitivity and proteolytic activation by exogenous protease.  
7.1 Characterisation of the IBV S glycosylation profile 
The first objective of the work described in this thesis involved characterisation of the 
glycosylation profile of the IBV S protein. Previous studies have identified glycosylation sites 
on the surface of the S protein but only recently have there been more detailed studies into 
the roles of specific sites. Most recently, a thorough assessment of the role of Beaudette S 
glycosylation was published, detailing the generation of mutant viruses with deleted 
glycosylation sites and the effects of these mutations on replication and fusion (Zheng et al. 
2018).  
The aims of Chapter 3 were set out to characterise the glycosylation profile of a wider range 
of more relevant IBVs, including pathogenic strains. A large number of predicted 
glycosylation sites were identified on the surface of the S protein and their locations mapped 
onto a model of the IBV M41-CK S protein. Glycosylation was confirmed at 18 of 29 predicted 
sites using mass spectrometry. The structures at six of these sites were predicted using EThcD 
mass spectrometry, providing initial insights into the heterogeneity of oligosaccharides 
present in the virus population. This work builds on other recent studies of the IBV S protein, 
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where 20 sites were identified during structural studies by cryo-EM in M41 (Shang et al., 
2018), and by mass spectrometry methods in a Vero-adapted strain of Beaudette where 8 
sites were confirmed as being glycosylated (Zheng et al., 2018). The former study identified 
glycosylation sites on recombinant S protein expressed in insect cells, whereas Zheng and 
colleagues studied the S protein in viruses propagated in cell culture. There were some 
differences in the sites identified in each study, which can probably be attributed to the 
methods of protein production used in each experiment. All of the sites identified by Shang 
and colleagues were present in the server predictions performed using NetNGlyc 1.0, but 
only 9 matched those identified as true glycosylation sites in the MS experiments described 
in Chapter 3. As the methods of protein expression and purification differed quite a lot, it is 
likely that each protein presented a different glycosylation profile. Tandem MS methods 
were used by Zheng et al. to identify 8 sites on the Beaudette S protein, 6 of which were also 
identified in Chapter 3. More sites were identified by the methods in Chapter 3, possibly 
because EThcD was used as well as LC-MS/MS. However the studies involved different strains 
and so cannot be directly compared. The study described here possibly presents more 
advantages and relevance to IBV research, as the protein was derived from whole, 
pathogenic virus rather than produced in an insect-based cellular expression system (Shang 
et al.) or derived from a non-pathogenic Vero-adapted strain (Zheng et al.). Despite the 
differences in each study, all highlight the high number of glycosylation sites on these viral 
proteins and provide a good basis for further, more detailed investigation into these sites.5 
N-linked glycans exist in different forms as a result of the processing pathways and cellular 
enzymes employed to modify proteins both during and post-translation. Different classes of 
glycan were identified on the S proteins of two strains of IBV, M41 and Beau-R, demonstrated 
by western blot following treatment with mannosidase inhibitors and deglycosylating 
enzymes. Some interesting results arose from these analyses, with different possible 
explanations for the changes observed. The loss of S2 recognition by the monoclonal 
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antibody in Beau-R highlights the importance of proper protein folding and the role that 
glycosylation plays within these processes but the other effects of the enzymatic 
deglycosylation treatments raised some more complicated questions about the mechanisms 
of each treatment. One possibility is that the deglycosylation of the protein further exposed 
cleavage sites and so rates of S1-S2 cleavage were increased, thus eliminating the uncleaved 
portion of S in the sample. Another explanation for the dramatic size change in these 
experiments is that glycosylation in the protein accounts for over half of the protein’s 
apparent molecular weight when analysed by western blot. Further investigation would be 
required to thoroughly assess the levels of each subunit in these samples. This could be 
achieved through use of another antibody against the S1 subunit. Given the lack of 
compatible reagents for this type of experiment however, this is somewhat difficult to 
achieve at present. As mentioned, future experiments should also include more robust 
controls to account for the changes observed with each treatment.  
The findings using Kif highlighted a role for complex glycans in the binding of monoclonal 
antibodies to their target epitopes, but only in Beau-R. Complex glycans were shown not to 
affect virus neutralisation by a monoclonal S1 antibody in either M41 or Beau-R. They were 
also shown to be dispensable for replication in CK cells. The loss of antibody recognition was 
confirmed by both western blot and IF, indicating that complex glycosylation is involved in 
monoclonal antibody recognition of both linear epitopes and conformational protein.  
The importance of N-linked glycans in IBV was noted following attempts to rescue a virus 
with multiple mutations in predicted glycosylation sites. After numerous attempts it was 
concluded that this combination of mutations was incompatible with virus rescue. Given the 
essential role of glycosylation in protein synthesis and folding pathways it could be assumed 
that the mutant protein could not be folded correctly or incorporated into the virion. With 
the information now available from the mass spectrometry data, as well as the published 
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results showing the impact of individual glycosylation mutants in IBV replication (Zheng et 
al., 2018), future directions for this study will include the generation of recombinant viruses 
with fewer mutations, in an attempt to investigate the role of specific glycosylation sites in 
viral replication and pathogenicity.  
7.2 Elucidating the role of the S protein in IBV pathogenicity  
The second and third objectives of the project included generation of two recombinant IBVs 
with modified S proteins, in order to study how the S protein influences pathogenicity. 
Previous work with IBV and other coronaviruses have found conflicting results concerning 
the role of the S protein in pathogenicity, where replacement of the S gene did not alter the 
pathogenicity of an attenuated strain of IBV, with the opposite effect observed in MHV 
(Phillips et al., 1999, Hodgson et al., 2004). The experiments described in Chapters 4 and 5 
demonstrate that the S gene is, in fact, a pathogenicity factor for IBV. The attenuation of 
M41-K following the insertion of the Beaudette-derived ectodomain sequence shows that 
the presence of this protein is sufficient to alter IBV pathogenicity in a pathogenic strain. The 
robustness of the reverse genetics system used to generate these viruses was further 
validated by the generation and characterisation of M41K-4/91(S), where the insertion of a 
heterologous S gene sequence did not alter the pathogenicity of the virus during infection in 
chickens. In addition, both these viruses adopted the tropism of the S protein donor strain, 
again proving that the S protein determines IBV tropism in vitro. The fact that M41K-4/91(S) 
remained pathogenic even with the insertion of a heterologous sequence approximately 18% 
divergent shows gives insight into the way the S protein functions as a whole and how it 
interacts with other viral proteins. It is clear that the recombinant virus is still able to replicate 
efficiently with the inserted sequence, indicating that the interaction with other viral 
proteins remains largely unaffected. It is important to remember that the signal sequence, 
transmembrane domain and cytoplasmic tail of these recombinant S proteins were 
preserved and homologous to the backbone strain, M41-K. As these domains are likely the 
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key partners in interactions with other viral proteins, theoretically there should be no change 
following the insertion of the modified ectodomain. In SARS, for example, it was shown that 
trafficking signals in the S protein cytoplasmic tail heavily influenced the outcome of 
infection, even following only very few mutations in this region (Youn et al., 2005). This could 
be studied in IBV using the same methodology of introducing targeted mutations in these 
domains to assess how they affect viral replication, giving clearer insight into which domains 
within the protein are required for maintaining the interactions between the viral proteins.  
Previous research has highlighted the importance of the secondary cleavage site in the 
extended host tropism of Beaudette in vitro (Bickerton et al., 2018) which could be translated 
to in vivo findings described here. As both the M41 and 4/91 S proteins lack this cleavage 
site, and are highly pathogenic, it stands to reason that M41K-BeauR(S) could be entering 
tissues by a different mechanism than the pathogenic viruses. This could lead to an altered 
immune response, meaning the virus may be cleared more quickly and hence inducing fewer 
clinical signs. This could provide an explanation for the attenuation observed with this 
recombinant virus, however, further experiments would be required to investigate this 
hypothesis.  
While the recombinant virus was without doubt pathogenic, the patterns of clinical signs 
induced in the infected birds over the course of the experiment differed slightly from the 
two parent viruses M41-K and 4/91. This indicates that the presence of the heterologous S 
gene sequence had some effect on the mechanisms by which the virus caused disease. 
Perhaps the interaction with the other viral proteins such as M has been slightly affected by 
the presence of the alternative sequence. As mentioned, it would be of interest to further 
examine the interactions of recombinant S proteins with other viral proteins, perhaps using 
M41K-4/91(S) as a tool to examine the effects of heterologous sequences within the protein. 
Studies in other coronaviruses have noted reduced incorporation of S during virion assembly 
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with modified M proteins (Kuo et al., 2016). It would be interesting to assess if the same 
effect would be seen with these recombinant S proteins.  
7.3 Defining the cellular requirements of IBV tropism  
The final objective of the work involved assessing the influence of the cellular environment 
on IBV infection and replication. Investigations into the cellular requirements of IBV infection 
have revealed some interesting results concerning temperature sensitivity, following initial 
findings that Beau-R was unable to replicate at 41°C. As the S gene has been shown to directly 
influence tropism in IBV, through the presence of the additional cleavage site in S2 (Bickerton 
et al., 2018), recombinant viruses were used to assess if this was also the defining factor in 
temperature sensitivity. Through assessment of replication kinetics in CK cells, it was found 
that the S gene did not dictate this restriction. M41K-BeauR(S) exhibits only a slight sensitivity 
to temperature compared to M41, providing a possible explanation for the recombinant 
virus’ ability to disseminate to the trachea of infected birds. This is in contrast to Beau-R 
which exhibits complete temperature sensitivity and is unable to disseminate from the sites 
of infection. In other recent studies, temperature sensitivity was linked to attenuation during 
characterisation of a strain of Urabe mumps virus, a paramyxovirus. The temperature 
sensitive mutant was found to replicate to much lower titres at the non-permissive 
temperature, while also exhibiting a lower neurovirulence. In this study, mutations were 
identified in the surface glycoprotein and in the polymerase gene, which were associated to 
the temperature sensitive phenotype. The temperature sensitive strain showed reduced 
levels of transcription and protein synthesis from ORFs towards the 3′ end of the genome, 
possibly suggesting the polymerase was less able to remain associated with the genome at 
the higher temperature (Schinkel et al., 2017). As Beau-R replicates very well at 37°C it could 
be hypothesised that the replication enzymes encoded in its genome are not adapted to 
replication at higher temperatures, meaning that the genome cannot be replicated 
efficiently in vivo.  
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Initial research into host tropism at 41°C showed that the Beaudette S gene is required to 
enter Vero cells but other parts of the genome are responsible for allowing the virus to 
efficiently replicate in these cells, as demonstrated through infections with the recombinant 
virus M41K-BeauR(S), where the insertion of the Beau-R S ectodomain allowed the virus to 
enter Vero cells and the M41 genome allowed the virus to replicate at higher temperatures, 
unlike any of the other viruses included in these experiments. This emphasises the fact that 
tropism can be defined as a multifactorial process, in that more than a permissive S gene is 
required to allow IBV replication in a given cell line. 
The results from the temperature sensitivity experiments present a multitude of directions 
for future investigation. Firstly, it would be prudent to assess if the restriction in replication 
at 41°C is unique to Beaudette. To this end, replication of a range of IBV strains should be 
assessed in these experiments, including available and suitable field strains. As the S gene 
has been ruled out as the direct cause for temperature sensitivity, other genes in the IBV 
genome could be responsible for the observed phenotype. In other coronaviruses, the 
replicase gene has been implicated in temperature sensitivity, or more specifically certain 
nsps encoded within it (Stobart et al., 2012). In other RNA viruses such as influenza A, 
temperature sensitivity has been linked to the polymerase gene, where directed mutations 
can alter virulence and result in attenuation (Da Costa et al., 2015). Previously, a recombinant 
IBV was generated including the Beaudette replicase gene and the structural and accessory 
genes of M41 to investigate the role of the replicase gene in pathogenicity (Armesto et al., 
2009). This virus could be used for assessment of replication kinetics at 41°C to confirm 
whether this gene was the cause of the temperature sensitivity observed with certain IBV 
strains. As other studies have linked temperature sensitivity to the viral replication 
machinery, effects on the synthesis of nascent IBV RNA under different conditions could be 
investigated using techniques such as northern blot. This could be assessed for both wild-
type and recombinant strains to ascertain whether the recombinant sequences influenced 
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RNA synthesis at higher temperatures, providing some insight into replication in different 
locations within the infected bird.  
The protease environment in the cell also plays a part in viral entry and host tropism, thought 
to be as a result of alternative proteolytic processing of the S protein. Vero cell infections 
with M41 in the presence of trypsin showed that the virus could utilise trypsin to enter these 
usually non-permissive cells. The same effect was seen with the field strain QX, providing a 
possible platform for propagation in cell culture. The replication pattern observed in these 
infections could not be maintained over multiple passage, indicating that other factors have 
affected how these viruses replicate under the additional S protein processing by exogenous 
trypsin. It could be that the S protein of these viruses has been processed incorrectly; 
perhaps there is an additional cleavage site present in the S protein sequence and the 
progeny viruses produced in the presence of the additional proteases are less able to infect 
cells due to overactive cleavage. The cleavage patterns of these viruses affected by the 
addition of trypsin should be investigated to identify regions susceptible for this activation 
and provide further insight into this phenomenon. 
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7.4 Future work  
Recombinant IBVs with mutated glycosylation sites will be generated  
To begin assessment of the importance of individual glycosylation sites during in vitro 
replication, fewer mutations should be introduced into the S protein of M41-K. This could be 
achieved through sequential repair of the plasmid used to generate the original mutant virus 
by site-directed mutagenesis. Following in vitro characterisation, pathogenicity studies could 
be carried out in chickens along with assessing the induction of neutralising antibodies in 
vivo, to examine whether the glycosylation sites affected pathogenesis following mutation.  
The involvement of complex glycans in virus neutralisation by polyclonal antibodies will be 
assessed 
Virus neutralisation will be assessed by plaque reduction assay as described for experiments 
with the monoclonal antibody against S1 (A13). Different antibodies, including polyclonal 
sera, will be used to further assess how complex glycans influence binding and neutralisation.   
M41K-BeauR(S) will be tested as a vaccine candidate  
The recombinant virus M41K-BeauR(S) was shown to be non-pathogenic, while still able to 
disseminate through the bird to the trachea. The virus will be used in a future vaccine-
challenge experiment in chickens to assess its potential for conferring protection against IBV 
challenge and its capabilities in inducing neutralising antibodies.  
Continuation of rIBV M41K-4/91(S) dissemination assessments  
To compare the potential for virus dissemination between M41-K, 4/91 and M41K-4/91(S), 
the remaining tissues from day 4 and 6 post-infection will be screened by RT-PCR for 
detection of IBV genome. This will also provide insight into any changes in in vivo tissue 
tropism that have occurred as a result of the insertion of the heterologous S gene into the 
M41 genome. 
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The mechanism of spike cleavage by trypsin will be assessed by western blot 
More experimental data is required to draw conclusions concerning the mechanisms 
involved in trypsin-mediated extension of host tropism. To address this, western blot 
techniques will be used to analyse the cleavage products under these conditions to assess 
the pattern of cleavage in the presence of trypsin.  
Temperature sensitivity: assessment of IBV adaptation to replication at 41°C 
A range of rIBVs will be passaged at 41°C to investigate the potential of IBV to adapt to 
replication at higher temperatures. Viruses will be sequenced following select passage 
numbers to identify any mutations acquired. A range of temperatures will also be tested, as 
the upper sections of the respiratory tract are unlikely to reach 41°C.  
 
7.5 Limitations  
There are certain limitations associated with the work described here and also with the 
techniques involved in future directions. The use of cellular inhibitors to assess the role of 
complex glycans presents issues that must be considered. The inhibitors are not specific to 
viral proteins and their action will also apply to other viral and cellular proteins, including 
receptor molecules. This should be taken into account when drawing conclusions concerning 
the involvement of these glycans in viral entry. There is also no accurate way of verifying the 
action of the inhibitor, aside from confirming the loss of S2 recognition by 26.1, as there are 
currently no other anti-S antibodies readily available that are compatible with western blot.  
The mass spectrometry techniques described here provide some useful insights into the 
glycosylation profile of the IBV M41-CK S protein. Ideally, these techniques would be used to 
analyse the S proteins in a range of IBV strains, but there are financial and ethical constraints 
associated with the sample preparation. For the results described in Chapter 3, volumes 
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upwards of 500ml of allantoic fluid was used to generate the purified virus. While the 
coverage of the protein was good it was incomplete, so a huge number of eggs would be 
required to produce the quantities of virus needed to gain sufficient coverage of the whole 
protein.  
The results from the in vivo analysis of rIBV M41K-BeauR(S) described in Chapter 4 are quite 
robust but there is some variation in the clinical signs between individual birds. As only 3 
birds were analysed on each day, a larger sample size may have provided more information 
and highlighted any outliers. A balance must be achieved between adequate sample sizes 
and reducing the number of animals used for experiments, in line with the principles of the 
3Rs. This was employed in the subsequent M41K-4/91(S) pathogenicity study described in 
Chapter 5, where five birds were analysed at each time point. The results from this study are 
much more consistent, allowing more definite conclusions to be drawn.  
As described in Chapter 6, the cell type used for assessment of tropism and temperature 
sensitivity should be considered carefully, as Vero cells are adapted to growth at 37°C. 
Beaudette strains can replicate in DF-1 cells, so using this avian cell type would provide a 
more biologically relevant alternative to mammalian Vero cells while still accommodating 
the extended tropism of Beaudette. These studies are also limited by the strain of IBV, as 
most of the available field strains do not replicate in cell culture, only in ex vivo systems. 
These systems, such as TOCs, are optimised to 37°C and as such would not be suitable for 
studying replication at higher temperatures without major adjustments.  
A general limitation of studying IBV is the availability of cells and tissues in which non-
laboratory adapted strains will replicate. As mentioned, investigations into field strains more 
relevant to the vaccine industry are limited by the feasibility of propagation in cell culture. 
While some strains do replicate in ex vivo systems, the cost and labour associated with these 
techniques is much higher than cell culture systems. The data described in Chapter 6 provide 
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a possible solution to this problem, allowing field strains to replicate in cell culture following 
the addition of exogenous protease.  
 
7.6 Impact   
Taken together, the results described in this thesis provide more insight into the importance 
of the coronavirus S protein during infection both in vitro and in vivo. The glycan presence 
on the surface of the IBV S protein is substantial and could provide a target for more effective 
vaccine design, much needed in the fight to control infectious bronchitis in commercial 
chicken flocks. Insertion of heterologous S genes into the IBV genome presents another 
method for rational vaccine design and using proteases as a potential platform for 
propagation in cell culture would dramatically improve the vaccine production process for 
this economically important disease.  
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8 Appendix  
8.1 NetNGlyc Raw data 
 
1. Beau-R 
 
 
 
(Threshold=0.5) 
-------------------------------------------------------------------- 
SeqName     Position  Potential   Jury    N-Glyc 
     Agreement result 
-------------------------------------------------------------------- 
Sequence      51 NISS   0.7529     (9/9)   +++  
Sequence      77 NASS   0.6344     (7/9)   +      
Sequence     103 NFSD   0.7079     (8/9)   +      
Sequence     144 NLTV   0.7906     (9/9)   +++    
Sequence     163 NLTS   0.6421     (9/9)   ++    
Sequence     178 NETI   0.6101     (6/9)   +      
Sequence     212 NGTA   0.7300     (9/9)   ++    
Sequence     237 NFSD   0.6116     (8/9)   +      
Sequence     247 NSSL   0.6269     (8/9)   +      
Sequence     264 NTTC   0.6341     (8/9)   +      
Sequence     276 NETG   0.6528     (8/9)   +      
Sequence     283 NPSG   0.5364     (8/9)   +    WARNING: PRO-X1.  
Sequence     306 NFSF   0.5353     (4/9)   +      
Sequence     425 NITL   0.6274     (8/9)   +      
Sequence     447 NVTD   0.7393     (9/9)   ++    
Sequence     513 NETG   0.4644     (5/9)   -      
Sequence     530 NGTR   0.7149     (9/9)   ++     
Sequence     579 NVTE   0.7121     (9/9)   ++     
Sequence     591 NLTV   0.5724     (8/9)   +     
Sequence     669 NVST   0.5543     (5/9)   +      
Sequence     676 NISL   0.6353     (8/9)   +      
Sequence     683 NPSS   0.6803     (9/9)   ++   WARNING: PRO-X1.  
Sequence     714 NCTA   0.3846     (8/9)   -      
Sequence     947 NVTA   0.6688     (9/9)   ++  
Sequence     960 NASQ   0.5179     (6/9)   +      
Sequence     979 NGSY   0.5788     (9/9)   ++   
Sequence    1014 NKTV   0.6479     (8/9)   +      
Sequence    1038 NDTK   0.6340     (8/9)   +      
Sequence    1051 NYTV   0.5902     (7/9)   +      
Sequence    1074 NDSL   0.4929     (5/9)   -      
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2. M41-CK:  
 
SeqName      Position  Potential   Jury    N-Glyc 
         Agreement result 
-------------------------------------------------------------------- 
Sequence      51 NISS   0.7274     (9/9)   ++    
Sequence      77 NASS   0.6411     (7/9)   +      
Sequence     103 NFSD   0.7079     (8/9)   +      
Sequence     144 NLTV   0.7907     (9/9)   +++   
Sequence     163 NLTS   0.6463     (9/9)   ++     
Sequence     178 NETT   0.5413     (4/9)   +      
Sequence     212 NGTA   0.7300     (9/9)   ++     
Sequence     237 NFSD   0.6000     (7/9)   +      
Sequence     247 NSSL   0.5964     (8/9)   +      
Sequence     264 NTTF   0.5748     (7/9)   +      
Sequence     271 NFTF   0.6053     (8/9)   +      
Sequence     276 NETG   0.5708     (7/9)   +      
Sequence     283 NPSG   0.5361     (8/9)   +    WARNING: PRO-X1.  
Sequence     306 NFSF   0.5200     (4/9)   +      
Sequence     425 NITL   0.6621     (9/9)   ++  
Sequence     447 NVTD   0.7393     (9/9)   ++     
Sequence     513 NETG   0.4646     (5/9)   -      
Sequence     530 NGTR   0.7149     (9/9)   ++    
Sequence     579 NVTE   0.7628     (9/9)   +++   
Sequence     591 NLTV   0.5722     (8/9)   + 
Sequence     669 NVST   0.5898     (8/9)   +      
Sequence     676 NISL   0.6146     (8/9)   +      
Sequence     714 NCTA   0.4120     (8/9)   -      
Sequence     947 NVTA   0.6688     (9/9)   ++     
Sequence     960 NASQ   0.5179     (6/9)   +      
Sequence     979 NGSY   0.5786     (9/9)   ++     
Sequence    1014 NKTV   0.6477     (8/9)   +      
Sequence    1038 NDTK   0.6340     (8/9)   +      
Sequence    1051 NYTV   0.5903     (7/9)   +      
Sequence    1074 NDSL   0.4928     (5/9)   -    
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3. QX-1148A: 
-------------------------------------------------------------------- 
SeqName      Position Potential   Jury    N-Glyc 
      Agreement result 
--------------------------------------------------------------------
Sequence      52 NSTN   0.6977     (9/9)   ++     
Sequence      55 NYTN   0.6417     (9/9)   ++     
Sequence      76 NQSV   0.5007     (5/9)   +      
Sequence     104 NFSE   0.6117     (7/9)   +      
Sequence     141 NGSL   0.5683     (7/9)   +      
Sequence     147 NLTV   0.7656     (9/9)   +++    
Sequence     166 NFTS   0.5869     (7/9)   +      
Sequence     181 NKTT   0.6548     (7/9)   +      
Sequence     200 NYSI   0.6987     (9/9)   ++       
Sequence     215 NGTA   0.7301     (9/9)   ++     
Sequence     240 NFSD   0.6109     (8/9)   +      
Sequence     250 NSTL   0.7169     (8/9)   +      
Sequence     267 NTTL   0.6844     (9/9)   ++     
Sequence     274 NFTF   0.6311     (9/9)   ++     
Sequence     279 NVSN   0.6077     (8/9)   +      
Sequence     309 NLSF   0.5778     (9/9)   ++     
Sequence     428 NITL   0.6603     (8/9)   +      
Sequence     450 NVTD   0.7147     (9/9)   ++     
Sequence     457 NFSY   0.4801     (3/9)   -      
Sequence     516 NETG   0.4480     (6/9)   -      
Sequence     533 NSSH   0.5707     (5/9)   +    
Sequence     545 NVTS   0.7170     (9/9)   ++     
Sequence     582 NITE   0.7402     (9/9)   ++     
Sequence     594 NLTV   0.5747     (8/9)   +      
Sequence     672 NVST   0.5952     (5/9)   +      
Sequence     679 NISL   0.6357     (8/9)   +      
Sequence     950 NVTA   0.6911     (9/9)   ++     
Sequence     963 NASQ   0.3972     (7/9)   -      
Sequence     982 NGTY   0.6466     (9/9)   ++     
Sequence    1017 NKTV   0.7158     (9/9)   ++     
Sequence    1041 NDTK   0.6106     (8/9)   +      
Sequence    1054 NYTV   0.5982     (6/9)   +      
Sequence    1061 NISG   0.4664     (6/9)   -      
Sequence    1077 NDSL   0.4601     (7/9)   -      
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4. 4/91  
 
------------------------------------------------------------------- 
    SeqName      Position Potential   Jury   N-Glyc 
                                    Agreement result 
------------------------------------------------------------------- 
   Sequence      54 NGTN   0.7207     (9/9)   ++ 
Sequence      75 NISA   0.6990     (9/9)   ++ 
Sequence     103 NFSD   0.6990     (8/9)   + 
Sequence     146 NLTV   0.8152     (9/9)   +++ 
Sequence     165 NSTS   0.6301     (9/9)   ++ 
Sequence     180 NETT   0.5936     (4/9)   + 
Sequence     214 NGTA   0.6777     (9/9)   ++ 
Sequence     239 NFSD   0.6113     (8/9)   + 
Sequence     249 NSSL   0.6587     (8/9)   + 
Sequence     266 NTTL   0.6573     (9/9)   ++ 
Sequence     273 NFTF   0.6424     (9/9)   ++ 
Sequence     278 NVSN   0.5724     (8/9)   + 
Sequence     281 NASP   0.1020     (9/9)   --- 
Sequence     308 NLSF   0.5904     (9/9)   ++ 
Sequence     427 NITL   0.6596     (8/9)   + 
Sequence     449 NVTE   0.6762     (9/9)   ++ 
Sequence     456 NYSY   0.4773     (5/9)   - 
Sequence     515 NETD   0.6186     (6/9)   + 
Sequence     532 NGTR   0.7059     (9/9)   ++ 
Sequence     544 NVTN   0.7063     (9/9)   ++ 
Sequence     581 NVTE   0.7607     (9/9)   +++ 
Sequence     593 NLTV   0.5864     (8/9)   + 
Sequence     671 NVST   0.5260     (5/9)   + 
Sequence     678 NISL   0.5891     (7/9)   + 
Sequence     949 NVTA   0.6914     (9/9)   ++ 
Sequence     962 NASQ   0.4101     (6/9)   - 
Sequence     981 NGSY   0.5616     (8/9)   + 
Sequence    1016 NKTV   0.6482     (8/9)   + 
Sequence    1040 NDTK   0.6311     (8/9)   + 
Sequence    1053 NYTV   0.6564     (9/9)   ++ 
Sequence    1060 NISN   0.4617     (6/9)   - 
Sequence    1076 NDSL   0.4871     (6/9)   - 
 
Figure A1: Raw data produced from NetNGlyc server PNGS predictions. Thresholds and 
algorithm predictions are displayed for Beau-R, M41-CK, QX-1148A and 4/91.  
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8.2 Cell viability assays (CellTiter-Glo) 
 
 
 
 
 
 
 
 
Figure A2: Kifunensine does not affect CK cell viability over 96 hours at most 
concentrations. Cells seeded in were treated with Kifunensine at varying concentrations 
(µM) and incubated at 37°C. Cell viability was measured according to the Promega CellTiter-
Glo Assay protocol. Data were analysed by One-Way ANOVA followed by Tukey’s multiple 
comparison test (* indicates p < 0.05).  
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Figure A3: DF-1 cell viability is not affected following 20µM Kif treatment. Cells were 
seeded in 96 well plates and treated with Kif at varying concentrations (µM). Cell viability 
was measured using Promega CellTiter-Glo reagents. Data were analysed by One-Way 
ANOVA followed by Tukey’s multiple comparison test (* indicates p = 0.02, ** indicates p = 
0.005, *** indicates p = 0.004). At 24h, Cell viability was increased following treatment with 
20µM Kif.  
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Figure A4: Vero cell viability at 41°C after 96 hours incubation. Cells were seeded in a 96 
well plate and incubated at 37°C or 41°C for 96 hours. Viability was assessed using Promega 
CellTiter-Glo reagents according to the manufacturer’s instructions. Data were analysed by 
unpaired t-test (**** indicates p = 0.0002 for all replicates).  
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8.3 Mass Spectra 
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Figure A5: Mass spectra of glycan structures observed at amino acid positions 144, 212, 
425, 513, 947 and 1014 in the IBV M41-CK S protein. Purified M41-CK samples were digested 
in chymotrypsin or trypsin and peptides were analysed using LC Nano MS/MS and EThcD 
mass spectrometers. Amino acid positions and digest conditions are indicated. 
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8.4 IBV S protein sequence alignment 
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Figure A6: Amino acid alignment of M41-CK, Beau-R, QX and 4/91 S protein sequences. 
Sequences were generated by RT-PCR using strain-specific primers covering the S gene 
followed by Sanger sequencing. Sequencing reads were processed and aligned using BioEdit. 
Numbers indicate amino acid positions from the S gene start codon and are specific to each 
strain. Potential N-linked glycosylation sites (PNGS) are highlighted in yellow at the 
appropriate Asn (N) residue, as identified by the online server NetNGlyc 1.0.  
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